DISPATCHES FROM THE GUILD CONFERENCE, SERIES #54

Anal Squamous Intraepithelial Lesions and Cancer: An Underappreciated Risk in IBD

Read Article

INTRODUCTION

Anal squamous intraepithelial lesions (SIL) are precancerous lesions of the anal squamous epithelium that can progress to anal cancer. Anal cancer is rare in the general population. However, rates are markedly higher among specific risk groups and have been steadily increasing in the past two decades. Anal squamous cell carcinoma is thought to occur through progression of high grade squamous intraepithelial lesions (HSIL) via the effect of particular high-risk subtypes of the human papilloma virus (HPV).

The risk of SIL and anal cancer are elevated in certain populations, especially in people living with human immunodeficiency virus (HIV). Identifying and treating these lesions reduces the risk of progression to anal cancer. Most recent society guidelines suggest screening for anal cancer in those with HIV. However, there are additional at-risk groups that may warrant consideration for screening. The risk of anal squamous intraepithelial lesions and anal cancer is elevated in inflammatory bowel disease (IBD). Patients with IBD appear to have increased prevalence of high-risk HPV subtypes. In an uncontrolled cross-sectional study of fortyfive sexually active male and female patients with IBD, 89.1% were positive for anal HPV, with HPV 16, the highest risk subtype, being the most prevalent strain. Four patients (8.7%) had HSIL present on biopsy, while twenty-four (43.5%) had low grade squamous intraepithelial lesions (LSIL).1 Anal cancer risk is highest in Crohn’s disease, particularly when perianal fistulizing disease is present. In a large cohort study, the incidence rate of anal squamous cell carcinoma (SCC) in patients with perianal Crohn’s disease was 26 per 100,000 person-years, which was greater than their risk of colon adenocarcinoma by about two-fold. In this cohort, most anorectal cancers associated with Crohn’s disease were adenocarcinomas, and were associated with fistulas.2 In a review of sixty one anal cancers arising from fistulas, adenocarcinoma was responsible in 59%, and anal SCC was responsible in 31%.3 This review will focus on anal cancer and HSIL to increase awareness among gastroenterologists who manage IBD. 

Anal Squamous Cell Carcinoma 

Anal cancer is a rare but increasingly more prevalent cancer that disproportionately affects certain population groups. SCC makes up the majority of anal cancers, comprising about two thirds of anal cancer cases in the United States.4 While rare in the general population (about 1 per 100,000 person-years), certain risk groups carry a much higher risk of anal SCC. Anal SCC incidence is estimated at 85 per 100,000 person-years in men who have sex with men (MSM) living with HIV which is the group with the highest known risk. Among men who have sex with women (MSW) living with HIV, the risk is lower at 32 per 100,000 person-years. In women with HIV, the risk is 22 per 100,000 person-years. Other groups with risk above the general population include women with prior HPV related gynecological precancerous lesions, solid organ transplant recipients, and patients with immune mediated diseases such as IBD and lupus.5 While other HIV associated cancers such as non- Hodgkin’s lymphoma and Kaposi Sarcoma have fallen in incidence since the emergence of HIV/ AIDS, anal cancer continues to rise in incidence, at 2.7% per year between 2001 and 2015.6 This rise in anal cancer rates may be related to the aging population of persons living with HIV, as rates have increased the most in people above age fifty.6

Presenting symptoms of anal SCC are bleeding or anal pain, although twenty percent of patients with anal SCC are asymptomatic at presentation. On exam, patients may have a palpable mass or area of bleeding. Anal cancer is staged by Tumor Nodes & Metastases (TNM) classification. Prognosis for early stage (I or II) is good with five-year survival of 86%, while T4 cancers or node positive cancers have five-year survival rates of about 50%.7 However, the prognosis for IBD patients is worse than in patients without IBD, as a systematic review of IBD patients with non-fistula associated anal SCC found an overall five-year survival of 37%.8 A more recent analysis of over 61,000 patients with HPV-related cancers found that patients with IBD and anal cancer had a median survival of 46 months versus 61 months in non-IBD patients.9 This difference in survival is thought to be due to more advanced malignancy at diagnosis and the presence of pelvic sepsis in Crohn’s disease limiting the ability to use radiotherapy.8 

Diagnostic evaluation includes physical exam with inguinal lymph node evaluation, biopsy of the lesion, chest and abdomen contrast-enhanced computed tomography (CT), pelvic CT or magnetic resonance imaging (MRI) with IV contrast, anoscopy, HIV testing (if unknown), gynecologic exam, and consideration of fertility risk counseling.10 Treatment of T1, node negative, well differentiated tumors is with local excision, while more advanced tumors are treated with combination chemoradiation.10 

Anal Squamous Intraepithelial Lesions 

Anal cancer is preceded by changes in the epithelial layer of the anal canal mediated by HPV which parallel the types of changes seen in the cervical epithelium. This has led to the adoption of the same nomenclature and classification used in the care of cervical precancerous lesions. Often referred to as “anal dysplasia”, these changes are now referred to as squamous intraepithelial lesions (SIL), with a two-tiered subdivision into LSIL and HSIL.11 This replaces the prior system of classification that utilized the terminology anal intraepithelial neoplasia (AIN). While LSIL is associated with condyloma and not thought to be a direct precursor to anal SCC, HSIL carries a markedly increased risk of progression to anal cancer. In a large population-based study, the 5-year risk of progression from HSIL to anal cancer in MSM living with HIV was 14.1%, and in MSM not living with HIV was 3.2%. In the same study, a diagnosis of LSIL carried a 5-year risk of 0.15%, which is higher than the risk if no LSIL was present.12 HSIL may spontaneously regress, with regression rates between 20-30%.13,14 

HPV is the major causative factor in inducing squamous intraepithelial lesions. Of the numerous subtypes of HPV, there are specific types that are most likely to cause ASIL. HPV 16 is the type most highly associated with HSIL and anal cancer.15 Other oncogenic HPV types that affect the anogenital area are 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68.16 HPV types 6 and 11 are responsible for benign genital warts. Overall it is estimated that high-risk HPV is a causative factor in over 90% of anal squamous cell carcinomas.17 

HSIL is usually asymptomatic, although it can be associated with anal pain, pruritis, or bleeding.18 Additionally, HSIL typically cannot be palpated during a digital anal rectal exam (DARE).19 In contrast, LSIL cause condylomas or warts, which are more readily identified by patients and providers.20 Methods of identifying underlying HSIL have borrowed from techniques used to identify cervical intraepithelial neoplasia, given their pathophysiologic similarities. Identifying the presence of HSIL involves both cytology and direct visualization techniques. Initial screening is with anal cytology, commonly referred to as an anal Pap smear. Using a moistened brush or nylon/ polyester swab, epithelial cells are scraped from the surface and the swab is placed into a transfer medium as in cervical cytology testing. This is then examined under microscopy. Anal cytology has modest sensitivity and specificity, with pooled sensitivity of 85% and pooled specificity of 43.2% for the identification of HSIL, which is comparable to the performance of cervical cytology.21,22 

As with in cervical cancer screening, if anal cytology identifies an anal squamous intraepithelial lesion, this should be followed by high resolution anoscopy (HRA), a procedure analogous to cervical colposcopy. In this procedure, the anorectal area is examined under high magnification by a colposcope. Acetic acid is applied to the anal epithelium along with lugol’s solution. Areas with squamous intraepithelial lesions will display characteristic patterns of acetowhitening, which can then be sampled via biopsy for histology. HRA has been found to be well tolerated with most patients reporting acceptable pain levels and willingness to follow-up as recommended.23 

At Risk Populations 

Those living with HIV, and particularly MSM with HIV, are at markedly increased risk for anal premalignant lesions as well as anal cancer. This is felt to be due to the effect of HIV on the immune system leading to increased HPV activity and persistence.24 HPV prevalence is highest in MSM with HIV, followed by MSM without HIV. People living with HIV are more likely to carry more than one oncogenic strain of HPV, which may also contribute to the higher risk.15 Among those with HIV, low current CD4 count was associated with HPV16 infection, HSIL, and HPV16-positive HSIL. Anal cancer incidence rate (IR) in MSM with HIV has been estimated in a recent meta-analysis at 85 per 100,000 person-years, while IR in MSW with HIV was 32 per 100,000 person-years, and IR in women with HIV was 22 per 100,000 person-years. The IR for MSM with HIV who are age ³ _60 was even higher at 107.5 per 100,00 person-years.5

MSM without HIV are also at increased risk. People identifying as MSM have a high prevalence of high-risk HPV subtypes, with about 14% prevalence of HPV16 versus 2% in men who are not MSM in a large meta-analysis. The pooled prevalence of HSIL in MSM patients without HIV in the same meta-analysis was 11.3%.25 Anal cancer incidence rate in MSM not living with HIV is estimated to be about 19 per 100,000 person-years, a nearly 20-fold increase in risk from the general population.5 

Women with prior cervical neoplasia are at particular risk for anal SCC. Numerically more anal SCC is diagnosed in women, particularly women above age 50.26 Women with cervical high-risk HPV strains are likelier to have high-risk anal HPV strains.27 In a cross sectional study of 324 women with prior cervical, vulvar, or vaginal high grade dysplasia or cancer, there was a 28% prevalence of anal high risk HPV and anal cytology was abnormal in 23%. In a large population-based cohort study involving 89,010 women with a diagnosis of cervical intraepithelial neoplasia grade 3 (CIN3) matched to an equal number of healthy controls, those with CIN3 had increased risk of AIN3 (HSIL) and anal cancer with incidence rate ratio of 6.68 (95% CI, 3.64 – 12.25) and 3.85 (95% CI: 2.32 – 6.37) respectively.28 

Other risk factors for anal SCC include solid organ transplantation, smoking, early sexual debut, multiple sexual partners, and receptive anal intercourse. Patients and providers should be aware that receptive anal intercourse is not required for the introduction of HPV to the anorectal region, and development of HSIL or anal cancer can occur without a history of receptive anal intercourse.19 

Screening 

Given the presence of a discrete precursor lesion and the identification of at-risk groups, programs have been proposed and developed for anal cancer prevention. The current available modalities for screening are physical exam with DARE, anal cytology, anal HPV testing, and HRA. Currently, only the New York State Department of Health AIDS Institute provides guidelines for anal cancer screening. In this algorithm, all patients with HIV ³ _35 years old should receive annual physical examination and DARE. For patients with HIV above age 35 who are transgender or MSM, annual anal cytology should be performed. If results of cytology indicate the presence LSIL or HSIL, patients should be referred for HRA. If results indicate abnormal squamous cells of undetermined significance (ASC-US), testing for high risk HPV should be performed, and if present, the patient should be referred for HRA.29 Other expert opinion suggests consideration of screening for additional at-risk populations, including: 1) MSM not living with HIV > age 40, 2) persons with a history of HPV-associated genital cancers, 3) solid organ transplant recipients, and 4) other immunocompromised people not living with HIV.19 

The results of the Anal Cancer HSIL Outcomes Research trial (ANCHOR) published in 2022 have now demonstrated benefit to treating HSIL lesions in MSM with HIV above age 35 when compared with active monitoring, with a cumulative progression to anal cancer of 0.9% at 48 months in the treatment arm versus 1.8% at 48 months in the active monitoring group. While the trial showed benefit to screening, it also highlighted the need for better ways of preventing progression to anal cancer, as not all cancer was prevented even with treatment.30 Treating HSIL when present in patients above age 35 has also been shown to be cost effective in a separate study.31 

It is likely that screening patients with IBD would provide benefit, especially for those on long-term immunosuppression or with multiple risk factors for anal cancer. There is a paucity of data examining the effect of immunosuppressing medication use on anal cancer risk in IBD patients. In patients who receive immunosuppression for solid organ transplantation, the risk of anal SCC is estimated to be as high as 49.6 per 100,000 person-years, which is comparable to patients living with HIV. The risk was higher the further from transplantation. In a recent review of heart transplant recipients, the incidence rate for anal SCC was even higher, at 136 per 100,000.5,32 IBD patients receive long term immunosuppression, often life-long, which may put them at a similar risk level. Although not currently recommended by published society guidelines, given the risks outlined, screening for anal cancer (including DARE, cytology, and HRA when indicated) should be strongly considered for IBD patients, and especially when multiple risk factors are present, such as MSM status, history of anal intercourse, or cervical dysplasia. 

HPV Vaccination 

HPV vaccination has been available since 2006 and offers the promise of decreasing the burden of HPV and its related cancers by preventing initial HPV infection. The current pentavalent Gardasil 9 covers HPV 6 and 11, which cause genital warts, and HPV 16, 18, 31, 33, 45, 52, and 58 which are responsible for anogenital and head and neck cancers. Current Center for Disease Control guidelines recommend vaccination for persons between age 12 and 26, and can be initiated as early as age 9. Vaccination can be extended to age 45 if it is felt it would provide benefit after shared clinical decision making with the patient. A two-dose series is recommended between 9 – 15 years of age. A three-dose series is recommended after age 15 and in immunocompromised people.33 Testing for HPV subtypes prior to administering the vaccine is not recommended, and administering the vaccine can be beneficial even after sexual debut, especially in high-risk populations.19 

HPV vaccination is approved only for preventive use and not for therapeutic use. Vaccination against HPV has been evaluated in MSM living with HIV as an adjunctive therapy to prevent HSIL recurrence after HSIL treatment, but data is limited. In a prospective study of MSM diagnosed with HSIL, vaccination with the quadrivalent HPV vaccine was associated with decreased recurrence of HSIL at one- and two-years post HSIL treatment but was non-significant at three years after treatment.34 

In IBD patients, HPV vaccination is recommended following the same guidelines as for the general population.35 No studies have looked at immunogenicity of HPV vaccination in IBD patients on immunosuppression. Studies in other immunocompromised groups show lower antibody titers in these patients compared to healthy controls, but the clinical significance of lower titers and impact on efficacy is unknown.36 Adherence to HPV vaccination guidelines has not been studied in men with IBD. However, in women with IBD, knowledge of HPV vaccination and uptake is low, despite women being the initial population identified as benefiting from vaccination and the well-studied risks of cervical neoplasia in women with IBD.37 Therefore, it is likely that knowledge of HPV vaccination and uptake is even lower in men with IBD. 

CONCLUSION 

Anal cancer is a rare but increasingly prevalent cancer that disproportionately affects at-risk groups including patients with IBD. Progression to anal SCC typically occurs through development of HSIL. This lesion can be identified by cytology or high resolution anoscopy, and treatment has been found to decrease progression to anal squamous cell cancer. IBD patients are at increased risk for anal cancer, and providers taking care of IBD patients should ensure all IBD patients regardless of sex are vaccinated for HPV and discuss screening with patients. Open discussion of sexual orientation and practices with IBD patients will help to risk stratify, as MSM patients and those participating in receptive anal intercourse are at further increased risk.

Anal cancer incidence has been shown to increase with age in immunocompromised populations, and as IBD patients age in the biologic era, the risk of anal SCC may increase further with time. Further data is needed regarding the differential risk of various IBD phenotypes and the impact of IBD medications on anal cancer risk. Established guidelines suggest screening in persons living with HIV who are older than 35, but these guidelines are likely to evolve as the evidence in favor of screening specific groups grows. Comprehensive care of IBD patients requires an awareness of anal cancer risk and initiating screening and prophylaxis when appropriate.

Justin Field, MD Advanced IBD Fellow, UCSF Center for Colitis & Crohn’s Disease

Uma Mahadevan MD, Professor of Medicine, UCSF Center for Colitis and Crohn’s Disease

References 

1. Cranston RD, Regueiro M, Hashash J, et al. A Pilot Study of the Prevalence of Anal Human Papillomavirus and Dysplasia in a Cohort of Patients With IBD. Dis Colon Rectum 2017;60(12):1307-1313. DOI: 10.1097/ DCR.0000000000000878. 

2. Beaugerie L, Carrat F, Nahon S, et al. High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease. Clinical Gastroenterology and Hepatology 2018;16(6):892-899.e2. DOI: 10.1016/j. cgh.2017.11.041. 

3. Thomas M, Bienkowski R, Vandermeer TJ, Trostle D, Cagir B. Malignant transformation in perianal fistulas of Crohn’s disease: a systematic review of literature. J Gastrointest Surg 2010;14(1):66-73. DOI: 10.1007/ s11605-009-1061-x. 

4. Kang YJ, Smith M, Canfell K. Anal cancer in high-income countries: Increasing burden of disease. PLoS One 2018;13(10):e0205105. DOI: 10.1371/journal. pone.0205105. 

5. Clifford GM, Georges D, Shiels MS, et al. A meta-analy­sis of anal cancer incidence by risk group: Toward a uni­fied anal cancer risk scale. Int J Cancer 2021;148(1):38-47. DOI: 10.1002/ijc.33185. 

6. Deshmukh AA, Suk R, Shiels MS, et al. Recent Trends in Squamous Cell Carcinoma of the Anus Incidence and Mortality in the United States, 2001-2015. J Natl Cancer Inst 2020;112(8):829-838. DOI: 10.1093/jnci/djz219. 

7. Touboul E, Schlienger M, Buffat L, et al. Epidermoid carci­noma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients. Cancer 1994;73(6):1569- 79. DOI: 10.1002/1097-0142(19940315)73:6<1569::aid-cncr2820730607>3.0.co;2-f. 

8. Slesser AA, Bhangu A, Bower M, Goldin R, Tekkis PP. A systematic review of anal squamous cell carcinoma in inflammatory bowel disease. Surg Oncol 2013;22(4):230- 7. DOI: 10.1016/j.suronc.2013.08.002. 

9. Segal JP, Askari A, Clark SK, Hart AL, Faiz OD. The Incidence and Prevalence of Human Papilloma Virus-associated Cancers in IBD. Inflamm Bowel Dis 2021;27(1):34-39. DOI: 10.1093/ibd/izaa035. 

10. Benson AB, Venook AP, Al-Hawary MM, et al. Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018;16(7):852-871. DOI: 10.6004/jnccn.2018.0060. 

11. Darragh TM, Colgan TJ, Thomas Cox J, et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013;32(1):76-115. DOI: 10.1097/PGP.0b013e31826916c7. 

12. Poynten IM, Jin F, Roberts JM, et al. The Natural History of Anal High-grade Squamous Intraepithelial Lesions in Gay and Bisexual Men. Clin Infect Dis 2021;72(5):853- 861. DOI: 10.1093/cid/ciaa166. 

13. Tong WW, Jin F, McHugh LC, et al. Progression to and spontaneous regression of high-grade anal squa­mous intraepithelial lesions in HIV-infected and unin­fected men. AIDS 2013;27(14):2233-43. DOI: 10.1097/ QAD.0b013e3283633111. 

14. Goldstone SE, Lensing SY, Stier EA, et al. A Randomized Clinical Trial of Infrared Coagulation Ablation Versus Active Monitoring of Intra-anal High-grade Dysplasia in Adults With Human Immunodeficiency Virus Infection: An AIDS Malignancy Consortium Trial. Clin Infect Dis 2019;68(7):1204-1212. DOI: 10.1093/cid/ciy615. 

15. Lin C, Franceschi S, Clifford GM. Human papillomavi­rus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. Lancet Infect Dis 2018;18(2):198-206. DOI: 10.1016/S1473-3099(17)30653-9. 

16. Svidler Lopez L, La Rosa L. Human Papilloma Virus Infection and Anal Squamous Intraepithelial Lesions. Clin Colon Rectal Surg 2019;32(5):347-357. DOI: 10.1055/s-0039-1687830. 

17. Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated anal can­cers in theUS. Cancer 2008;113(S10):2892-2900. DOI: https://doi.org/10.1002/cncr.23744.

18. Hicks CW, Wick EC, Leeds IL, et al. Patient Symptomatology in Anal Dysplasia. JAMA Surg 2015;150(6):563-9. DOI: 10.1001/jamasurg.2015.28. 

19. Barroso LF, Stier EA, Hillman R, Palefsky J. Anal Cancer Screening and Prevention: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infection Guidelines. Clin Infect Dis 2022;74(Suppl_2):S179-S192. DOI: 10.1093/cid/ciac044. 

20. Bejarano PA, Boutros M, Berho M. Anal Squamous Intraepithelial Neoplasia. Gastroenterology Clinics of North America 2013;42(4):893-912. DOI: https://doi. org/10.1016/j.gtc.2013.09.005. 

21. Goncalves JCN, Macedo ACL, Madeira K, et al. Accuracy of Anal Cytology for Diagnostic of Precursor Lesions of Anal Cancer: Systematic Review and Meta-analysis. Dis Colon Rectum 2019;62(1):112-120. DOI: 10.1097/DCR.0000000000001231. 

22. Cachay ER, Agmas W, Mathews WC. Relative accuracy of cervical and anal cytology for detection of high grade lesions by colposcope guided biopsy: a cut-point meta-analytic comparison. PLoS One 2012;7(7):e38956. DOI: 10.1371/journal.pone.0038956. 

23. Lam JO, Barnell GM, Merchant M, Ellis CG, Silverberg MJ. Acceptability of high-resolution anoscopy for anal cancer screening in HIV-infected patients. HIV Med 2018;19(10):716-723. DOI: 10.1111/hiv.12663. 

24. Davis KG, Orangio GR. Basic Science, Epidemiology, and Screening for Anal Intraepithelial Neoplasia and Its Relationship to Anal Squamous Cell Cancer. Clin Colon Rectal Surg 2018;31(6):368-378. DOI: 10.1055/s-0038- 1668107. 

25. Wei F, Gaisa MM, D’Souza G, et al. Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. Lancet HIV 2021;8(9):e531-e543. DOI: 10.1016/S2352-3018(21)00108-9. 

26. Shiels MS, Kreimer AR, Coghill AE, Darragh TM, Devesa SS. Anal Cancer Incidence in the United States, 1977-2011: Distinct Patterns by Histology and Behavior. Cancer Epidemiol Biomarkers Prev 2015;24(10):1548-56. DOI: 10.1158/1055-9965.EPI-15-0044. 

27. Jacot-Guillarmod M, Balaya V, Mathis J, et al. Women with Cervical High-Risk Human Papillomavirus: Be Aware of Your Anus! The ANGY Cross-Sectional Clinical Study. Cancers (Basel) 2022;14(20). DOI: 10.3390/cancers14205096. 

28. Ebisch RMF, Rutten DWE, IntHout J, et al. Long- Lasting Increased Risk of Human Papillomavirus- Related Carcinomas and Premalignancies After Cervical Intraepithelial Neoplasia Grade 3: A Population-Based Cohort Study. J Clin Oncol 2017;35(22):2542-2550. DOI: 10.1200/JCO.2016.71.4543. 

29. Hirsch BE, McGowan JP, Fine SM, et al. Screening for Anal Dysplasia and Cancer in Adults With HIV. Baltimore (MD)2022. 

30. Palefsky JM, Lee JY, Jay N, et al. Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. N Engl J Med 2022;386(24):2273-2282. DOI: 10.1056/NEJMoa2201048. 

31. Deshmukh AA, Chiao EY, Cantor SB, et al. Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effective­ness. Cancer 2017;123(23):4709-4719. DOI: 10.1002/ cncr.31035. 

32. Roelandt P, Droogne W, Voros G, Van Aelst L, Rega F, van Cleemput J. Are heart transplant recipients more at risk for anal squamous carcinoma than other solid organ transplant recipients? Int J Cancer 2022;151(1):156-157. DOI: 10.1002/ijc.33994. 

33. Petrosky E, Bocchini JA, Jr., Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory com­mittee on immunization practices. MMWR Morb Mortal Wkly Rep 2015;64(11):300-4. (https://www.ncbi.nlm. nih.gov/pubmed/25811679). 

34. Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis 2012;54(7):891-8. DOI: 10.1093/cid/cir1036. 

35. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2017;112(2):241-258. DOI: 10.1038/ajg.2016.537. 

36. Garland SM, Brotherton JML, Moscicki AB, et al. HPV vaccination of immunocompromised hosts. Papillomavirus Res 2017;4:35-38. DOI: 10.1016/j. pvr.2017.06.002. 

37. Waszczuk E, Waszczuk K, Bohdanowicz-Pawlak A, Florjanski J. Women with inflammatory bowel diseases have a suboptimal cervical cancer screening rate and are not aware of the recommended human papilloma virus vaccine. Gynecol Endocrinol 2018;34(8):656-658. DOI: 10.1080/09513590.2017.1416466.

Download Tables, Images & References

FUNDAMENTALS OF ERCP, SERIES #8

Stents…stents…stents! Biliary and Pancreatic Stents for ERCP!

Read Article

INTRODUCTION 

A large portion of the thousands of ERCP procedures performed the world over every day involve the placement of a stent in the bile ducts, the pancreatic ducts, or both. The clinical indications for stent placement can range from prevention of post-ERCP pancreatitis (PEP) to palliative decompression of the biliary system in cholangiocarcinoma patients. Depending on the clinical indication, the stent itself can be a permanent destination therapy to provide biliary decompression or a temporary therapy with multiple exchanges and up-sizing to help relieve the obstruction. Additionally, stents can be a very handy tool for a community gastroenterologist to 

 employ to help stabilize a patient, and act as a bridge while the patient awaits care with a senior therapeutic endoscopist at a tertiary referral center. Whatever the indication, the placement of a stent is, in general, a reliable, safe and easy modality. The ability to place a stent into the desired duct is a skill that every endoscopist who performs ERCP must master. 

Stents are small, thin, tubular tools made of biocompatible plastic, metal, or a combination thereof. The first stent placed via ERCP to provide biliary drainage was reported in 1980. The stent in this particular case was a plastic single-pigtail stent fashioned out of an angiography catheter.1 Although technically successful at relieving the obstruction, the stent ultimately migrated into the biliary tree. Following this, double-pigtail stents were designed to prevent migration out of the biliary tree to the duodenum or proximally into the bile ducts. Further innovations resulted in the creation of side flaps to keep stents in proper position without having to resort to pigtails, which can be cumbersome to deploy and remove at a later date. Theoretically, all stents provide drainage and ductal decompression, whether they are in the bile duct or the pancreatic duct. A “good” stent is one that is easy to deploy, with minimal risk of malfunction, and that is resistant to clogging by bacterial biofilm, stone or sludge particles, or enteric contents. 

This article will review the currently available biliary and pancreatic stents used in the context of ERCP, describing all types, subtypes, and permutations. We will also review the different roles for each of these stents and discuss the pros and cons of various stent designs. We will discuss stent deployment techniques, endoscopic requirements, and tools that help in stent placement. We will then share our experience with stent malfunctions and 

tips on troubleshooting if needed. Finally, we will talk about adverse events, stent patency duration and the need for repeat procedures. 

Plastic biliary stents 

Currently, multiple types of plastic stents (PS) are available commercially for use in ERCP. They come in various sizes, lengths, diameters and are made of different biocompatible plastic materials such as polyurethane, polyethylene and polytetrafluorethylene (Teflon). Polyethylene stents are the most common in current clinical practice. A comprehensive list of commercially available plastic biliary stents is summarized in Table 1. The manufacturers make a myriad of shapes including straight stents, stents with a duodenal bend, or a center bend to accommodate for the intraduodenal portion of the CBD, and with combinations of flaps or double pigtails to prevent stent migration. Proximal flaps prevent distal migration, distal flaps prevent proximal migration (somewhat counterintuitively). The multiple combinations of length, diameter, shape and flap helps the endoscopist to make an appropriate choice of stent for the patient on the procedure table. Commonly used diameters include 7, 8.5 and 10 Fr stents (1 Fr = 0.33 mm) with lengths ranging between 5 and 15 cm. (Figure 1)

The underlying clinical indication determines the utility of plastic stents, as they are limited by their fixed-diameter and durability. The size of the working channel of the duodenoscope limits the maximum size of plastic stent to 12 Fr (4 mm), although in practice most plastic biliary stents in common use do not exceed 10 Fr. The majority of the plastic stents occlude in about 50% of patients in a period of 4 to 6 months. Self-expanding metal stents (SEMS) overcome some of these limitations. Although initially used as a permanent therapy for palliative purposes in patients with malignant biliary strictures, SEMS are now increasingly being used for benign indications as well. 

Metal biliary stents 

In the past, biliary self-expanding metal stents were made of stainless steel. Today, majority of the commercially available biliary SEMS are made of a nickel-titanium alloy known as nitinol. Nitinol became popular owing to its superior biocompatibility and ‘thermal memory’ properties. Nitinol stent was initially developed by the U.S. Navy. Its ‘thermal memory’ property allows the stent to be made at a certain diameter, cooled and compressed onto a delivery system. When deployed, the nitinol mesh tends to expand back to its original shape when exposed to body heat, thereby providing excellent dilation and durability in the treatment of biliary strictures. 

Biliary SEMS are available as uncovered (UC-SEMS), partially covered (PC-SEMS) or fully covered (FC-SEMS) devices. (Figures 2 and 3) The covering membranes are made from various materials, the common ones being silicon, polyurethane or polytetrafluoroethylene. Table 2 summarizes the various commercially available uncovered biliary SEMS. Biliary SEMS have lengths ranging from 4 to 12 cm and diameters from 6 to 10 mm. The stents come mounted on a delivery system with diameters ranging from 5.0 to 10.5 Fr. A 0.035 diameter wire can usually be threaded into the system for placement into the biliary tree. 

All SEMS are highly visible on fluoroscopy and additionally, the delivery systems have radiographic markers at both ends to enable visualization of placement before deployment. Individual stent types may be more visible than others. The outer sheath of the system is transparent allowing for visualization of the distal end of the stent during release as a means of reducing the risk of mis-deployment. Some stents can be recaptured until 80% of their deployment has been achieved but others cannot be re-constrained at all i.e. Viabil stents. Some commercial brands have a ‘point of no return’ marker on the stent delivery system, beyond which re-constrainment can no longer be achieved. Some, but not all, PC-SEMS and FC-SEMS have flanges at the ends to prevent migration. Additionally, to aid removal these devices can have a string or a lasso or even a prominent metal strut at one of the ends, which can be pulled with any grasping forceps to collapse the stent and allow it to be removed in one piece. Table 3 and Table 4 summarize the commercially available PC-SEMS and FC-SEMS, respectively. 

Mechanical properties of biliary metal stents 

The mechanical properties of a metal stent are defined by the stent design, type of metal used, covering materials and the braid pattern. Clinical outcomes are primarily affected by the radial and axial forces exerted by the SEMS that result from a combination of these factors. The radial force determines the patency of the stent by counteracting the inward force of a stricture. The immediate expansion of a SEMS is usually partial after deployment. With time, usually a few days after deployment, the ‘shape memory’ of the metal alloy gradually expands the SEMS to its full capacity. In some SEMS, the axial force maintains conformability of the stent to the duct in which it is placed. 

FC-SEMS can be further classified into laser-cut and braided SEMS. Braided SEMS are also sometimes referred to as woven. Laser-cut FC-SEMS have larger cells and mesh as compared to the braided type and demonstrate minimal to no stent foreshortening due to lower axial forces. These features, by and large, enable accurate placement in the desired location. 

SEMS made out of biodegradable materials and FC-SEMS with chemotherapy drug eluting properties have long been being investigated for use in malignant biliary strictures, but have yet to come to market.2 Data for biodegradable biliary stents is limited at this time. In a single center retrospective analysis of adult patients who underwent percutaneous placement of biodegradable biliary stents for post-liver transplant biliary strictures, the patency rate was 80% (n = 12/15) at 12-months follow-up.3 A large, multicenter, prospective study from Spain demonstrated stent patency rates of 78.9% at 60-months follow up with percutaneous placement of biodegradable biliary stents for benign strictures. Only 12% (n = 18/40) needed a second stent placement.4 

SEMS with drug-eluting properties are not available for commercial use at this time. In drug-eluting stents, the stent covering is impregnated with therapeutic agents such as 5-fluorouracil, paclitaxil and gemcitabine with the goal of chemotherapy drug delivery at the tumor site. Theoretically, the idea underpinning a drug-eluting biliary stent is to prevent tumor in-growth in addition to local cancer treatment, but in practice this has been difficult to demonstrate. A meta-analysis of limited data demonstrated no added benefit of a drug eluting biliary metal stent as compared to covered SEMS.5 Biliary stents complexed with chemicals such as sodium cholate and EDTA (ethylenediaminetetraacetic acid) have been found to help dissolve biliary stones, but these are not commercially available.6

Clinical indications 

Common clinical situations where a stent is indicated in an ERCP procedure are as follows: 

benign and malignant bile duct strictures, chronic pancreatitis related bile duct strictures, post liver transplantation or surgery related post anastomotic strictures, bile leaks, bile duct stones with incomplete clearance or large duct stones that need endoscopic electro-hydraulic lithotripsy, post-sphincterotomy bleeding, and primary sclerosing cholangitis, among others. Common causes of malignant biliary obstruction include cholangiocarcinoma, pancreatic adenocarcinoma, ampullary carcinoma, metastatic disease to the liver, lymphadenopathy of porta hepatis nodes or metastatic disease. 

Stent choice

The clinical indication, cholangiogram findings and overall disease prognosis can help guide the endoscopist’s decision regarding a temporary or permanent stent requirement. Based on that, the decision for plastic or metal stents can be made. Theoretically, either a plastic stent or a metal stent can be used for palliation in patients with malignant biliary obstruction. A larger size plastic stent (10 Fr or above) provides better patency than smaller size (7 Fr or lower) for obvious reasons. A metal stent, on the other hand, is designed with a larger diameter with goals to achieve a longer duration of patency as compared to plastic stents, and can reduce the rate of re-interventions. In a large meta-analysis, SEMS and PS were comparable in the palliation of malignant biliary strictures; however, SEMS demonstrated longer stent patency, lower complications and fewer re-interventions.7

An uncovered SEMS is almost always used in the therapy of patients with malignant biliary strictures with the goal of palliation. UC-SEMS are associated with a lower rate of migration compared to a FC-SEMS. UC-SEMS are subject to tumor ingrowth and are, for all intents and purposes, permanent and not removable. (Figure 4 and Figure 5) Nevertheless, an UC-SEMS would be the ideal choice in situations where stenting is required across side branches, the cystic duct orifice in patients with an intact gallbladder, or in patients with cholangiocarcinoma in order to avoid blockage of the ducts being traversed. (Figure 6) 

FC-SEMS on the other hand, have demonstrated longer patency as compared to UC-SEMS. However, sludge formation and stent migration can occur with these devices. Newer FC-SEMS with anti-migration systems have been developed to limit stent migration events. The Hanaro M.I Tech stent has ‘anchoring flaps’ in the proximal end, flared ends to prevent migration; and comes with one proximal and one distal end lasso for easy retrieval. The Viabil stent system from Gore & Associates, Inc., has fully covered ‘anchoring fins’ that reduce the rate of migration and this device has a non-foreshortening design to enable precise stent placement. 

As mentioned earlier, FC-SEMS can be further classified into laser-cut and braided stents. Laser-cut FC-SEMS have larger cells and mesh as compared to the braided type and demonstrate minimal to no stent shortening due to lower axial force. These features promote easy and accurate placement in the desired location. However, laser-cut stents are generally uncovered and are difficult to remove in patients with recurrent malignant biliary obstruction. Data is limited as to the comparative efficacy of laser-cut FC-SEMS to braided FC-SEMS. In a retrospective study from Japan that assessed 47 patients (24 laser-cut stents and 23 braided), braided FC-SEMS demonstrated a longer time to recurrent biliary obstruction as compared to laser-cut FC-SEMS. Stent migration rates were comparable between the two.8 

Choosing a stent length 

The choice of length of the stent to be deployed is based on the assessment of the length of the stricture as seen on cholangiogram. Very often this assessment is based on the endoscopist’s experience. Ideal positioning of the stent should allow for drainage of bile from a location above the proximal end of a stricture. This can be achieved by positioning the stent at least 1-2 cm above the upper edge of the stricture as visualized on the fluoroscopy image and the intestinal end should extend at least 1cm into the duodenum. A given stent length usually reflects the entire length of the stent, however in some stent types this length might represent the portion between the flaps. The endoscopist should always check the information on the cover of the stent package before opening it to ensure proper understanding of the device being selected. 

Assessing the length of a stricture can be carried out in multiple ways. The endoscopist can use the initial cannulating catheter to gauge the length by measuring the distance from the top end of the stricture on the fluoroscopy image to just when the catheter tip is out of the papilla on the endoscopic view. During the entire process of the withdrawal, the endoscopist holds the cannulating catheter outside the biopsy port to measure the length or mark the cannulating catheter at the biopsy port before initiating the withdrawal. The radiograph length on the fluoroscopy can be used as well to assess the length, with the duodenoscope providing a ruler in each image. Some catheters have fluoroscopic markers to aid in the measurement of the length of a stricture. Dilation balloon catheters have radio-opaque markers which can be used to measure the length as well. In practice, many experienced endoscopists can “eyeball” the stenosis length with great accuracy without the aid of devices to measure it precisely. 

Delivery system and accessories 

A variety of stent delivery systems make the deployment process possible. Plastic stents <8.5 Fr can be placed directly over a guidewire and pushed into position using a pusher tube or with a sphincterotome, a balloon catheter, or other wire-guided devices. A key aspect in this technique is to be careful not to inadvertently push the stent fully into the bile duct, as pulling it back out into position would then require an additional modality such as using a ‘raptor’ or ‘rat-tooth’ forceps and can consume significant time. Using a guidewire helps provide rigidity to the stent and keeps it stable when being advanced across the stricture or above a stone. Once the stricture margins are defined by contrast injection following deep cannulation and wire insertion, the guidewire must be placed well proximal to the stricture into the bile ducts. More than one guidewire might be necessary based on the duct systems to be drained to achieve resolution of cholestasis. 

All standard duodenoscopes have a 4.2 mm working channel that can accommodate stents up to 11.5 Fr. A 3.7 mm operative channel can accommodate a PS up to 10 Fr. Usually, an 8.5 Fr stent can be placed without the need for sphincterotomy or stricture dilation. A 10 Fr stent may require sphincterotomy and/or stricture dilation. However, placing more than one stent would, in general, require sphincterotomy depending on the size of the native papilla. Similarly, dilation of the stricture might be needed to accommodate the stents being placed. When needed, stricture dilation can be achieved by various tools, such as a biliary dilation balloon or a Soehendra biliary dilation catheter. Rarely, a Soehendra stent retriever or a RFA (radiofrequency ablation) catheter can be used to open ‘dilation-resistant’ strictures. 

Stent placement Plastic stent placement 

Based on the stent delivery systems, either the inner guiding catheter alone or with the stent is advanced over the guidewire. Minimal resistance and easy passage should always be felt, and unwanted excessive pressure should be avoided while passing any stent system. The elevator must remain closed when advancing the stent system into the working channel. When the stent impacts the elevator, it is gently opened to reveal the tip of the stent system, and the stent and any delivery system is advanced over the guidewire into the papilla. A short endoscopic position is often helpful in maintaining a stable position. 

The stent is often advanced into position by repeated small ‘open close’ movements of the elevator with gentle stable push from the endoscopist. This is also sometimes referred to as “walking the stent up the duct.” This ensures small step-by-step advancement of the stent into the biliary duct. Once an optimal positioning is ascertained on the radiograph image, the inner guiding catheter and/or guidewire is then removed while the endoscopist maintains forward pressure for the stent to deploy in the right position. A post-placement radiograph image should be checked to ensure contrast medium drains through the stent and that image is often saved for documentation purposes. The final placement of a pigtail plastic stent differs slightly in that the duodenoscope has to be partially withdrawn to endoscopically visualize and make room for the intestinal pigtail segment to allow it to open up and curl into proper position. 

When placing multiple stents, it could be a useful strategy to place a slightly longer stent first to reduce the risk of proximal migration due to friction alongside the walls from the subsequent stent. Use of a sterile lubricant such as silicon spray can sometimes help reduce friction, but in practice is rarely needed. 

Metal stent placement 

The majority of the steps involved in metal biliary stent placement are similar to those used during the plastic stent deployment. In most cases, the release of a SEMS is performed under endoscopic and fluoroscopic guidance. Unlike a PS, the SEMS is constrained on the delivery system catheter by an outer plastic sheath or a string release mechanism. After the stent, constrained onto the delivery system, is advanced into the bile duct and the correct position is finalized over a guidewire, the outer sheath is gradually and carefully withdrawn. During the deployment process, the stent should be maintained at the correct position by maintaining a back-tension on the device, as it tends to move away from the endoscope and proximally into the duct if left unattended. If such proximal displacement occurs, the majority of SEMS can be recaptured as long as the deployment is up to 80% complete. Successful deployment of a biliary SEMS requires prior knowledge of the stent system, its foreshortening properties, and a good communication between the endoscopist and the technician to adjust and avoid mis-deployment before the stent can be recaptured. 

A final cholangiogram picture should be captured to check, confirm and document stent placement. Endoscopic and fluoroscopic images showing the passage of bile and contrast, respectively, can be used to confirm successful biliary drainage. If the SEMS has been deployed in an excessively proximal position, it can be pulled into position immediately after deployment with a snare or a rat-tooth grasping device and adjusted distally, even if it is an uncovered SEMS. In cases where the SEMS is deployed too distally, often hanging low into the lumen of the duodenum, the stent can either be removed and replaced with a new stent or, rarely, the excess luminal portion of the stent can be cut using argon plasma coagulation. In practice it is easier to adjust a SEMS into a more distal position than into a more proximal one. Excessive stent length in the duodenum can result in ulceration, bleeding and, rarely, perforation of the contralateral duodenal wall. 

Suprapapillary placement of a biliary SEMS is often warranted in patients with malignant proximal biliary strictures, involving the hepatic hilum or locations above. In these patients, the length of the SEMS might not be adequate to traverse the ampulla. Indeed, if the stricture is very proximal, there is often no reason to bridge the entire stent down to the duodenum. In these patients, the stent can be placed fully within the biliary tree. Such stents are referred to as “fully internalized” or “all internal” stents. In patients who have not undergone prior biliary sphincterotomy, fully internalized stents provide a theoretical advantage of preventing duodenal content reflux into the bile duct. In general, fully internalized stents can be accessed from below via ERCP on subsequent procedures, if required. 

Biliary drainage 

Knowledge about drainage holes on any given stent is paramount to achieve the best and sustained results of biliary decompression. The location of end holes and side holes must be taken into account. The drainage hole distribution is different in a straight PS with end flaps as compared to double pigtail plastic stent. Stents bearing the same brand name can differ based on the presence or absence of side drainage holes, such as the Viabil FC-SEMS. Challenging situations can arise when obstructions extend into multiple side branches of the bile ducts (as in Bismuth type 4 cholangiocarcinoma). More than one plastic stent might be needed in such situations to achieve adequate palliation. 

Distal biliary drainage 

Benign indications 

Distal biliary obstructions are one of the most straightforward clinical indications for stent placement. In situations of short, benign distal biliary strictures such as seen in chronic pancreatitis patients, post-sphincterotomy ampullary strictures or idiopathic cases, a 8.5-10 Fr, 5 cm PS would usually be ideal. Sometimes, multiple stents can be placed alongside to help dilate the ampulla. Data supports the placement of more than one wide bore PS, side-by-side, to achieve best clinical outcomes as compared to one 10 Fr PS. This strategy demonstrated excellent effectiveness (80% to 90%) in the treatment of postoperative biliary strictures.9 In modern practice, the idea of placing multiple PS in a side-by-side manner has mostly given way to the placement of a single FC-SEMS for ease of placement and simplicity. In cases of irretrievable bile duct stones, plastic pigtail stents are usually better suited than straight plastic stents for maintaining drainage over the long term. An important limitation when PS are used is the need to undergo multiple ERCP procedures for stent exchange. In vitro studies exist that have analyzed stents that elute chemicals like sodium cholate and EDTA with goals of dissolving biliary stones.2

These stents are still experimental and are not commercially available. 

The placement of a FC-SEMS instead of multiple PS can reduce the number of repeat ERCPs needed for stent exchange. A meta-analysis of eight RCTs comparing covered SEMS to multiple PS in benign biliary strictures, demonstrated comparable stricture resolution rate (risk ratio = 1.02, 0.96- 1.1) and stricture recurrence rate (risk ratio = 1.68, 0.72-3.88). However, the mean number of ERCPs was significantly lower with covered SEMS.10 The FC-SEMS were left in-situ for 10-12 months in chronic pancreatitis patients and 4 to 6 months in post liver-transplant patients.10 The Wallflex RMV stent by Boston Scientific is approved by US FDA for an indwell time of 12-months in the treatment of biliary strictures secondary to chronic pancreatitis. 

Although SEMS are more expensive than PS, the overall lesser number of repeat ERCP procedures with SEMS as compared to PS seems to offset the overall cost. Covered SEMS are avoided by some endoscopists if the gallbladder is still present to avoid potential cystic duct occlusion and the risk of cholecystitis. If unavoidable, a small plastic stent can be placed inside the cystic duct prior to placing a FC-SEMS in the CBD, but in practice this is rarely performed. Similarly, acute pancreatitis secondary to pancreatic duct obstruction is also reported when FC-SEMS are used. Nonetheless, FC-SEMS are widely used in patients with and without an intact gallbladder in current clinical practice. 

Malignant indications 

Data thus far have demonstrated comparable clinical outcomes in terms of technical and therapeutic success rates, mortality and overall adverse events between SEMS and PS in patients with malignant biliary obstruction.7 A meta-analysis of twelve studies reported superior performance of covered SEMS as compared to UC-SEMS in prevention of recurrent biliary obstruction in patients with malignant distal biliary obstruction. The pooled mean difference was 45.51 days (11.79-79.24) longer with a covered SEMS. However, rates of stent migration, sludge formation and tissue overgrowth were higher with covered SEMS and tissue ingrowth was noted more frequently in patients receiving UC-SEMS.11 Data comparing PC-SEMS and FC-SEMS are limited. PC-SEMS might have better clinical performance in terms of time to recurrent biliary obstruction secondary to malignancy. In a retrospective study of 101 patients who received SEMS for unresectable malignant distal biliary obstruction (44 UC-SEMS, 28 PC-SEMS, 29 FC-SEMS), no survival differences were noted, however median time to recurrent biliary obstruction was 199 days, 444 days & 194 days respectively with UC-SEMS, PC-SEMS and FC-SEMS.12 

Proximal biliary obstruction 

Patients presenting with cholestasis secondary to hilar or more proximal biliary obstruction can present interesting challenges for successful stent placement. Cross-sectional imaging with CT or MRI is generally obtained and reviewed prior to planning the procedure to ascertain the anatomy and plan the modality of stent placement. 

Many patients with proximal biliary obstruction warrant consideration of bilateral stent placement. Biliary drainage in these patients is technically challenging even for experienced endoscopists, as there is often very little room for stents to fit at a hilum already crowded via tumor. Bilateral drainage can be achieved by either a ‘side-by-side’ stent insertion or a ‘stent-in-stent’ technique. To achieve this, two or more guidewires are placed inside the biliary systems to be drained, followed by placement of equal sized or one big and one small caliber plastic stents depending on the intra-procedure situation. 

SEMS can also be used to treat hilar obstruction, usually in patients with unresectable disease. Bilateral SEMS placement is also technically challenging and complicated by the self-expanding nature of these devices. I.e., the first stent may take up more than its “share” of the room at the hilum, and the placement of the second SEMS is often more difficult than the first. In the ‘stent-in-stent’ technique, a balloon dilation is performed through the meshes of the first stent followed by placement of the second stent through the widened mesh, if needed. Some SEMS come designed with large diameter mesh cells to facilitate deployment of the second SEMS. Niti-S (Taewoong Medical, South Korea) and Flexxus (ConMed, California, USA) have large mesh areas to allow passage of a second SEMS. Additionally, smaller stent delivery introducers like the 6 Fr introducer, Zilver 635 (Cook Medical, Bloomington, Indiana, USA); can come very handy. 

Post-procedure cholangitis is a risk if both lobes of the liver are opacified with contrast and liver segments are not fully drained via stent placement. Contrast injection is often kept to a minimum to avoid bacterial seeding into the obstructed/non-draining portions of the intrahepatic ducts. Drainage of both lobes of the liver is usually recommended. However, in a multicenter, international retrospective study, bilateral stent placement was associated with higher risk of death and adverse events in the treatment of cholangiocarcinoma.13 Therefore, the issue is not decided. Selective drainage of specific liver areas can be planned and performed based on preprocedural review of MRCP images. Sometimes, additional percutaneous biliary drainage might be needed to achieve adequate decompression of the obstructed areas. 

Preoperative stent placement 

In preoperative patients, a Monte Carlo decision analysis study and a meta-analysis of five studies that compared SEMS to PS, concluded that in patients with resectable distal pancreaticobiliary cancer, the placement of a short-length UC-SEMS provided equal or superior efficacy and reduced overall cost as compared to PS placement. An infra-hilar placement of a 4 to 6 cm SEMS should be considered on a patient-by-patient basis before anticipated resection.14,15 In clinical practice, this approach is widely used. 

Adverse events 

Post-ERCP pancreatitis is more often related to the ERCP procedure per se than to the stent itself. Data seems to suggest that sphincterotomy is not protective against post-ERCP pancreatitis before placing a stent in patients with distal biliary obstruction. On the contrary, in patients with biliary leak, sphincterotomy demonstrated risk reduction in prevention of post-ERCP pancreatitis.16 Immediate adverse events related to stent placement include device related issues, including failure to deploy and malpositioning. Failure to adequately lubricate the delivery device channels can, on rare occasions, cause arrested withdrawal of the outer sheath resulting in deployment failure and/or a misplaced stent. 

Other adverse events related to stent placement can include cholangitis, hemobilia and bile duct or luminal perforation. Ineffective drainage of segments opacified during cholangiogram can lead to cholangitis. Persistent cholangitis despite antibiotics can warrant a repeat procedure. Stent placement in a patient with a friable tumor can cause hemobilia. Retrieval of blood clot might sometimes be necessary if causing clinically significant cholestasis. However, the majority of hemobilia usually self resolves without causing any clinically significant issues. A malpositioned stent can cause ulceration, perforation and bleeding of the contralateral duodenal wall. 

Commonly reported stent-related late adverse events are migration and occlusion. Tumor ingrowth, biliary sludge, biofilm formation, cell hyperplasia and food-bezoar are common causes for stent occlusion. Migration is more common with FC-SEMS and cholecystitis can occur with FC-SEMS in patients with intact gallbladder as previously mentioned. 

Pancreatic duct stents 

Pancreatic duct (PD) stents are usually plastic stents of small caliber. Usually, 3 to 7 Fr in terms of size. The stent diameter size is chosen based on the clinical indication. 3 to 5 Fr are usually used for prevention of post-ERCP pancreatitis in high-risk patients, with 5 Fr being the most commonly employed. The goal is for the stent to aid in pancreatic fluid drainage and provide pancreatic duct decompression. A 5 Fr x 5 cm unflanged pancreatic duct stent is usually ideal to prevent post-ERCP pancreatitis, but individual opinions on stents vary and many options are available. Various commercially available pancreatic duct stents are summarized in Table 5. Pancreatic stents are available as straight stents, single pigtails, double pigtails, and with or without internal and/ or external flaps. 

In addition to end drainage holes, all pancreatic duct stents come with multiple side holes to aid drainage of secretions via pancreatic side-branches. Stents with anti-migration side flaps are used when spontaneous stent passage is undesirable such as in patients with chronic pancreatitis induced PD strictures, pancreatic duct stones, etc. A stent without internal flaps is popular for prophylaxis of post-ERCP pancreatitis as it can spontaneously pass in a few days after placement, while others prefer stents with internal flaps that need to be retrieved at a later date to ensure that the stent does not migrate, which may produce a superior effect when reducing post-ERCP pancreatitis rates. (Figure 7) 

Placement of a pancreatic duct stent involves a guidewire into the pancreatic duct to a point deep enough that the wire is stable. This is usually performed when the site of pathology is identified on pancreatogram, i.e., a stricture. The pancreatic duct stents are passed over the guidewire, generally without an inner guiding catheter/delivery system as they are often not needed. A pusher tube or similar device such as standard catheter, balloon catheter or the sphincterotome can be used to push most pancreatic stents into position. Dilation of the lesion can be performed if necessary prior to stent placement. With the pusher catheter in position, the guidewire is removed, and the stent is left in place after the pusher catheter is withdrawn. 

The Taewoong Medical, Bumpy – Niti – S stent is a SEMS designed for drainage of the main pancreatic duct. It has an atypical mesh design with irregular cell sizes that exert different radial forces in different sections of the stent. Owing to this property, the stent does not completely compress and occlude the PD side branches. Other FC-SEMS can be used off-label with good results; however, the size, length and drainage holes should be considered for effective clinical outcomes. To enable smooth placement, pre-dilation of the PD stricture is sometimes helpful, which can be usually achieved with a small sized balloon such as the Hurricane 4 mm by 4 mm balloon. 

Placing a short, small caliber pancreatic duct stent can be risky for inadvertent deep placement. An inward migrated pancreatic duct stent can be very difficult to retrieve. Maneuvers to try and retrieve the stent can result in further distal displacement into a side branch or to the pancreatic tail. A single pigtail stent with the pigtail in the duodenum is available in such situations and in situations where deep pancreatic duct drainage is warranted such as in cases with pancreatic leak in the distal body or tail of the pancreas, or a disconnected duct, although even stents with external pigtails can migrate proximally. Proximally migrated pancreatic duct stents can be difficult to remove and often require significant interventions. 

Future directions 

The 1980s witnessed the introduction of SEMS for the treatment of biliary obstruction in the context of ERCP. Bare metal SEMS paved the way for partially covered and fully covered metal stents with various biocompatible polymer coatings to prevent tissue ingrowth. Multiple sizes and shapes of SEMS are being investigated with goals of easy delivery, reduced rates of migration and enhanced durability. 

Biodegradable biliary stents and drug eluting biliary stents might gather increasing attention over the next many years. A fully biodegradable helical structured biliary stent ARCHIMEDES developed by Q3 Medical Devices Ltd., has obtained CE certification in 2018. Studies have evaluated the clinical outcomes of PDX biliary stent made by ELLA-CS, Hradec Kralove, Czech Republic. Effectiveness and safety have been demonstrated in the treatment of benign biliary strictures secondary to liver transplantation.2 These biliary stents have been designed with three rates of degradation (fast, medium, and slow) to meet patients’ needs based on the clinical condition being treated. 

Research is underway on inventing the best possible biodegradable polymer that can withstand as well as be compatible with pancreatico-biliary enzymes. Biodegradable magnesium alloys have been considered potential options after their excellent performance in the cardiovascular field. UNITY-B developed by Q3 Medical Devices Ltd., is one such magnesium based biodegradable stent developed for use in biliary strictures that has obtained CE certification. 

As with drug eluting SEMS, drug eluting biodegradable biliary stent is another area of exciting research. Multiple chemotherapeutic drugs are being investigated with various biodegradable polymers. Studies at this time are limited to in-vitro porcine models. Innovative stents designed using 3-Dprinting technology and made by tissue engineering approach, with goals of customizing it to individual patient anatomy, sounds more exciting than ever.2 

In conclusion, placement of a biliary and/or pancreatic stent is an integral skill to know and master in ERCP procedures. Multiple stent types exist with a myriad of shapes, sizes, lengths, anti-migration flaps, and drainage holes for the endoscopist to choose from. The choice of stent should be based on the clinical indication, underlying pathology, cholangiogram findings and anticipation of repeat procedures. Although the stent systems are manufactured with easy-to-use standard mechanisms, subtle nuances in the deployment process of certain stents must be taken into account, and measures should be taken to avoid deployment complications. 

References 

  1. Soehendra N, Reynders-Frederix V. Palliative bile duct drainage-a new endoscopic method of introducing a transpapillary drain. Endoscopy 1980;12:8-11. 
  2. Song G, Zhao HQ, Liu Q, et al. A review on biodegrad­able biliary stents: materials and future trends. Bioactive Materials 2022;17:488-495. 
  3. Abulqasim S, Arabi M, Almasar K, et al. Percutaneous Transhepatic Biodegradable Biliary Stent Placement for Benign Biliary Strictures. Digestive Disease Interventions 2021;5:307-310. 
  4. De Gregorio MA, Criado E, Guirola JA, et al. Absorbable stents for treatment of benign biliary strictures: long-term follow-up in the prospective Spanish registry. Eur Radiol 2020;30:4486-4495. 
  5. Mohan BP, Canakis A, Khan SR, et al. Drug Eluting Versus Covered Metal Stents in Malignant Biliary Strictures-Is There a Clinical Benefit?: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2021;55:271-277. 
  6. Huang C, Cai X-B, Guo L-L, et al. Drug-eluting fully covered self-expanding metal stent for dissolution of bile duct stones in vitro. World Journal of Gastroenterology 2019;25:3370. 
  7. Almadi MA, Barkun A, Martel M. Plastic vs. Self- Expandable Metal Stents for Palliation in Malignant Biliary Obstruction: A Series of Meta-Analyses. Am J Gastroenterol 2017;112:260-273. 
  8. Kitagawa K, Mitoro A, Ozutsumi T, et al. Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study. Clin Endosc 2022;55:434-442. 
  9. Costamagna G, Pandolfi M, Mutignani M, et al. Long-term results of endoscopic management of postoperative bile duct strictures with increasing numbers of stents. Gastrointest Endosc 2001;54:162-168. 
  10. Kamal F, Ali Khan M, Lee-Smith W, et al. Metal versus plastic stents in the management of benign biliary stric­tures: systematic review and meta-analysis of randomized controlled trials. European journal of gastroenterology & hepatology 2022;34:478-487. 
  11. Yamashita Y, Tachikawa A, Shimokawa T, et al. Covered versus uncovered metal stent for endoscopic drainage of a malignant distal biliary obstruction: Meta-analysis. Digestive Endoscopy 2022;34:938-951. 
  12. Yokota Y, Fukasawa M, Takano S, et al. Partially covered metal stents have longer patency than uncovered and fully covered metal stents in the management of distal malignant biliary obstruction: a retrospective study. BMC gastroenterology 2017;17:1-10. 
  13. Staub J, Siddiqui A, Murphy M, et al. Unilateral ver­sus bilateral hilar stents for the treatment of cholan­giocarcinoma: a multicenter international study. Ann Gastroenterol. 2020 Mar-Apr;33(2):202-209. 
  14. Chen VK, Arguedas MR, Baron TH. Expandable metal biliary stents before pancreaticoduodenectomy for pan­creatic cancer: a Monte-Carlo decision analysis. Clinical Gastroenterology and Hepatology 2005;3:1229-1237. 
  15. Crippa S, Cirocchi R, Partelli S, et al. Systematic review and meta-analysis of metal versus plastic stents for pre­operative biliary drainage in resectable periampullary or pancreatic head tumors. European Journal of Surgical Oncology (EJSO) 2016;42:1278-1285. 
  16. Sofi AA, Nawras A, Alaradi OH, et al. Does endo­scopic sphincterotomy reduce the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis after biliary stenting? A systematic review and meta-analysis. Digestive Endoscopy 2016;28:394-404. 

Babu P. Mohan MDDouglas G. Adler MD2

1Orlando Gastroenterology PA, Orlando, FL

2Gastroenterology, Center for Advanced Therapeutic

Endoscopy, Centura Health, Denver, CO

Download Tables, Images & References

MEDICAL BULLETIN BOARD

Young Adult Population-Hepatitis Viruses Main Target

Concerned about the alarming increase in hepatitis infections among the country’s vulnerable young adult population, LHI has teamed up with John Parkinson, Assistant Managing Editor at Contagion Live to arm teens and their caregivers with information needed to understand why and how to protect their life supporting liver that is under attack by hepatitis A, B, and C. Attached is a link to a brief article called Talking to Teens About Hepatitis that explains a few of the basics about the viruses and how they invade our bodies and make their way to our amazing liver. Once there they attack its millions of microscopic miracle-performing liver cells that convert the food we ingest into hundreds of life creating and sustaining body parts and functions 24/7, turning them into scar tissue called cirrhosis. 

Visit contagionlive.com/view/talking-to-teens-about-hepatitis to pick up some tips on talking to your kids.

 Two teens share their “take” on the information provided in a video called Give Your Liver a Break, encouraging their peers to avoid the tragic consequences of “ignorance” about the liver and how sneaky invisible hepatitis viruses can invade their bodies and cause havoc to their internal life supporting chemical refinery, their amazing miracle working liver. View the award winning video on LHI’s website at Liver-health.org.

Six teens involved in a community Substance Abuse Prevention program reaching out to their peers calling attention to the hazards of misuse and abuse of drugs and alcohol attended a brief zoom meeting to learn about their body’s mysterious life creating liver cells (quazi computer chips) that they take for granted every day. Obviously, they were surprised to learn about the hundreds of amazing life creating and sustaining tasks their amazing microscopic liver cells perform 24/7. To empower them to share what they learned, we share personalized, understandable, relatable and even entertaining descriptions of some of the liver’s daily miracles that keep our bodies functioning non stop. The key to their success is sharing what they have learned. 

Learn more about the successes we have had providing 20–30 minute zoom training sessions for various age groups from teens to seniors, empowering them to protect themselves and to share information learned with others. Understanding how to protect the liver SAVES LIVES. 

Effective teaching tools are available. Just give us a call: 

Thelma King Thiel, Chair 

Phone: 301-625-9076 

Email: livrlady@gmail.com 

Website: liver-health.org 

Twitter: @the_liver_lady

Download Tables, Images & References

NUTRITION REVIEWS IN GASTROENTEROLOGY, SERIES #5

Superior Mesenteric Artery Syndrome: A Nutrition-Oriented Review

Read Article

Superior mesenteric artery syndrome, a rare condition, is the result of duodenal compression between the aorta and the superior mesenteric artery. This compression is caused by decreased mesenteric fat tissue or abnormal anatomy leading to a narrowed aortomesenteric angle and ultimately duodenal compression. Patients can present with abdominal pain, lack of appetite, nausea, vomiting, and unintentional weight loss. The syndrome is a diagnosis of exclusion and as such, is often overlooked. An upper gastrointestinal series is typically used for diagnosis, however, computed tomography angiography can solidify the diagnosis. Generally, treatment requires weight gain with surgery only if conservative measures fail. This review will describe the syndrome, diagnostic criteria, and treatment options including medical nutrition therapy.

INTRODUCTION 

Superior mesenteric artery (SMA) syndrome is a rare condition also known as duodenal ileus, aortomesenteric artery compression, Cast syndrome, Wilkie’s disease, and duodenal arterial mesenteric compression. The syndrome was originally described by Rotikansky in 1842 when he completed autopsies of thin young women with history of abdominal pain and emesis.1 Wilkie published his comprehensive case series and detailed the pathophysiology and diagnostic findings of the syndrome in 1921.2 SMA syndrome is characterized by compression of the third segment of the duodenum due to reduced space between the SMA and aorta.3 

SMA syndrome occurs either from a congenital anomaly in children or a significant, unintentional weight loss in adults, predominantly affecting young women, with the majority of patients between the ages of 10-39 years.4,5 The incidence of SMA syndrome is reported as 0.013%-0.3% in the general population, 0.3% in hospitalized patients, 1.1% in burn patients, and 4.9% in patients with unexplained abdominal pain.6 The diagnosis can be somewhat challenging and may take many years to diagnose in patients with nonspecific symptoms that do not correlate with duodenal compression nor resolve with empiric treatments.4 Most often SMA syndrome is treated conservatively with weight gain in order to expand the mesenteric fat mass to relieve the obstruction. The purpose of this review is to describe the syndrome’s pathophysiology, etiology, presentation, diagnostic criteria, and treatment with a special focus on nutrition therapy. 

Pathophysiology

Normally, the duodenum crosses the abdomen anterior to the aorta at the level of the third lumbar vertebral body, suspended by the ligament of Treitz, and passes between the aorta and the SMA.7 The SMA arises from the anterior abdominal aorta, behind the body of the pancreas at the level of the first lumbar vertebral body, adjacent to the origin of the celiac trunk. The SMA runs inferiorly, forming a small arch to the right with its convexity to the left, crossing over the third part of the duodenum (see Figure 1). Together, the SMA and the aorta form an acute aortomesenteric angle (AMA) that the third portion of the duodenum passes through. The AMA is normally between 25º–60º, is related to the retroperitoneal fat tissue which holds the SMA off the spine, and is correlated with the patient’s body mass index (BMI).2,8 The aortomesenteric distance (AMD), defined as the length between the aorta and SMA, is typically 10-28 millimeters.8 Irrespective of the inciting disorder, reduction of the AMA to < 25º and the AMD to < 8-10 millimeters raises the risk of duodenal pinching and small bowel obstruction (SBO).9-11  predisposing patients for weight loss and SMA syndrome are broadly stratified into two categories: loss of mesenteric fat tissue and abnormal anatomy (Table 1). In healthy adolescents, SMA syndrome is reported after inadequate weight gain relative to height growth, causing duodenal compression without weight loss but decreased BMI.12 Abnormal anatomy is generally seen as congenital anomalies in children and post-surgical alterations in adults. 

Symptoms 

Symptoms of SMA syndrome are often attributed to limited flow of chyme through the duodenum. It may present acutely or progressively over time. The severity of symptoms ranges from mild postprandial discomfort to bilious emesis and weight loss depending on the degree of the compression. Acute presentations often occur in post-surgical cases due to overextension of the SMA.13 Progressive cases are more likely seen when patients have epigastric pain, nausea, and/ or weight loss.14 Patients with chronic symptoms of SMA syndrome may anticipate postprandial discomfort and develop aversions to food, perpetuating further weight and mesenteric fat tissue losses. 

Establishing the Diagnosis 

The diagnosis of SMA syndrome is often a diagnosis of exclusion since the symptoms can be nonspecific and mimic other gastrointestinal (GI) and non-GI disorders. Clinical symptoms alongside imaging studies are used to diagnose the disorder. Common physical examination findings are listed in Table 2.15 Laboratory values are usually normal, with the exception of patients with severe vomiting and dehydration who present with significant electrolyte abnormalities such as metabolic alkalosis or hypokalemia. Delay in diagnosis results in continuation of duodenal compression, discomfort, weight loss, malnutrition, electrolyte abnormalities, gastric dilation and perforation, peptic ulcer disease, pancreatitis, and even death.6 

Diagnostic Testing 

The vague and nonspecific symptoms of SMA syndrome often lead to inconclusive diagnostic testing. The radiologic tests most sensitive for SMA syndrome are upper gastrointestinal series (UGI) and computed tomography angiography (CTA) as depicted in Figures 2-4.6 Table 3 describes the usual findings from both UGI and CTA testing. 

An upper GI series can demonstrate prolonged retention of barium proximal to the third portion of duodenum, dilation of the duodenum and stomach, and backward flow of contrast from reverse peristalsis (known as “to and fro” peristalsis). Postural changes during an upper GI study can demonstrate changes in vascular compression of the duodenum; obstruction is typically greatest

Etiology 

SMA syndrome in adults is most often a consequence of significant weight loss related to an underlying disorder. The various disorders in the supine position and improved in the prone and left lateral decubitus position.16 An UGI series allows for real-time evaluation by the radiologist to administer proper test maneuvers and evaluate the flow of contrast through the duodenum for an accurate diagnosis of SMA syndrome (Figure 3). 

CTA using a three-dimensional technique provides a precise method for measurement of the aortomesenteric angle and distance. CTA may demonstrate narrowed AMA, decreased AMD, and dilated duodenum and stomach to secure the diagnosis of SMA syndrome.17,18 An advantage of CTA is that it can shed light on SMA etiologies and preexisting anatomical conditions (Figures 3,4).19 

Upper endoscopy can be useful for differentiating SMA syndrome from other etiologies.15 It does not serve as a diagnostic tool but should trigger a workup to confirm the diagnosis. Endoscopic ultrasound (EUS) has been used to diagnose SMA syndrome. The ultrasound probe allows for identification of the anatomical cause of the obstruction, and in some cases may be used to perform a minimally invasive bypass of the obstruction. 

Treatment and Management 

The fundamental treatment of SMA syndrome aims to provide symptom relief, treat and manage the underlying disorder, weight restoration, and/ or pursue surgery if weight gain is not successful. Surgical procedures should only be utilized when conservative measures fail or for anatomical reconstruction. There are no protocols or guidelines regarding the duration of conservative management nor optimal timing of surgery after failure; symptomatic improvements are observed within a few days or may take as long as a few months.6 Nevertheless, whether managed conservatively or surgically, a multidisciplinary team approach is beneficial including gastroenterologists, dietitians, radiologists, and psychiatrists is cardinal to ensure the patient’s well-being and quality of care. 

Nutrition Therapy 

Nutrition assessment of patients with SMA syndrome includes: diet recall, weight history, anthropometric evaluation, biochemical data, and physical examination to assess for fat mass loss, muscle mass loss, fluid status, and signs of micronutrient deficiencies. First, the best route of feeding must be determined (Table 4). Many patients with SMA are not only at risk of refeeding syndrome, but also Wernicke’s encephalopathy if emesis has been an ongoing issue. Once past the refeeding stage, energy needs to support weight restoration should be determined. Medical nutrition therapy (MNT) requires a calorie surplus to promote anabolism and fat mass expansion in the epigastric area to alleviate obstructive symptoms. Depending on the patient’s weight history and anthropometric data, full recovery of lost weight is not always necessary, as small gains may be sufficient for symptomatic relief.20 

The gold standard for measuring energy expenditure in the clinical setting is indirect calorimetry, which is particularly useful for underweight or malnourished patients as predictive equations are less accurate for patients with abnormal body composition.21 If indirect calorimetry is available to measure resting energy expenditure (REE), this value is then multiplied by an activity factor. When indirect calorimetry is unavailable, using 30 kilocalories/kilogram or a predictive equation may best approximate REE, which is bolstered by multiplying by activity and stress factors or adding a fixed amount of additional kilocalories.21,22 

Case reports of MNT for SMA syndrome are heterogeneous; therefore, clear MNT guidelines have not been established. For example, management with a dense (4 kcal/mL), low-volume formula was effective in an 83-year-old male suffering from post-operative SMA when given in small doses orally.20 In a 16-year-old female with anorexia nervosa, providing half of the needed calories through a nasojejunal tube to supplement oral intake was beneficial for weight gain.23 Some patients may be unable to tolerate adequate oral intake despite their efforts,24 others may be able to tolerate enteral nutrition (EN) with proper tube placement that takes gastrointestinal anatomy and function into account,25 and others are unable to tolerate parenteral nutrition (PN) due to fluid overload or hepatotoxicity.26 Successful weight restoration is possible via oral, enteral, or parenteral routes, but often requires a combination of modalities. Clinicians must use judgement to apply interventions based upon the etiology of the compression and weigh the risks and benefits of treatment plans for each individual patient. 

Patients with SMA syndrome may best tolerate small frequent meals. Liquids will be easiest to pass through the compressed area; high-calorie, high-protein liquids should be encouraged to optimize oral intake.20 Positional maneuvers can provide symptomatic relief by removing tension from the mesentery and increasing the AMD. Lying prone or on the left side postprandially and using prokinetics or antiemetics may improve tolerance to oral intake.27 

If oral feeding fails, the enteral route should be pursued next. Endoscopic tube placement beyond the duodenal compression is useful for both diagnostic and therapeutic purposes.26 For a short-term trial, a temporary nasojejunal tube may be placed. If EN is tolerated and the anticipated need exceeds one month, then more permanent enteral access such as a gastrostomy tube with a jejunal extender or a direct jejunostomy tube may be required. If EN is poorly tolerated or fails to improve symptoms, then PN should be utilized. Parenteral support can be used in the short term until there is enough weight gain to allow for tolerance to oral intake, after which it is best to combine PN with oral intake or EN to provide adequate calories, expedite weight restoration, and minimize complications.26 

Many patients with SMA syndrome presenting with intolerance of oral intake and weight loss meet malnutrition criteria. When initiating EN or PN support in a malnourished patient, it is prudent to take precautions against and monitor symptoms of refeeding syndrome. This is accomplished by “starting low and going slow” with general guidelines to initiate nutrition with 50-150 grams carbohydrates, or 10-20 kilocalories/kilogram, and advance by 33% of goal every 1-2 days. While advancing nutrition support, potassium, phosphorus, and magnesium levels should be monitored every 12 hours for repletion as needed. Given the high risk for refeeding syndrome in those with SMA syndrome, it is recommended to supplement with 100 mg thiamin supplementation for 5-7 days in addition to a therapeutic vitamin with mineral supplement until full nutrition support is achieved.28 

Nutritional restoration is frequently met with physical and psychological challenges that impact resolution of SMA syndrome. Table 5 lists clinical conditions associated with SMA syndrome and suggested nutrition interventions to prevent or reduce the likelihood of mesenteric fat tissue loss. Collaboration of care with a registered dietitian will help patients achieve their nutrition therapy goals, with timely adjustments to the nutrition care plan for optimal recovery from catabolic illnesses and reduced sequela of malnutrition. 

CONCLUSION 

SMA syndrome is associated with a significant, unintentional weight loss in a wide range of predisposing clinical settings. The syndrome is characterized by compression of the third portion of the duodenum resulting in unexplained postprandial abdominal pain, anorexia, nausea, vomiting, or weight loss. When suspecting SMA syndrome, clinicians should begin with an upper GI series for evaluation and assessment of an obstruction. CTA with oral contrast can solidify the diagnosis and offer information about the underlying etiology of obstruction. Initial treatment is conservative and focuses on weight gain. Surgery may be required if medical management fails or there are predisposing factors such as abnormal anatomy. Employing a multidisciplinary team is imperative for successful treatment of SMA syndrome.

References 

1. Rokitansky, C., Handbuch der pathologischen Anatomie 1st Ed. Vienna Branmuller and Seidel, 1842. 3: p. 187. 

2. Wilkie D. Chronic duodenal ileus. Br J Surg. 1921;201:254. 

3. Diab S, Hayek F. Combined superior mesenteric artery syndrome and nutcracker syndrome in a young patient: a case report and review of the literature. Am J Case Reports. 2020;21: e922619-1. 

4. Jain R. Superior mesenteric artery syndrome. Curr Treatm Opt Gastroenterolo. 2007; 10(1):24-27. 

5. Ganss A, Rampado S, Savarino E, et al., Superior mes¬enteric artery syndrome: a prospective study in a single institution. J Gastro Surg. 2019;23(5):997-1005. 

6. Welsch T, Büchler MW, Kienle P, Recalling superior mes¬enteric artery syndrome. Dig surg. 2007;24(3):149-156. 

7. Akin JT, Gray SW, Skandalakis JE, Vascular compression of the duodenum: presentation of ten cases and review of the literature. Surg. 1976;79(5):515-522. 

8. Ozkurt H, Cenker MM, Bas N, et al., Measurement of the distance and angle between the aorta and superior mes¬enteric artery: normal values in different BMI categories. Surg and Radiol Ana. 2007;29(7):595-599. 

9. Neri S, Signorelli SS, Mondati E, et al. Ultrasound imag¬ing in diagnosis of superior mesenteric artery syndrome. J Intern Med. 2005;257(4):346-351. 

10. Hines JR., Gore RM, Ballantyne GH, Superior mesen¬teric artery syndrome: diagnostic criteria and therapeutic approaches. Am J Surg. 1984;148(5): p. 630-632. 

11. Baltazar U, Dunn J, Floresguerra C, et al., Superior mes¬enteric artery syndrome: an uncommon cause of intestinal obstruction.SMJ. 2000;93(6):606-608. 

12. Okamoto T, Sato T, Sasaki Y. Superior mesenteric artery syndrome in a healthy active adolescent. BMJ Case Reports CP. 2019;12(8):e228758. 

13. Payawal JH, Cohen AJ, Stamos MJ, Superior mesenteric artery syndrome involving the duodenum and jejunum. Emerg Radiol. 2004;10(5):273-275. 

14. Hokama A, Tomiyama R, Kishimoto K, et al. Chronic intermittent vomiting after scoliosis surgery. Gut. 2005;54(2):222.

15. Sinagra E, Raimondo D, Albano D., et al. Superior mesen¬teric artery syndrome: clinical, endoscopic, and radiologi¬cal findings. Gastrenterology Res Pratc. 2018;2018. doi. org/10.1155/2018/1937416. 

16. Warncke ES, Gursahaney DL, Mascolo M, Dee E. Superior mesenteric artery syndrome: A radiographic review. Abdom Radiol. 2019;44(9):3188-3194. 

17. Lamba R, Tanner DT, Sekhons S, et al. Multidetector CT of vascular compression syndromes in the abdomen and pelvis. Radiographics. 2014;34(1):93-115. 

18. Griffiths GJ, Whitehouse GH. Radiological features of vascular compression of the duodenum occurring as a complication of the treatment of scoliosis (the cast syn¬drome). Clin Radiol. 1978;29(1):77-83. 

19. Anderson, F, Megaduodenum. Am J Gastro. 1974;62(6). 

20. Akashi T, Hashimoto R, Funakoshi A. Effect of a novel, energy-dense, low-volume nutritional food in the treat¬ment of superior mesenteric artery syndrome. Cureus. 2021;13(5):e15243. 

21. Roza A, Shizgal H, The Harris Benedict energy require¬ments equation reevaluated: resting and the body cell mass. Am J Clin Nutr. 1984;40:168-182. 

22. Ahmad A, Duerksen DR, Munroe S, Bistrian BR. An evaluation of resting energy expenditure in hospitalized, severely underweight patients. Nutrition. 1999;15(5):384- 388. 

23. Verhoef PA, Rampal A, Unique challenges for appropriate management of a 16-year-old girl with superior mesen-teric artery syndrome as a result of anorexia nervosa: a case report. J Med Case Reports. 2009;3(1):1-5. 

24. Kurisu K, Yamanaka Y, Yamazaki T, et al. A clinical course of a patient with anorexia nervosa receiving surgery for superior mesenteric artery syndrome. J Eat Disord. 2021;9(1):1-4. 

25. Esmat HA, Najah DM. Superior mesenteric artery syn¬drome caused by acute weight loss in a 16-year-old polytrauma patient: A rare case report and review of the literature. Ann Med Surg. 2021;65: 102284. 

26. Kim J, Yang S, Im YC, Park I. Superior mesenteric artery syndrome treated successfully by endoscopy-assisted jejunal feeding tube placement. BMJ Case Reports. 2021;14(11):e245104. 

27. Anderson CM, Dalrymple MA, Podberesky DJ, Coppola CP. Superior mesenteric artery syndrome in a basic mili-tary trainee. Mil Med. 2007;172(1):24-26. 

28. da Silva JS, Seres DS, Sabino K, et al. ASPEN consen¬sus recommendations for refeeding syndrome. Nutr Clin Pract. 2020;35(2):178-195.  

Download Tables, Images & References

Medical Bulletin Board

Gastro Office Breaks New Ground For Patients By Becoming The First Practice In Ohio To Use Cellvizio To Improve The Diagnosis And Treatment Of Barrett’s Esophagus

GASTRO OFFICE BREAKS NEW GROUND FOR PATIENTS BY BECOMING THE FIRST PRACTICE IN OHIO TO USE CELLVIZIO TO IMPROVE THE DIAGNOSIS AND TREATMENT OF BARRETT’S ESOPHAGUS

to remove precancerous tissue in the hopes of preventing further spread of the disease.

Cellvizio, from Mauna Kea Technologies, is the only device that uses confocal laser endomicroscopy (CLE) to give physicians the power to see in vivo real-time cellular changes and responses to therapies

Gastro Office serves patients in the greater Columbus, OH area, treating conditions that affect the health of the digestive tract, including the esophagus, stomach, small and large intestines, pancreas, gallbladder, bile ducts, and liver.

Boston (May 31, 2023) – Patients in Ohio who suffer from persistent heartburn, reflux, and upper gastrointestinal pain and discomfort now have access to advanced imaging technology that can deliver a more accurate diagnosis in less time, thanks to Gastro Office. Hilliard Endo Center in Hilliard, OH is a surgery center affiliated with Gastro Office, which became the first center in Ohio to use Cellvizio® for these health conditions.

To learn more about their services, visit

GastroOffice.com

or call 614-385-5900

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point- in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients.

TAKEDA ANNOUNCES FDA ACCEPTANCE OF BLA RESUBMISSION FOR INVESTIGATIONAL SUBCUTANEOUS ADMINISTRATION OF ENTYVIO® (VEDOLIZUMAB) FOR MAINTENANCE THERAPY IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

OSAKA, Japan and CAMBRIDGE, Massachusetts, April 27, 2023 – Takeda (TSE:4502/NYSE:TAK) (“Takeda”) announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) resubmission for the investigational subcutaneous (SC) administration of Entyvio® (vedolizumab) for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) after induction therapy with Entyvio intravenous. The resubmission is intended to address FDA feedback in a December 2019 Complete Response Letter (CRL).

“Takeda has remained committed to the pursuit of a subcutaneous administration for Entyvio in the U.S. so that patients might have a choice between receiving Entyvio maintenance therapy via intravenous infusion by a health care professional or administering it themselves with a single-dose injection – whichever suits their medical and personal needs. This resubmission is a major step forward in delivering on that commitment,” said

Vijay Yajnik, M.D., Ph.D., vice president,head of U.S. Medical for Gastroenterology, Takeda. “We have great confidence in the future of Entyvio SC and strongly believe that offering a SC formulation can help meet the varied needs of patients who live with moderate to severe ulcerative colitis, pending approval.”

alpha4beta7 integrin is expressed on a subset of circulating white blood cells.5 These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn’s disease (CD).5,7,8 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.5

Adult Crohn’s Disease (CD)

ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active CD.

About Ulcerative Colitis and Crohn’s Disease

Ulcerative colitis (UC) and Crohn’s disease (CD) are two of the most common forms of inflammatory bowel disease (IBD).9 Both UC and CD are chronic, relapsing, remitting, inflammatory conditions of the gastrointestinal tract.10,11 UC only involves the large intestine as opposed to CD which can affect any part of the GI tract from mouth to anus.12,13 CD can also affect the entire thickness of the bowel wall, while UC only involves the innermost lining of the large intestine.12,13 UC can present with symptoms of abdominal discomfort or loose bowel movements, including blood.12,14 CD can present with symptoms of abdominal pain, diarrhea, and weight loss.10 The cause of UC or CD is not fully understood; however, research suggests that an interplay between environmental factors, genetics, and intestinal microbiota may contribute to the development of UC or CD.12,15,16

Takeda expects a decision from the FDA by the end of 2023.

with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point.1

About Entyvio® (vedolizumab)

Vedolizumab is a biologic therapy and is approved in intravenous (IV) and subcutaneous (SC) formulations (approvals vary by market; vedolizumab is not currently approved in the SC formulation in the U.S.).2,3 Vedolizumab SC has been granted marketing authorization in the European Union and more than 50 countries. Vedolizumab IV has been granted marketing authorization in more than 70 countries, including the United States and European Union, with more than 1,000,000 patient years of exposure to date.4 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1).5 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.6 The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.5 These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn’s disease (CD).5,7,8 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.5

Adult Crohn’s Disease (CD)

ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active CD.

About Ulcerative Colitis and Crohn’s Disease

Ulcerative colitis (UC) and Crohn’s disease (CD) are two of the most common forms of inflammatory bowel disease (IBD).9 Both UC and CD are chronic, relapsing, remitting, inflammatory conditions of the gastrointestinal tract.10,11 UC only involves the large intestine as opposed to CD which can affect any part of the GI tract from mouth to anus.12,13 CD can also affect the entire thickness of the bowel wall, while UC only involves the innermost lining of the large intestine.12,13 UC can present with symptoms of abdominal discomfort or loose bowel movements, including blood.12,14 CD can present with symptoms of abdominal pain, diarrhea, and weight loss.10 The cause of UC or CD is not fully understood; however, research suggests that an interplay between environmental factors, genetics, and intestinal microbiota may contribute to the development of UC or CD.12,15,16

REFERENCES

Sandborn WJ, Baert F, Danese S, et al.Gastroenterology. 2020;158(3):562-572.
Entyvio Prescribing Information. Available at: https://general.take- dapharm.com/ENTYVIOPI.Last updated: June 2022. Last accessed: January 2023.

Entyvio Summary of Product Characteristics (SmPC). Available at: https://www.ema.europa.eu/en/documents/product-information/ entyvio-epar-product-information_en.pdf. Last updated: October 2022. Last accessed: February 2023.

Takeda data on file (VV-SUP-91507): Vedolizumab Patient Exposure from Marketing Experience. 2021.
Soler D, Chapman T, Yang LL, et al. J Pharmacol Exp Ther. 2009;330:864-875.

Briskin M, Winsor-Hines D, Shyjan A, et al. Am J Pathol. 1997;151:97-110.
Eksteen B, Liaskou E, Adams DH. Inflamm Bowel Dis. 2008;14:1298-1312.

Wyant T, Fedyk E, Abhyankar B. J Crohns Colitis. 2016;10:1437-1444. Baumgart DC, Carding SR. Lancet. 2007;369:1627-1640.
Baumgart DC, Sandborn WJ. Lancet. 2012;380:1590-1605.
Torres J, Billioud V, Sachar DB, et al. Inflamm Bowel Dis. 2012;18:1356-1363.

Ordas I, Eckmann L, Talamini M, et al. Lancet. 2012;380:1606-1619. Feuerstein JD, Cheifetz AS. Mayo Clin Proc. 2017;92:1088-1103. Sands BE. Gastroenterology. 2004;126:1518-1532.
Kobayashi T, Siegmund B, Le Berre C, et al. Nat Rev Dis Primers. 2020;6(74).

Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Lancet. 2017; 389(10080):1741-1755.

Download Tables, Images & References

DISPATCHES FROM THE GUILD CONFERENCE, SERIES #53

Practical Approach to Stricture Management in Crohn’s Disease

Read Article

Stricturing complications are an important and common event during the course of Crohn’s
disease (CD) and may lead to significant disability. It is a leading indication for surgery
among patients with CD. Strictures are diagnosed most commonly during colonoscopy or on
cross-sectional imaging, appear as a narrowing in the bowel lumen and may be associated
with a variety of concomitant features, such as internal penetrating disease. Standardized
radiologic diagnostic criteria have been proposed by the CONSTRICT group. Abdominal
cross-sectional imaging is crucial in the evaluation of strictures and helps guide treatment.
Management of strictures is often multidisciplinary and involves a combination of medical,
endoscopic and surgical options. However, despite recent advances in medical therapies, the
progression to stricturing complications has not been significantly altered and only a subset of
patients improve on medical therapy temporarily, highlighting the need for durable treatment
options. Anti-fibrotics are being evaluated in this setting and further data are eagerly awaited.

INTRODUCTION 

Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are immune-mediated conditions leading to chronic relapsing and remitting inflammation of the gastrointestinal tract. Although the pathophysiology of IBD has not yet been fully elucidated, it appears to be due to a combination of environmental, microbial and genetic factors.1 

While ulcerative colitis only affects the colon, Crohn’s disease can affect any part of the gastrointestinal (GI) tract. It is also a transmural disease and involves deeper layers of the bowel. It therefore can lead to a variety of manifestations, depending on the location of the disease, and can lead to several types of complications and phenotypes due to its transmural nature. It is a progressive disease with accumulating bowel damage over time.1 Complications may include strictures (narrowing of the bowel lumen) as well as fistulas (tracts communicating between different bowel segments or from the GI tract to another organ) and infectious complications such as abscesses. Malnutrition, vitamin deficiencies and extra-intestinal manifestations are also common. 

Stricturing complications are an important and common event in the course of the disease, and are associated with significant morbidity. This review will aim to provide an overview of Crohn’s disease strictures and propose a practical approach to management. 

Epidemiology and natural history of stricturing Crohn’s disease 

Up to 29% of patients with Crohn’s disease may present with a complication at the time of diagnosis, including 21% with strictures.2 In patients without complications at diagnosis, approximately 10% of patients are estimated to develop stricturing complications at 5 years,2 and about 21% by 20 years.3 

Stricturing disease, in addition to penetrating disease, are the most common indications for surgery in CD and account for up to 70% of surgical interventions during the first 10 years of disease.4 Unfortunately, CD recurs postoperatively and repeat surgery is required in about 35% of patients within 10 years of the initial resection.5 Strictures 

can recur at the site of anastomosis (anastomotic strictures). 

Although strictures manifest anywhere along the gastrointestinal tract, they are most commonly found in the small bowel. Colon strictures are less common than small bowel strictures but are associated with a higher rate of dysplasia.6 Colonic strictures can also occur in patients with ulcerative colitis in up to 11% of patients.7 Although most of them are benign, they harbor risk for malignancy. It is therefore important to monitor patients with colonic strictures closely and a lower threshold for surgery should be considered. 

Patients with strictures can also have associated internal penetrating disease, including abscesses, phlegmon and abdominal fistulas. In fact, most patients with internal fistulizing disease have an associated stricture.8 One study assessing surgically resected segments with fistulas found that 96.3% of specimens had an underlying stricture.9 This has led to the hypothesis – although not supported by prospective data – that fistulas may arise in the area of pre-stricture dilation, which is considered a ‘high pressure zone’ of the intestinal lumen. 

Unfortunately, the progression towards stricturing complications has not been significantly modified by current medical treatment options, perhaps because tissue damage may already have developed by the time CD is diagnosed.8,10 

Clinical manifestations of stricturing Crohn’s disease 

Patients with Crohn’s disease may present with a variety of symptoms depending on disease severity, location and complications. General clinical features of CD include abdominal pain, diarrhea, unintentional weight loss, anorexia, rectal bleeding, fatigue, in addition to extra-intestinal features in up to 50% of patients such as ocular, joint or skin manifestations.1 Strictures can often be clinically “silent” without obvious obstructive symptoms. In a recent cohort study assessing patients with CD-associated small bowel strictures, up to 40% had no obstructive symptoms at the time of baseline assessment.11 When present, symptoms suggestive of obstruction may include post-prandial abdominal pain, change in food intake, nausea, vomiting, bloating, and abdominal distention.12 Careful 

history-taking is important as patients may not complain of specific symptoms other than tight dietary restrictions in order to avoid symptoms. 

Diagnosis of stricturing Crohn’s disease 

Several endoscopic and imaging modalities can help in the diagnosis of strictures. Endoscopically, strictures appear as a narrowing of the bowel lumen and are difficult or impossible to traverse with a regular endoscope or colonoscope.13 Biopsies of the stenosed areas should be obtained in order to evaluate for associated dysplasia or malignancy. However, histopathologic changes can be patchy and involve deeper layers of the bowel wall. Dysplasia and malignancy, therefore, cannot be entirely ruled out despite negative biopsies. 

Cross-sectional imaging is fundamental in the diagnosis and management of strictures. It provides important information regarding the presence of concomitant complications such as penetrating disease (abscesses, fistulas) or malignancy. In addition, it allows assessment of proximal disease or lesions and helps characterize the location, length of strictures and their associated features such as signs of inflammation or bowel wall thickening, pre-stenotic dilatation, etc., thereby ultimately guiding management.14 

Several types of imaging modalities are available for stricture diagnosis. Abdominal ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI) can diagnose strictures with sensitivity ranging from 75% to 100%. Specificity ranges from 91% to 100% for CT and MR enterography. MR enterography, when available, is usually favored given its high diagnostic accuracy and the absence of ionizing radiation.12 

In order to standardize the definition of strictures on cross-sectional imaging, a set of diagnostic criteria has been proposed by the CrOhN’s disease anti-fibrotic STRICTure therapies (CONSTRICT) expert consensus12 and can be found in Figure 1

Management 

General approach to strictures 

Several different treatment modalities are available in the management of stricturing CD, including 

medical, endoscopic and surgical options (Figure 2). Strictures are therefore best addressed in a multidisciplinary approach, with involvement from gastroenterologists, radiologists, surgeons and other IBD team members as needed. Ultimately, treatment will depend on stricture and disease characteristics, complications (fistula, abscess, etc.) and patient preference. 

Acute small bowel obstruction 

Patients with Crohn’s disease presenting with a suspected acute small bowel obstruction (SBO) should be urgently assessed. Symptoms suggestive of an acute SBO include severe abdominal pain and distention, vomiting, high-pitched bowel sounds, along with inability to pass flatus and/or stool. Cross-sectional imaging should be obtained promptly in order to rule out complications such as perforation, fistulizing disease or abscess. Patients should be initially kept nil per os (NPO) and hydrated adequately. Nasogastric tube insertion might be necessary, particularly with recurrent vomiting or persistent obstruction.8 

Serial imaging with abdominal x-rays should be obtained. Intravenous corticosteroids are widely used in such cases, despite limited evidence to support their use in this setting. In a small study, 25 out of 26 patients with CD with an acute SBO improved clinically at 72 hours.15 However, more than 70% of patients had recurrent obstruction during follow-up, highlighting the importance of a durable treatment strategy, as outlined below. In case of persistent obstruction, endoscopic balloon dilation or surgery may be required urgently. 

Overview of treatment options in stricturing Crohn’s disease 

Medical therapy: 

Immunomodulators have been evaluated in this setting. In a randomized controlled trial (RCT) of 72 patients with CD and ileal stricturing disease comparing mesalamine and azathioprine, the latter was found to be associated with a reduced rate of surgery and hospitalization during follow-up.16 Of note, methotrexate has never been evaluated 

specifically for the treatment of strictures in Crohn’s disease. 

Anti-tumor necrosis factor (anti-TNF) agents have been widely used in the management of fibrostenosing CD. Most of the evidence supporting their use stems from retrospective and single-arm prospective studies.17 There is only very limited evidence on the use of non-anti-TNF drugs such as vedolizumab and ustekinumab in this setting and further data are awaited. 

In a prospective single arm observational study (the “CREOLE” study) evaluating adalimumab treatment in patients with CD-associated small bowel strictures, drug persistence was 64% at 24 weeks and 29% at 4 years.18 About half of the cohort had surgery during the 4-year follow-up. Some of the predictors of adalimumab persistence were the use of immunomodulators at treatment onset, a high obstructive symptom score, pre-stenotic bowel dilation, stricture shorter than 12cm, obstructive symptom onset of less than 5 weeks at baseline, and the absence of underlying fistulas. 

A systematic review of available studies evaluating systemic medical treatment in stricturing CD found a pooled rate of up to 28.3% (95% CI: 18.2%−41.3%) of patients requiring surgery over a median follow-up of 23 months.17 

A recent open-label RCT from Australia compared an intensive high-dose adalimumab regimen combined with azathioprine with a “treat-to-target” approach to a standard adalimumab regimen in patients with intestinal CD strictures.19 Although rates of radiologic improvement on MRI as measured by the MaRIA score at 12 months were significantly higher in the intensive regimen arm, the improvement in obstructive symptoms was not statistically significant. In addition, surgery rates, intestinal ultrasound findings and biomarkers were not significantly different among the groups.19 

Although these findings – in line with the above 

literature – suggest a role for biologic treatment in stricturing disease, they do highlight the need for alternative and more effective treatment options in this setting. The problem may lie in the fact that once fibrosis is present, the damage may be “too far gone” for anti-inflammatory agents to help.10,11,20 Targeting intestinal fibrosis is a promising avenue and randomized controlled trials of antifibrotics are under way to help address this unmet need (National Clinical Trial registration number NCT05013385). 

Endoscopic treatment 

Endoscopic options are available for patients with persistent obstructive symptoms with strictures that are amenable to endoscopic interventions. Endoscopic balloon dilation (EBD) is the most established endoscopic intervention for strictures and involves dilating the stricture while inflating a through-the-scope balloon.8 This procedure can be performed in small bowel, colonic or upper gastrointestinal tract locations and in both naïve and anastomotic (postoperative) strictures. Strictures amenable to EBD should be endoscopically accessible, shorter than 5 cm and should never be associated with an underlying abscess, fistula or suspected malignancy. Technical success rates (i.e. successful dilation during endoscopy) are estimated to approach close to 90% while clinical efficacy rates (improvement in clinical symptoms) are around 80%.21 Complications are estimated to occur in 2.8% of patients and include fever, bleeding and perforation.21 Of note, a significant portion of patients (about 42% at 2 years) still require surgery given recurrent or persistent symptoms.21 

Additional endoscopic techniques have been studied, including intralesional anti-TNF or corticosteroid injection into the stricture, stent insertion as well as needle-knife stricturotomy, which involves slicing open the stenotic area using an endoscopic knife. However, these have not yet been incorporated into routine clinical practice given limited safety and controlled efficacy data.22 

Surgery 

Surgery is indicated in patients with persistent obstructive symptoms with strictures that are felt 

to be either not amenable or refractory to medical and/or endoscopic intervention,23 as well as in cases where penetrating disease or malignancy are suspected. Several surgical options are available. Resection of the stenotic segment is the most commonly used procedure along with bowel anastomosis and possibly a temporary diverting loop ileostomy in certain cases.23 

Strictureplasty is another surgical option that involves widening of the narrowed area without resecting the affected segment. Given its bowel-sparing nature, strictureplasty is particularly helpful in patients with multiple prior surgical resections and at risk for short bowel syndrome, as well as in the setting of multifocal strictures separated by long segments of normal bowel.23 Several types of strictureplasty techniques are used depending on the length of the stricture. Of note, since strictures are not resected and are left in situ, this procedure should be avoided in patients with suspected malignancy or dysplasia or any other complication such as perforation, penetrating disease or malnutrition.23 

Importantly, regardless of the selected surgical technique, preoperative nutritional status should be optimized and smoking cessation should be addressed to prevent complications and postoperative recurrence. Postoperatively, patients should be closely observed for disease recurrence and patients at high risk of recurrence should be started or continued on a biologic treatment with monitoring of their response.8,24,25 

Identifying patients at risk for intervention 

The natural history of stricturing CD and factors associated with the need for endoscopic or surgical intervention have been studied but have remained poorly defined given heterogeneity of patient populations, the absence of a standardized definition of strictures, inclusion of patients with concomitant fistulizing disease or colonic strictures. In a recent well-defined US cohort looking at the disease course of established CD strictures as defined by the CONSTRICT criteria,12 stricture length, duration and obstructive symptoms were found to be independent and validated predictors for the need of intervention (combined endpoint of EBD and/or surgery).11 In this cohort, 26% and 

45% of patients required intervention at 1 and 4 years, respectively. An online risk calculator was developed to help clinicians estimate the need for intervention and thereby guide patient discussions and shared-decision making.11 The calculator can be accessed at: riskcalc.org/ CrohnsDiseaseSmallBowelStricture

CONCLUSION 

Stricturing disease is an important and common complication in patients with Crohn’s disease. A combination of different treatment modalities are available including medical, endoscopic and surgical options. However, strictures are still a leading indication for surgery in CD, and the frequency of progression to stricturing complications has not been significantly altered over the last few years despite considerable advances in the medical treatment landscape. Important goals in the management of CD over the next few years will therefore be to attempt to target fibrosis through antifibrotics, but also ultimately to continue to work on preventing the development of fibrosis. The Stenosis Therapy and Anti-Fibrotic Research (STAR) consortium, a group of experts in stricturing CD, have been working on determining appropriate endpoints and definitions in stricturing CD in order to help pave the way for further research and clinical trials of anti-fibrotic agents, which are under way. 

Sara El Ouali1,2 Miguel Regueiro2 Joseph Sleiman3 Florian Rieder2,4 1Digestive Disease
Institute, Cleveland Clinic Abu Dhabi, United Arab Emirates 2Department of Gastroenterology,
Hepatology & Nutrition; Digestive Diseases and Surgery Institute; Cleveland Clinic
Foundation, Cleveland, OH 3Department of Gastroenterology, Hepatology and Nutrition,
University of Pittsburgh Medical Center, Pittsburgh, PA, 4Department of Inflammation
and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH
Disclosures: SE has received lecture fees from Janssen and AbbVie. MR is on the advisory
board or consultant for AbbVie, Janssen, UCB, Takeda, Pfizer, BMS, Organon, Amgen,
Genentech, Gilead, Salix, Prometheus, Lilly, Celgene, TARGET Pharma Solutions,Trellis,
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) JS has no relevant disclosure. FR is
on the advisory board or consultant for Agomab, Allergan, AbbVie, Boehringer Ingelheim,
Celgene, CDISC, Cowen, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Index
Pharma, Janssen, Koutif, Metacrine, Morphic, Pfizer, Pliant, Prometheus Biosciences,
Receptos, RedX, Roche, Samsung, Takeda, Techlab, Theravance, Thetis, UCB.

References 

1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389(10080):1741-1755. 

2. Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2019;68(3):423-433. 

3. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV, Jr. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139(4):1147-1155. 

4. Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn’s disease complicated by strictures: a systematic review. Gut. 2013;62(7):1072-1084. 

5. Frolkis AD, Lipton DS, Fiest KM, et al. Cumulative incidence of second intestinal resection in Crohn’s disease: a systematic review and meta-analysis of population-based studies. Am J Gastroenterol. 2014;109(11):1739-1748. 

6. Fumery M, Pineton de Chambrun G, Stefanescu C, et al. Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures. Clin Gastroenterol Hepatol. 2015;13(10):1770-1775. 

7. Rieder F, Fiocchi C, Rogler G. Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017;152(2):340-350 e346. 

8. El Ouali S, Click B, Holubar SD, Rieder F. Natural history, diagnosis and treatment approach to fibrostenosing Crohn’s disease. United European Gastroenterol J. 2020;8(3):263- 270. 

9. Oberhuber G, Stangl PC, Vogelsang H, Schober E, Herbst F, Gasche C. Significant association of strictures and internal fistula formation in Crohn’s disease. Virchows Arch. 2000;437(3):293-297. 

10. Jeuring SF, van den Heuvel TR, Liu LY, et al. Improvements in the Long-Term Outcome of Crohn’s Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort. Am J Gastroenterol. 2017;112(2):325-336. 

11. El Ouali S, Baker ME, Lyu R, et al. Validation of stricture length, duration and obstructive symptoms as predictors for intervention in ileal stricturing Crohn’s disease. United European Gastroenterology Journal. 2022;10(9):958-972. 

12. Rieder F, Bettenworth D, Ma C, et al. An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn’s disease. Aliment Pharmacol Ther. 2018;48(3):347-357. 

13. Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505-512. 

14. Sleiman J, Chirra P, Gandhi NS, et al. Crohn’s disease related strictures in cross-sectional imaging: More than meets the eye? United European Gastroenterology Journal. 2022;10(10):1167-1178. 

15. Yaffe BH, Korelitz BI. Prognosis for nonoperative management of small-bowel obstruction in Crohn’s disease. J Clin Gastroenterol. 1983;5(3):211-215. 

16. de Souza GS, Vidigal FM, Chebli LA, et al. Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn’s disease patients. Med Sci Monit. 2013;19:716-722. 

17. Lu C, Baraty B, Lee Robertson H, et al. Systematic review: medical therapy for fibrostenosing Crohn’s disease. Alimentary Pharmacology & Therapeutics. 2020;51(12):1233-1246. 

18. Bouhnik Y, Carbonnel F, Laharie D, et al. Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018;67(1):53-60. 

19. Schulberg JD, Wright EK, Holt BA, et al. Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn’s disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial. The Lancet Gastroenterology & Hepatology. 2022;7(4):318-331. 

20. Lazarev M, Ullman T, Schraut WH, Kip KE, Saul M, Regueiro M. Small bowel resection rates in Crohn’s disease and the indication for surgery over time: experience from a large tertiary care center. Inflamm Bowel Dis. 2010;16(5):830-835. 

21. Bettenworth D, Gustavsson A, Atreja A, et al. A Pooled Analysis of Efficacy, Safety, and Long-term Outcome of Endoscopic Balloon Dilation Therapy for Patients with Stricturing Crohn’s Disease. Inflamm Bowel Dis. 2017;23(1):133-142. 

22. Sleiman J, El Ouali S, Qazi T, et al. Prevention and Treatment of Stricturing Crohn’s Disease – Perspectives and Challenges. Expert Review of Gastroenterology & Hepatology. 2021;15(4):401-411. 

23. Lightner AL, Vogel JD, Carmichael JC, et al. The American Society of Colon And Rectal Surgeons clinical practice guidelines for the surgical management of Crohn’s disease. Diseases of the Colon & Rectum. 2020;63(8):1028-1052. 

24. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956-963. 

25. Regueiro M, Velayos F, Greer JB, et al. American Gastroenterological Association Institute technical review on the management of Crohn’s disease after surgical resection. Gastroenterology. 2017;152(1):277-295. e273.PRACTICAL GASTROENTEROLOGY 47Years Established 1977 

Download Tables, Images & References

ERCP Stone Extraction: Complex

Read Article

INTRODUCTION

Choledocholithiasis remains the most common indication for ERCP. The management of choledocholithiasis has evolved substantially in the last three decades, with ERCP-based therapies centered around endoscopic stone extraction replacing open common bile duct exploration surgery and percutaneous biliary drainage. National registries show that 96.1% of interventions for the management of choledocholithiasis were performed during ERCP,1 reaffirming ERCP as the gold-standard approach for the management of biliary stone disease. ERCP is safe, minimally-invasive and effective for the management of choledocholithiasis. The vast majority of biliary stones are readily extracted by ERCP with the conventional techniques of endoscopic sphincterotomy and balloon extraction; however, extraction may be challenging in approximately 10%-15% of cases in which the stone disease is designated to be complex.2 This article will focus on defining complex stone disease and reviewing best practices in the evaluation and management of complex choledocholithiasis. 

Complex biliary stone disease arises due to characteristics of the stone itself and the characteristics of the biliary tree and patient’s surrounding biliary and small bowel anatomy. Broadly defined, complex choledocholithiasis requires more than conventional ERCP with endoscopic sphincterotomy and balloon extraction approaches. Alternatively, stone extraction requiring more than one ERCP for complete stone clearance may be considered complex.5 Stone extraction can be challenging for numerous reasons (Table 1), including large stone size (>10mm), the presence of multiple stones, difficult location of stones (intrahepatic duct, cystic duct, impacted stones, stones proximal to a biliary stricture or a combination thereof), irregular stone morphology (triangular or tubular stones) and the presence of altered anatomy from prior surgical intervention or underlying disease such that access to the ampulla or bile duct is limited and/or technically challenging.2,3 Examples of anatomical factors that lead to difficult ERCP include an ampulla within a periampullary diverticulum and surgically altered anatomy such as gastrojejunostomy with Roux- en-Y reconstruction, or a history of Bilroth II surgery. In these cases, the main challenge is access to, and deep cannulation of, the bile duct. In some cases, multiple factors, including patient/anatomic and stone characteristics may contribute to complex stone disease and technically challenging stone extraction. Tailoring the approach to endoscopic stone extraction to address these specific factors that contribute to stone extraction complexity and utilizing a combination of equipment and techniques can overcome the challenge of achieving complete stone clearance in these cases. 

Prospective studies have identified a variety of factors that predict the difficulty of stone extraction by ERCP (Table 2), including a very elevated direct bilirubin, low CBD/stone diameter ratio, a short 

Techniques for Complex Biliary Stone Extraction
The most common obstacle to clearance of choledocholithiasis is the presence of large stones.4 In general, stones greater than 10mm in diameter can be considered large, however, varying definitions exist in the literature. Some studies refer to large stones as those with a diameter >15mm, others focus on the size ratio between the stone and bile duct diameter, considering a stone ‘large’ when it is larger than the diameter of the bile duct.8,9 Regardless of the size threshold used to define large choledocholithiasis, studies demonstrate that larger stone size is inversely correlated with successful clearance of the bile duct in a single ERCP.4,5,10 

When a large stone is encountered, a range of techniques may be employed to maximize the success of clearance of large and complex biliary stones. These techniques include extended endoscopic biliary sphincterotomy, mechanical lithotripsy, endoscopic papillary large balloon dilation and cholangioscopy-assisted lithotripsy and will each be reviewed in detail in this chapter. Figure 1 illustrates a case wherein multiple techniques were used to perform complex stone extraction. 

Endoscopic Biliary Sphincterotomy 

The mainstay of biliary stone extraction is endoscopic biliary sphincterotomy (ES), by which the opening of the bile duct, the sphincter choledochus, at the ampulla, is incised to allow access to the bile duct and passage of stones out of the bile duct. Understanding key features of the ampulla and sphincter of Oddi is integral to understanding the techniques that facilitate complex stone management. Successful ERCP first relies on identification of the ampulla and the surrounding sphincter of Oddi in the second portion of the duodenum. For this reason, we will briefly review relevant ampullary anatomy here. The ampulla appears as a nodular mound protruding from the lateral wall of the second duodenum, approximately 8cm distal to the pylorus.6 It is composed of a complex network of muscular fibers termed the sphincter of Oddi, which is comprised of the sphincter choledochus, the opening to the bile duct, the sphincter pancreaticus, the opening to the pancreatic duct, and the sphincter ampullae.7 The muscle fibres of the sphincter of Oddi are thick and dense, acting as the main barrier to stone expulsion. The principle of sphincterotomy is to cut through those dense fibers at the sphincter choledochus using an electrocautery current, which reduces the resistance of the biliary outflow tract by effectively shortening the sphincter length and markedly widens the biliary orifice. The decrease in resistance of the biliary outflow tract enables the passage of stones, debris and biliary sludge and also allows for the introduction of an extraction balloon into the bile duct over a wire. A balloon catheter can then be advanced over the guidewire to a point proximal to the biliary stone, inflated and withdrawn to sweep the stone and any associated debris, out of the bile duct. For stones less than 10mm, balloon extraction by this method is highly effective, however, the efficacy of this technique declines as the size of the stone increases and in cases where the stone size is larger than the size of the distal CBD diameter, dropping to a success rate of 12% for stones larger than 15mm in diameter.10 As described further in this article, additional techniques are often necessary if balloon extraction is incomplete or ineffective. 

When large stones are encountered, the first consideration is often whether the size of the sphincterotomy is adequate for stone extraction. This can be assessed, armed with the anatomical knowledge described above, by determining whether each of these sphincters has been adequately incised to maximize the size of the extraction orifice. Extension of the sphincterotomy as possible, often facilitates extraction of large stones that might otherwise require advanced approaches. Utilization of advanced stone extraction approaches such as mechanical lithotripsy with a small or inadequate biliary sphincterotomy may lead to increased trauma to and edema of the ampulla, which could become another barrier to extraction of stone fragments and may increase a patient’s risk for developing post-ERCP pancreatitis. In these cases, the next reasonable steps in management include decreasing the size of the stone(s) by fragmenting them and/or increasing the size of the biliary orifice to decrease resistance to extraction, or a combination thereof. Increasing the size of the biliary orifice beyond that of conventional endoscopic sphincterotomy can be accomplished by endoscopic papillary balloon dilation (EPBD) and endoscopic papillary large balloon dilation. Fragmentation of large stones can be achieved by various lithotripsy techniques, including mechanical, electrohydraulic and laser lithotripsy. 

Endoscopic Papillary Balloon Dilation 

EPBD was first described in 1982 as an alternative technique to biliary stone extraction with sphincterotomy.11 EPBD is performed by inserting and inflating a concentric dilation balloon up to 10mm in diameter at the ampullary orifice to dilate the biliary outflow tract and reduce the resistance to flow by dilating the entire length of the sphincter choledochus. Whereas endoscopic sphincterotomy cuts through the sphincter mechanism to shorten the sphincter length and may rarely lead to complications such as bleeding and perforation, EPBD stretches the sphincter, preserving the integrity of the sphincter mechanism, theoretically reducing the risk of bleeding, perforation and long- term reflux of intestinal contents into the biliary tract. However, the use of EPBD in stone extraction has been controversial. 

Studies initially showed that EPBD and ES techniques for choledocholithiasis were equally effective, with some studies showing higher rates of post-ERCP pancreatitis in cases where EPBD was employed, and increased rates of bleeding in cases where ES was used.12-15 A subsequent multicenter randomized control trial in the US showed that EPBD without ES was associated with significantly higher rates of adverse events compared to ES alone for stones less than 10mm in diameter. These adverse events that occurred most often in patients undergoing EPBD without ES were a higher rate of post-ERCP pancreatitis (15.4% vs. 0.8%) and two mortalities in the EPBD group.16 The postulated reason for the higher rates of pancreatitis after EPBD is that the radial force exerted by the dilation balloon extends to the sphincter pancreaticus, which may lead to subsequent pancreatic outflow obstruction from tissue edema leading to functional obstruction of the sphincter. Meta-analyses align with the multicenter randomized controlled trial data, finding that EPBD alone, specifically in the absence of sphincterotomy, is associated with higher rates of post-ERCP pancreatitis and, in some cases, lower success rates compared to ES.17,18 Newer data suggest that longer dilation times up to five minutes vs. one minute may reduce adverse events associated with EPBD.19,20 While the risk of EPBD may appear to outweigh the benefits of using EPBD, it may have a role in patients with uncorrected coagulopathy, where the risk of bleeding from ES is high. Still, EPBD may cause local tissue trauma that can result in bleeding for these high bleeding risk patients as well. When ampullary bleeding is encountered in post-EPBD patients who do not have a prior sphincterotomy, endotherapy for hemostasis may be relatively limited as most hemostasis techniques rely upon access to the actual sphincterotomy site itself. 

Sphincterotomy with Papillary Balloon Dilation
Although the risk profile of EPBD without sphincterotomy is unfavorable in most cases of choledocholithiasis, papillary balloon dilation is still a relevant technique for endoscopic biliary stone clearance and is a useful technique in the management of complex stone disease. A significant limitation to EPBD is the ability to dilate the biliary orifice only up to limited sizes, i.e. 10mm, therefore the technique has been innovated over the years to overcome that with a technique called endoscopic papillary large balloon dilation (EPLBD). EPLBD is a technique whereby a limited or incomplete ES is performed, immediately followed by a large balloon dilation (to >12mm) of the biliary orifice. It was first described in 2003 by Ersoz et al.21 The rationale for this method is that large 

balloon dilation can stretch the biliary orifice to diameters larger than 12mm, facilitating large stone extraction. Furthermore, performing the dilation after an ES reduces the radial force and associated trauma of the balloon dilation to the ampulla and sphincter pancreaticus when subsequent additional techniques (e.g. Lithotripsy, balloon extraction) are performed, thereby decreasing the risk of pancreatitis. Figure 2 illustrates a case wherein EPBD was used successfully as an adjunct to sphincterotomy for complex stone extraction. 

Since the advent of EPLBD, multiple studies have demonstrated that EPLBD with a limited ES is equally effective as standard ES with conventional stone extraction techniques, with decreased costs, decreased need for mechanical lithotripsy and lower rates of cholangitis.22-24 Subsequent systematic reviews have demonstrated that EPLBD is effective and associated with lower risks of bleeding, perforation and overall complications.25-29 

Large balloon dilation alone may be an appropriate approach to large stones in patients who have an increased risk of bleeding or perforation from sphincterotomy, but in practice this is rarely performed.30,31 

With data supporting the use of EPLBD, international consensus guidelines were published in 2016.32 The consensus statements from the guidelines based on level 1 evidence is presented in Table 3 below. 

While these consensus statements serve as a general guide of how to apply EPLBD, there are several details about the technique in complex biliary stone disease that remain unaddressed in the literature, such as the duration of balloon dilation and optimal size of balloon inflation/dilation, the level at which dilation should ideally occur (e.g., ampulla, distal CBD and ampulla) and whether ES is necessary prior to EPBLD. General rules of thumb are to avoid EPLBD in cases where there is a CBD stricture and to size the balloon to no more than the maximal diameter of the bile duct just proximal to the ampulla to avoid complications such as perforation and bile duct injury. From the evidence thus far, it appears that EPLBD is a technique that is especially useful in situations where ES may be high risk, for instance in cases where the patient is coagulopathic, there is the presence of a peri-ampullary diverticulum making the risk of perforation with ES high and in cases of surgically altered anatomy where a biliary anastomosis is present rather than an ampulla. 

It is also worth noting that EPBD and EPLBD can be performed in patients with a prior complete, and not just a limited, biliary sphincterotomy. Many times, a patient is referred who has undergone a prior biliary sphincterotomy and may warrant a balloon dilation. It is fully within the standard of care to perform these balloon dilations even if the extent of the prior sphincterotomy is unknown as long as some degree of sphincterotomy has been performed. 

Mechanical Lithotripsy 

Along with balloon extraction, mechanical lithotripsy is one of the most frequently applied techniques for clearance of choledocholithiasis. It was first described in 198233 and, since its initial description, mechanical lithotripters have been continuously innovated to exert and withstand high tensile forces to fragment large biliary stones. In general, mechanical lithotripters are comprised of a metal basket (of various sizes and with several shapes available) in a plastic sheath within a metal sheath. The lithotripter is advanced over a guidewire into the bile duct and is then opened in the bile duct, maneuvered to capture biliary stones within the basket and then closed using external mechanical closure to crush the stones. 

Mechanical lithotripsy is widely available, effective and inexpensive compared to other techniques for stone fragmentation and extraction; however, it does require skill and time to maneuver the stones within the basket wires to capture and crush them. Still, the success rates of bile duct clearance using mechanical lithotripsy is up to 84% at index ERCP (34-39) and up to a 90-98% cumulative success rate with multiple sequential ERCPs.34,35,37  Predictors of unsuccessful mechanical lithotripsy are large stone size, impacted stones and stones with a high stone/bile duct diameter ratio.38,39 Each of these factors associated with unsuccessful mechanical lithotripsy is associated with potential difficulty maneuvering the basket around stones within the bile duct. Techniques to optimize the success of mechanical lithotripsy have been described and include opening the basket below the level of the stone, then advancing the basket to capture the stone, and using short-term biliary stents to potentially erode and fragment a large stone and render it more amenable to mechanical lithotripsy during a subsequent ERCP session. A randomized trial studying optimal basket technique showed that opening the basket below the stone instead of above it, increased the capture rates from 33.3% to 94.1%.40 

While the adverse events associated with mechanical lithotripsy are similar to those associated with other stone extraction techniques, such as bleeding, perforation, pancreatitis and cholangitis, a complication specific to the use of mechanical lithotripsy is impaction. After stone capture, basket impaction can develop when the lithotripter handle is actuated to crush the stone; however, the basket ruptures at either the distal or the proximal end of the tool. If the basket ruptures at the distal end, it is retrievable as it remains connected to the sheath proximally. If the proximal end of the basket ruptures, or the basket fails to rupture but cannot crush or release the stone, special retrieval maneuvers such as using a second basket as a salvage device, extending the sphincterotomy and retrieving the basket using grasper forceps, laser or electrohydraulic lithotripsy, cholangioscopy and retrieval or using a large external lithotripter may be utilized, with varying rates of success for each approach.42-45 

The rate of basket impaction was previously reported to be 5.9%,46-48 however, with advances in lithotripter design, the incidence of basket impaction is now reported to be lower, approximately 0.8% in one study.49 Predictors of basket impaction and unsuccessful mechanical lithotripsy have been reported to be large stone size, typically over 25mm,36,50 multiple stones50 and impacted stones in the bile duct leading to inadequate space to manipulate the lithotripsy basket between the stones and the bile duct walls.38 

Electrohydraulic and Laser Lithotripsy 

In cases requiring fragmentation of biliary stones prior to extraction, electrohydraulic (EHL) and laser lithotripsy are alternatives to mechanical lithotripsy. Both of these lithotripsy approaches are accomplished via cholangioscopy. Cholangioscopy is a technique wherein direct visualization of the bile duct and management of intraductal pathology is possible using either direct peroral cholangioscopy (DPOC) with an ultraslim endoscope or as single-operator catheter-based digital cholangioscope (SpyGlass DS; Boston Scientific, Natick, MA, USA). While EHL and laser lithotripsy can be accomplished by either method of cholangioscopy, the more commonly applied method of direct intraductal visualization is via the single-operator digital cholangioscope, which has a 10Fr catheter containing a 1.2mm working channel and an irrigation port. This single operator digital cholangioscope can be inserted into the duodenoscope working channel and controlled by a single endoscopist using four- way steering knobs. The newer iterations of the system allow for high-resolution images and easy setup. Application of the technique, however, is limited by availability and cost. There is high biliary cannulation and intervention success rates with the use of this catheter-based system, as it is easier to manipulate and maintain positional stability relative to use of an ultraslim endoscope for direct peroral cholangioscopy. In the latter, there can be significant looping of the endoscope in the stomach, leading to limited mechanical advantage for maneuvering and resulting in a more challenging cannulation.51,52 Various tools have been developed to facilitate direct peroral cholangioscopy, such as the use of overtubes and anchoring balloons to stabilize the endoscope and improve biliary cannulation rates,53-56 however, this approach remains a cumbersome technique and carries a risk of gas embolism from insufflation of the biliary system, although it is felt that gas embolism is less like to occur when using carbon dioxide for insufflation. This rare but catastrophic adverse event associated with DPOC may be fatal.57,58 For these reasons, DPOC has become a less commonly utilized technique. 

Cholangioscope-facilitated lithotripsy using either the DPOC or the digital single-catheter based cholangioscope, involves the direct intraductal application of energy to fragment biliary stones. This is achieved by two modalities of energy application: electrohydraulic lithotripsy (EHL) and pulsed laser lithotripsy (LL). 

Electrohydraulic Lithotripsy (EHL) 

In EHL, a coaxial bipolar device generates sparks suspended in a liquid medium (saline) that, consequently, produces a hydraulic pressure wave that causes stone fragmentation. The EHL probe is advanced through either the working channel of the ultraslim endoscope in DPOC, or the working channel of the single-operator catheter-based cholangioscope. The tip of the probe should be approximately 2mm from the target stone to be effective, but ideally should not be in physical contact with the stone. EHL should be performed after saline instillation to facilitate conduction and optimal stone fragmentation. Contact of the catheter tip to the stone is unnecessary as it is the pressure waves generated in the medium that induce fragmentation (Figure 3). 

Laser Lithotripsy (LL) 

In LL, a quartz fiber is advanced through the working channel and a pulsed laser energy generator is used to deliver laser pulses at a specific wavelength, leading to creation of a mechanical shockwave adjacent to the stone. Contact between the laser tip and the stone is not necessary, as the shockwave is responsible for fragmentation. 

In terms of efficacy, cholangioscope-facilitated laser lithotripsy by either the DPOC or digital cholangioscopy is successful in 78-100% of cases according to a recent meta-analysis, with an overall stone clearance rate of 88% and an adverse event rate of 7%.59 In a large multicenter study of 407 patients using the digital cholangioscope (SpyGlass DS; Boston Scientific) with EHL and LL, index biliary clearance was achieved in 77.4% of cases (74.5% EHL and 86.1% LL) and overall clearance achieved in 97.3% of cases (96.7% EHL and 99% LL).60 In the latter study, EHL was used three times more frequently than LL, however, EHL required longer procedure times than LL (74 vs. 50 minutes).60 

These lithotripsy modalities are useful in settings where ML is unlikely to provide adequate stone fragmentation or has been tried without success; for example, in patients with stone size over 2cm, impacted stones, stones in locations that are challenging for extraction such as in Mirizzi syndrome, stones proximal to biliary strictures or in intrahepatic or cystic ducts. Another advantage of EHL or LL over ML is that these approaches are performed under direct visualization, which may reduce the risk of bile duct wall damage which is, admittedly, rare. 

There are a few maneuvers than can be employed to optimize the success of EHL or LL via cholangioscopy. First and foremost, patient safety is a key factor, and in cases where significant irrigation of the bile duct is necessary, airway protection with intubation should be considered. In addition, antibiotic prophylaxis to prevent cholangitis is recommended in all cases where cholangioscopy-facilitated lithotripsy is performed, due to the increased risk of cholangitis reported with the use of this modality.61 This increased risk of cholangitis may relate to stone fragmentation, coupled with saline insufflation within the bile duct that raises intra-biliary pressures and increases the potential for bacterial translocation and bacteremia. Other technical tips include advancing the cholangioscope deep into the bile duct to provide a straighter passage for the lithotripsy catheter by decreasing pressure at the elevator of the duodenoscope, or inserting the catheter through the cholangioscope prior to insertion of the cholangioscope into the bile duct and minimizing contrast injection to improve direct visualization without the need for copious irrigation of the bile duct to clear injected contrast. 

Extracorporeal shock wave lithotripsy can also be performed to assist with stone dissolution in addition to ERCP and may improve clearance at subsequent ERCP, though this approach is most commonly utilized for pancreatic duct stones that are refractory to EHL, however, biliary applications of this lithotripsy approach have been reported in a limited manner.64-66 

Biliary Stenting 

If there is evidence of residual stone disease or significant concern for incomplete clearance of stone fragments after lithotripsy, a biliary stent is typically placed to secure biliary drainage until complete eradication of choledocholithiasis can be performed, with the proximal end of the biliary stent extending above the stone/fragments to ensure ongoing drainage of bile from the duct. The rate of endoscopic clearance of complex stones at an index ERCP is 80% and approaches an overall success rate of 99%,62 thus endoscopic management has largely replaced surgical and percutaneous management of biliary stone disease. However, endoscopists should recognize the limitations of endoscopic management and individualize the approach to patient-specific factors as well as recognizing and informing the patient that complete biliary clearance may not be achieved at an index procedure. In the setting of abundant or complex stone disease, in many cases it is reasonable to achieve partial stone clearance and place a biliary stent to ensure biliary drainage, with the intention of repeating the ERCP for full stone clearance. Such an approach may be the safest, most effective way to manage complex stone disease in patients who are elderly or have co-morbidities, or who may be at high risk of procedural complications. It also ensures drainage to prevent cholangitis and may improve changes of successful clearance at subsequent ERCP. 

There are data suggesting that in the interim between procedures, biliary stenting along with ursodeoxycholic acid and terpene may lead to improved clearance compared to stenting alone,63 however, in our experience this is rarely utilized in modern endoscopic practice 

In general, plastic stents are placed for the purpose of maintaining biliary drainage between procedures. Anecdotal reports indicate that the presence of these plastic biliary stents may fragment and promote clearance of residual stones, however, data surrounding this theory are limited. There are, however, data that demonstrate some success with the placement of fully-covered self- expandable metal stents for a longer in-dwelling time (up to six months) for management of complex stone disease.67,68 The placement of fully-covered metal stents for a longer in-dwelling time may be applicable in cases where a benign distal biliary stricture is present in addition to complex stone disease. In the end, the choice of stent type is left to the endoscopist. 

Regardless of the specific endoscopic strategy used to manage complex biliary stone disease, maintenance of biliary drainage for patient safety is of critical importance. In some clinical scenarios, management of complex stone disease is optimally accomplished with multiple procedures, employing various techniques for bile duct clearance and minimizing the duration and anesthesia time of any single procedure. 

Stone Eradication in Patients with Altered Anatomy
Complex biliary stone disease in patients with surgically altered anatomy poses a significant challenge to endoscopists. Obtaining access to the biliary tree in patients who have undergone prior Billroth 2, Whipple, Roux-en-Y hepaticojejunostomy and Roux-en-Y gastric bypass surgeries may be cumbersome due to the inability to use standard duodenoscopes, the need for deep enteroscopy, lower success rates of ampulla cannulation/biliary access and limitations on the use of standard equipment through enteroscopes. The first step in devising an endoscopic strategy for ERCP in the setting of surgically altered anatomy is to understand the details of the patient’s history and anatomy in as much detail as possible and to correlate that with current imaging prior to undertaking the procedure. 

Hepaticojejunostomy and Roux-en-Y gastric bypass anatomies are particularly challenging because they often require deep enteroscopy- assisted ERCP to reach the ampulla. In a multicenter study, the success rate is reported to be 63% in those cases and there was a relatively high adverse event rate of 12.4%.69 Percutaneous biliary access and laparoscopy-assisted ERCP via a gastrostomy have higher success rates in such cases. However, they are fraught with other challenges, including long-term catheter-related complications in percutaneous therapy reported to be up to 25%70,71 and the invasiveness of laparoscopy-assisted ERCP with adverse event rates of up to 36%.72-74 Another consideration with respect to laparoscopy-assisted ERCP is whether or not repeat procedures will be necessary and the percutaneous access that will be necessary for these subsequent procedures. 

Alternatives to laparoscopic and percutaneous biliary access in post-Roux-en-Y gastric bypass anatomy include EUS-guided biliary access. EUS- directed transgastric ERCP (EDGE) has been described as minimally-invasive technique for ERCP in this setting. It involves placing a lumen- apposing metal stent to create a gastro-gastric or gastro-jejunal fistula, effectively reversing the Roux-en-Y gastric bypass such that a standard duodenoscope can be used to access the bile duct. In a multicenter study, EDGE was shown to be non-inferior to laparoscopy-assisted ERCP in efficacy and safety and was associated with shorter lengths of hospital stay as well as procedure time.75 A common concern with respect to EDGE is the potential for weight gain after reversal of the Roux-en-Y gastric bypass, however, there is data to suggest that patients actually lose weight after EDGE,75 and the reversal is temporary. In general, weight gain has not proved to be a clinical issue of concern. 

EUS-guided biliary access can also be applied to patients who have a hepaticojejunostomy. EUS can be used to localize and create a hepaticoenterostomy from the left intrahepatic biliary tree from either the stomach or jejunum, using a fully-covered metal stent, after which an ultraslim endoscope or cholangioscope can be used to access the bile duct from an antegrade approach and stones can be treated. Typically, this approach is performed at expert centers, however, it may become more widely applied in the future as experience with the technique increases. EUS- guided hepaticoenterostomy has been associated with improved clinical outcomes and fewer adverse events compared to percutaneous biliary drainage in meta-analysis.76 In addition, EUS-guided approaches may offer a quality-of-life advantage over percutaneous biliary drainage. 

In post-Whipple anatomy, the bilioenteric anastomosis can be accessed with a colonoscope in up to 84% of cases.77 In patients with Billroth 2 anatomy, a duodenoscope can be used to reach the ampulla, however, the cannulation rate is variable, reported to be between 49-92%, which in some part is due to the inverted orientation of the ampulla in that scenario. Rotatable and straight catheters are usually used to access the ampulla from the inverted position. Once the biliary orifice is cannulated, sphincterotomy can be challenging but can usually be accomplished. EPLBD may be a useful technique to employ in these patients.78 A major adverse event to consider in Billroth 2 anatomy is the risk of perforation at the gastrojejunal anastomosis, which reportedly occurs in up to 3.6% of cases.79 

Endoscopic techniques for the management of choledocholithiasis in altered anatomy are ever- evolving and as EUS-guided approaches and devices designed for altered anatomy are further developed, endoscopic therapy will be more accessible to this patient population.

Endoscopic Management of Choledocholithiasis in Challenging Locations
Choledocholithiasis in the intrahepatic biliary ducts, around acute angulations in the bile duct or proximal to a biliary stricture pose a significant challenge to endoscopic stone removal by ERCP. Hepatolithiasis, or choledocholithiasis within the intrahepatic biliary tree, is arguably the most challenging type of complex stone disease to manage endoscopically, not only due to the proximal location of the choledocholithiasis, but also because in many cases these stones are associated with intrahepatic bile duct strictures. The presence of both stone disease and intrahepatic bile duct strictures are a main factor in endoscopic treatment failure due to inadequate access or inability to extract the stones. In these cases, management of the stricture through dilation or serial stent placement and dilation is often necessary to facilitate stone extraction. This can lead to the need for multiple ERCPs prior to even attempted stone extraction. Risk factors for hepatolithiasis include primary sclerosing cholangitis, hepatic artery ischemia, surgical bile duct injuries, foreign bodies, hemolytic disorders, prior liver transplantation, and gallstone disease. Stones in these locations may also form primarily within the liver. When choledocholithiasis in challenging locations is encountered, the standard tool kit for stone extraction, described early in this article, is typically applied; however, serial management of obstacles to stone clearance, such as strictures between the duodenoscope and the stone, must be managed first to accomplish stone clearance. 

CONCLUSION

In conclusion, management of choledocholithiasis has evolved substantially in the last three decades, with endoscopic stone extraction replacing open bile duct exploration surgery and percutaneous biliary drainage. The vast majority of biliary stones are readily extracted by ERCP with the conventional techniques of endoscopic sphincterotomy and balloon extraction, however, extraction proves to be more challenging in approximately 10%-15% of cases in which the stone disease is complex. 

As choledocholithiasis management further evolves, multi-center and population level analyses of complex stone disease management during ERCP will be informative and help guide the continued evolution of endoscopic biliary interventions. the ampulla, however, the cannulation rate is variable, reported to be between 49-92%, which in some part is due to the inverted orientation of the ampulla in that scenario. Rotatable and straight catheters are usually used to access the ampulla from the inverted position. Once the biliary orifice is cannulated, sphincterotomy can be challenging but can usually be accomplished. EPLBD may be a useful technique to employ in these patients.78 A major adverse event to consider in Billroth 2 anatomy is the risk of perforation at the gastrojejunal anastomosis, which reportedly occurs in up to 3.6% of cases.79 

Endoscopic techniques for the management of choledocholithiasis in altered anatomy are ever- evolving and as EUS-guided approaches and devices designed for altered anatomy are further developed, endoscopic therapy will be more accessible to this patient population.

Endoscopic Management of Choledocholithiasis in Challenging Locations
Choledocholithiasis in the intrahepatic biliary ducts, around acute angulations in the bile duct or proximal to a biliary stricture pose a significant challenge to endoscopic stone removal by ERCP. Hepatolithiasis, or choledocholithiasis within the intrahepatic biliary tree, is arguably the most challenging type of complex stone disease to manage endoscopically, not only due to the proximal location of the choledocholithiasis, but also because in many cases these stones are associated with intrahepatic bile duct strictures. The presence of both stone disease and intrahepatic bile duct strictures are a main factor in endoscopic treatment failure due to inadequate access or inability to extract the stones. In these cases, management of the stricture through dilation or serial stent placement and dilation is often necessary to facilitate stone extraction. This can lead to the need for multiple ERCPs prior to even attempted stone extraction. Risk factors for hepatolithiasis include primary sclerosing cholangitis, hepatic artery ischemia, surgical bile duct injuries, foreign bodies, hemolytic disorders, prior liver transplantation, and gallstone disease. Stones in these locations may also form primarily within the liver. When choledocholithiasis in challenging locations is encountered, the standard tool kit for stone extraction, described early in this article, is typically applied; however, serial management of obstacles to stone clearance, such as strictures between the duodenoscope and the stone, must be managed first to accomplish stone clearance. 

CONCLUSION

In conclusion, management of choledocholithiasis has evolved substantially in the last three decades, with endoscopic stone extraction replacing open bile duct exploration surgery and percutaneous biliary drainage. The vast majority of biliary stones are readily extracted by ERCP with the conventional techniques of endoscopic sphincterotomy and balloon extraction, however, extraction proves to be more challenging in approximately 10%-15% of cases in which the stone disease is complex. 

As choledocholithiasis management further evolves, multi-center and population level analyses of complex stone disease management during ERCP will be informative and help guide the continued evolution of endoscopic biliary interventions. 

References

  1. Huang RJ, Thosani NC, Barakat MT, et al. Evolution in the utilization of biliary in- terven­tions in the United States: results of a nationwide longitudinal study from 1998 to 2013. Gastrointest Endosc 2017;86(2):319–26.
  2. Trikudanathan G, Arain MA, Attam R, et al. Advances in the endoscopic man- agement of common bile duct stones. Nat Rev Gastroenterol Hepatol 2014; 11(9):535–44.
  3. Kedia P, Tarnasky PR. Endoscopic Management of Complex Biliary Stone Disease. Gastrointest Endosc Clin N Am. 2019 Apr;29(2):257-275.
  4. Kim HJ, Choi HS, Park JH, et al. Factors influenc­ing the technical difficulty of endoscopic clear­ance of bile duct stones. Gastrointest Endosc 2007;66(6): 1154–60.
  5. U ̈sku ̈dar O, Parlak E, Dis‚ibeyaz S, et al. Major predictors for difficult common bile duct stone. Turk J Gastroenterol 2013;24(5):423–9.
  6. Horiguchi S, Kamisawa T: Major Duodenal Papilla and Its Normal Anatomy. Dig Surg 2010;27:90-93. doi: 10.1159/000288841
  7. Ding J, Li F, Zhu HY, Zhang XW. Endoscopic treatment of difficult extrahepatic bile duct stones, EPBD or EST: An anatomic view. World J Gastrointest Endosc 2015; 7(3): 274-277
    Doshi B, Yasuda I, Ryozawa S, et al. Current endoscopic strategies for managing large bile duct
    stones. Dig Endosc 2018;30(30):59–66.
  8. Sharma SS, Jain P. Should we redefine large common bile duct stone? World J Gastroenterol 2008;14(4):651–2.
  9. Lauri A, Horton RC, Davidson BR, et al. Endoscopic extraction of bile duct stones: management related to stone size. Gut 1993;34(12):1718–21.
  10. Staritz M, Ewe KM, zum BK. Endoscopic papil­lary dilation, a possible alternative to endoscopic papillotomy. Lancet 1982;1(8284):1306–7.
  11. Fujita N, Maguchi H, Komatsu Y, et al. Endoscopic sphincterotomy and endoscopic papillary balloon dilatation for bile duct stones: a prospective ran­domized controlled multicenter trial. Gastrointest Endosc 2003;57(2):151–5.
  12. Bergman JJ, Rauws EAJ, Fockens P, et al. Randomised trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bile duct stones. Lancet 1997;349(9059):1124–9.
  13. Komatsu Y, Kawabe T, Toda N, et al. Endoscopic papillary balloon dilation for the management of common bile duct stones: experience of 226 cases. Endoscopy 1998;30(1):12–7.
  14. Mathuna PM, White P, Clarke E, et al. Endoscopic balloon sphincteroplasty (papillary dilation) for bile duct stones: efficacy, safety, and follow-up in 100 patients. Gastrointest Endosc 1995;42(5):468–74.
  15. Disario JA, Freeman ML, Bjorkman DJ, et al. Endoscopic balloon dilation compared with sphincterotomy for extraction of bile duct stones. Gastroenterology 2004;127(5):1291–9.
  16. Baron TH, Harewood GC. Endoscopic balloon dilation of the biliary sphincter compared to endoscopic biliary sphincterotomy for removal of common bile duct stones during ERCP: a meta-analysis of randomized, controlled trials. Am J Gastroenterol 2004;99(8):1455–60.
  17. Weinberg BM, Shindy W, Lo S. Endoscopic bal­loon sphincter dilation (sphincteroplasty) versus sphincterotomy for common bile duct stones. Cochrane Data- base Syst Rev 2006;(4).
  18. Liao WC, Tu YK, Wu MS, et al. Balloon dilation with adequate duration is safer than sphincter­otomy for extracting bile duct stones: a system­atic review and meta-analyses. Clin Gastroenterol Hepatol 2012;10(10):1101–9.
  19. Liao WC, Lee CT, Chang CY, et al. Randomized trial of 1-minute versus 5-minute endoscopic bal­loon dilation for extraction of bile duct stones. Gastrointest Endosc 2010;72(6):1154–62.
  20. Ersoz G, Tekesin O, Ozutemiz AO. Biliary sphinc­terotomy plus dilation with a large balloon for bile duct stones that are difficult to extract. Gastrointest Endosc 2003;57(2):156–9.
  21. Heo JH, Kang DH, Jung HJ, et al. Endoscopic sphincterotomy plus large- balloon dilation versus endoscopic sphincterotomy for removal of bile-duct stones. Gastrointest Endosc 2007;66(4):720–6.
  22. Stefanidis G, Viazis N, Pleskow D, et al. Large balloon dilation vs. mechanical lithotripsy for the management of large bile duct stones: a pro­spective randomized study. Am J Gastroenterol 2011;106(2):278–85.
  23. Teoh AYB, Cheung FKY, Hu B, et al. Randomized trial of endoscopic sphincterotomy with balloon dilation versus endoscopic sphincterotomy alone for removal of bile duct stones. Gastroenterology 2013;144(2):341–5.
  24. Feng Y, Zhu H, Chen X, et al. Comparison of endoscopic papillary large balloon dilation and endoscopic sphincterotomy for retrieval of choled­ocholithiasis: a meta-analysis of randomized con­trolled trials. J Gastroenterol 2012;47(6): 655–63.
  25. Yang XM, Hu B. Endoscopic sphincterotomy plus large-balloon dilation vs endoscopic sphincter­otomy for choledocholithiasis: a meta-analysis. World J Gastroenterol 2013;19(48):9453–60.
  26. Liu Y, Su P, Lin Y, et al. Endoscopic sphincterotomy plus balloon dilation versus endoscopic sphincter­otomy for choledocholithiasis: a meta-analysis. J Gastroenterol Hepatol 2013;28(6):937–45.
  27. Sakai Y, Tsuyuguchi T, Kawaguchi Y, et al. Endoscopic papillary large balloon dilation for removal of bile duct stones. World J Gastroenterol 2014;20(45): 17148–54.
  28. Xu L, Kyaw MH, Tse YK, et al. Endoscopic sphincterotomy with large balloon dilation versus endoscopic sphincterotomy for bile duct stones: a systematic review and meta-analysis. Biomed Res Int 2015;2015:673103.
  29. Hwang JC, Kim JH, Lim SG, et al. Endoscopic large-balloon dilation alone versus endoscopic sphincterotomy plus large-balloon dilation for the treatment of large bile duct stones. BMC Gastroenterol 2013;13(1).
  30. Cheon YK, Lee TY, Kim SN, et al. Impact of endo­scopic papillary large-balloon dilation on sphincter of Oddi function: a prospective randomized study. Gastrointest Endosc 2017;85(4):782–90.
  31. Kim TH, Kim JH, Seo DW, et al. International consensus guidelines for endo- scopic papil­lary large-balloon dilation. Gastrointest Endosc 2016;83(1):37–47.
  32. Demling L, Seuberth KRJ. A mechical lithotriptor. Endoscopy 1982;14(3):100–1.
  33. Hintze RE, Adler AVW. Outcome of mechanical lithotripsy of bile duct stones in an unselected series of 704 patients. Hepatogastroenterology 1996;43(9): 473–6.
  34. Siegel JH, Ben-Zvi JS, Pullano WE. Mechanical lithotripsy of common duct stones. Gastrointest Endosc 1990;36(4):351–6.
  35. Cipolletta L, Costamagna G, Bianco MA, et al. Endoscopic mechanical lithotripsy of difficult com­mon bile duct stones. Br J Surg 1997;84(10):1407–9.
  36. Chang WH, Chu CH, Wang TE, et al. Outcome of simple use of mechanical lithotripsy of difficult common bile duct stones. World J Gastroenterol 2005;11(4): 593–6.
  37. Garg PK, Tandon RK, Ahuja V, et al. Predictors
    of unsuccessful mechanical lithotripsy and endoscopic clearance of large bile duct stones. Gastrointest Endosc 2004;59(6):601–5.
  38. Lee SH, Park JK, Yoon WJ, et al. How to predict the outcome of endoscopic mechanical lithotripsy in patients with difficult bile duct stones? Scand J Gastroenterol 2007;42(8):1006–10.
  39. Shi D, Yu C-G. Comparison of two capture meth­ods for endoscopic removal of large common bile duct stones. J Laparoendosc Adv Surg Tech A 2014;24(7): 457–61.
  40. Sharma SS, Jhajharia AMS. Short-term biliary stenting before mechanical lithotripsy for dif­ficult bile duct stones. Indian J Gastroenterol 2014;33(3):237–40.
  41. Liu W, Zhang LP, Xu M, et al. “Post-cut”: an endo­scopic technique for managing impacted biliary stone within an entrapped extraction basket. Arab J Gastroenterol 2018;19(1):37–41.
  42. Fenner J, Croglio MP, Tzimas D, et al. Successful treatment of an impacted lithotripter basket in the common bile duct with intracorporeal electrohy­draulic lithotripsy. Endoscopy 2018;50(4):447–8.
  43. Benatta MA, Desjeux A, Barthet M, et al. Case Report impacted and fractured biliary basket : a second basket rescue technique. Case Rep Med 2016;1–2.
  44. Wong JC, Wong MY, Lam KL, et al. Second-generation peroral cholangioscopy and holmium:YAG laser lithotripsy for rescue of impacted biliary stone extraction basket. Gastrointest Endosc 2016;83(4):837–8.
  45. Attila T, May GR, Kortan P. Nonsurgical manage­ment of an impacted mechanical lithotriptor with fractured traction wires: endoscopic intracorporeal electrohydraulic shock wave lithotripsy followed by extra-endoscopic mechanical lithotripsy. Can J Gastroenterol. 2008;22:699–702.
  46. Schneider MU, Matek W, Bauer R, Domschke W. Mechanical lithotripsy of bile duct stones in 209 patients–effect of technical advances. Endoscopy. 1988;20:248–253.
  47. Sauter G, Sackmann M, Holl J, Pauletzki J, Sauerbruch T, Paumgartner G. Dormia baskets impacted in the bile duct: release by extracorporeal shock-wave lithotripsy. Endoscopy. 1995;27:384– 387.
  48. Schreurs WH, Juttmann JR, Stuifbergen WN, Oostvogel HJ, van Vroonhoven TJ. Management of common bile duct stones: selective endo­scopic retrograde cholangiography and endoscopic sphincterotomy: short- and long-term results. Surg Endosc. 2002;16:1068–1072.
  49. Fujita R, Yamamura M, Fujita Y. Combined endo­scopic sphincterotomy and percutaneous tran­shepatic cholangioscopic lithotripsy. Gastrointest Endosc. 1988;34:91–94.
  50. Terheggen G, Neuhaus H. New options of chol­angioscopy. Gastroenterol Clin North Am 2010;39(4):827–44.
  51. Moon JH, Ko BM, Choi HJ, et al. Direct peroral cholangioscopy using an ultra-slim upper endo­scope for the treatment of retained bile duct stones. Am J Gas- troenterol 2009;104(11):2729–33.
  52. Article O, Li J, Guo S, et al. A new hybrid anchor­ing balloon for direct peroral cholangioscopy using an ultraslim upper endoscope. Dig Endosc 2018;30(3): 364–71.
  53. Huang YH, Chang H, Yao W, et al. A snare-assisted peroral direct choledochoscopy and pancreatos­copy using an ultra-slim upper endoscope: a case series study. Dig Liver Dis 2017;49(6):657–63.
  54. Choi HJ, Moon JH, Ko BM, et al. Overtube-balloon-assisted direct per- oral cholangioscopy by using an ultra-slim upper endoscope (with videos). Gastrointest Endosc 2009;69(4):935–40.
  55. Moon JH, Ko BM, Choi HJ, et al. Intraductal balloon-guided direct peroral cholangioscopy with an ultraslim upper endoscope (with videos). Gastrointest Endosc 2009;70(2):297–302.
  56. Efthymiou M, Raftopoulos S, Chirinos JA, et al. Air embolism complicated by left hemiparesis after direct cholangioscopy with an intraductal balloon anchoring system. Gastrointest Endosc 2012;75(1):221–3.
  57. Kondo H, Naitoh I, Nakazawa T, et al. Development of fatal systemic gas embolism during direct per­oral cholangioscopy under carbon dioxide insuffla­tion. Endoscopy 2016;48:E215–6.
  58. Korrapati P, Ciolino J, Wani S, et al. The efficacy of peroral cholangioscopy for difficult bile duct stones and indeterminate strictures: a system­atic review and meta-analysis. Endosc Int Open 2016;04(03):E263–75.
  59. Brewer Gutierrez OI, Bekkali NLH, Raijman I, et al. Efficacy and safety of digital single-operator cholangioscopy for difficult biliary stones. Clin Gastroenterol Hepatol 2018;16(6):918–26.e1.
  60. Sethi A, Chen YK, Austin GL, et al. ERCP with cholangiopancreatoscopy may be associated with higher rates of complications than ERCP alone: a single-center experience. Gastrointest Endosc 2011;73(2):251–6.
  61. Brown NG, Camilo J, Nordstrom E, et al. Advanced ERCP techniques for the extraction of complex bil­iary stones: a single referral center’s 12-year expe­rience. Scand J Gastroenterol 2018;53(5):626–31.
  62. Lee TH, Han JH, Kim HJ, et al. Is the addition of choleretic agents in multiple double-pigtail bili­ary stents effective for difficult common bile duct stones in elderly patients? A prospective, multi­center study. Gastrointest Endosc 2011; 74(1):96– 102.
     
    stenting combined with ursodeoxycholic acid and terpene treatment on retained common bile duct stones in elderly patients: a multicenter study. Am J Gastroenterol 2009;104(10): 2418–21.
  63. Lee TH, Han JH, Kim HJ, et al. Is the addition of choleretic agents in multiple double-pigtail bili­ary stents effective for difficult common bile duct stones in elderly patients? A prospective, multi­center study. Gastrointest Endosc 2011; 74(1):96– 102.
  64. Garc ́ıa-Cano J, Reyes-Guevara AK, Mart ́ınez-Pe ́rez T, et al. Fully covered self- expanding metal stents in the management of difficult common bile duct stones. Rev Esp Enferm Dig 2013;105(1):7– 12.
  65. Hartery K, Lee CS, Doherty GA, et al. Covered self-expanding metal stents for the management of common bile duct stones. Gastrointest Endosc 2017;85(1): 181–6.
  66. Shah RJ, Smolkin M, Yen R, et al. A multicenter, U.S. experience of single- balloon, double-bal­loon, and rotational overtube-assisted enteroscopy ERCP in patients with surgically altered pancre­aticobiliary anatomy (with video). Gas- trointest Endosc 2013;77(4):593–600.
  67. Kedia P, Sharaiha RZ, Kumta N a, et al. Endoscopic gallbladder drainage compared with percutaneous drainage. Gastrointest Endosc 2015;82(6): 1031–6.
  68. Kint JF, van den Bergh JE, van Gelder RE, et al. Percutaneous treatment of com- mon bile duct stones: results and complications in 110 consecu­tive patients. Dig Surg 2015;32(1):9–15.
  69. Schreiner MA, Chang L, Gluck M, et al. Laparoscopy-assisted versus balloon enteros­copy-assisted ERCP in bariatric post-Roux-en-Y gastric bypass pa- tients. Gastrointest Endosc 2012;75(4):748–56.
  70. Frederiksen NA, Tveskov L, Helgstrand F, et al. Treatment of common bile duct stones in gas­tric bypass patients with laparoscopic transgastric endoscopic retrograde cholangiopancreatography. Obes Surg 2017. https://doi.org/10. 1007/s11695- 016-2524-2.
  71. Gutierrez JM, Lederer H, Krook JC, et al. Surgical gastrostomy for pancreatobiliary and duodenal access following Roux en Y gastric bypass. J Gastrointest Surg 2009;13(12):2170–5.
  72. Kedia P, Tarnasky PR, Nieto J, et al. EUS-directed transgastric ERCP (EDGE) versus laparoscopy-assisted ERCP (LA-ERCP) for Roux-en-Y Gastric bypass (RYGB) anatomy: a multicenter early comparative experience of clinical outcomes. J Clin Gastroenterol 2018. https://doi.org/10.1097/ MCG.0000000000001037.
  73. Sharaiha RZ, Khan MA, Kamal F, et al. Efficacy and safety of EUS-guided biliary drainage in comparison with percutaneous biliary drainage when ERCP fails: a systematic review and meta-analysis. Gastrointest Endosc 2017;85(5):904–14.
  74. Chahal P, Baron T, Topazian M. Endoscopic retro­grade cholangiopancreatography in post-Whipple patients background. Endoscopy 2006;38:1241–5.
  75. Nakai Y, Kogure H, Yamada A, et al. Endoscopic management of bile duct stones in patients with sur­gically altered anatomy. Dig Endosc 2018;30:67– 74.
  76. Park TY, Bang CS, Choi SH, et al. Forward-viewing endoscope for ERCP in patients with Billroth II gas­trectomy: a systematic review and meta-analysis. Surg Endosc 2018;32(11):4598–613.
  77. Fukino N, Oida T, Kawasaki A et al.. Impaction of a lithotripsy basket during endoscopic lithotomy of a common bile duct stone. World J Gastroenterol 2010; 16 (22): 2832-2834.
  78. Tao T, Zhang M, Zhang Q-J, et al. Outcome of a session of extracorporeal shock wave lithotripsy before endoscopic retrograde cholangiopancre­atography for problematic and large common bile duct stones. World J Gastroenterol 2017; 23(27):4950.
  79. Han J, Moon JH, Koo HC, et al. Effect of biliary
     

Download Tables, Images & References

Acute Severe Ulcerative Colitis

Read Article

Acute severe ulcerative colitis (ASUC) will affect at least one in four patients with ulcerative colitis,

requiring hospitalization and induction therapy to achieve remission. The initial assessment should

include measurement of inflammation, testing for infection, and evaluating for toxic megacolon. All

patients will need prophylaxis against venous thromboembolism, and most will require significant

IV hydration. Early endoscopy with biopsies will rule out cytomegalovirus (CMV) and herpes

simplex virus (HSV) and help assess severity. First line therapy with intravenous corticosteroids

is effective in 2/3rds of patients, while rescue therapy with cyclosporine or infliximab is effective

in 80% of the remaining 1/3rd. Roughly 10% will require colectomy in the initial hospitalization,

and another 5% will need a colectomy in the next 90 days. Close monitoring after discharge and

timely adjustment of maintenance therapy to maintain remission is essential in these high-risk

patients. First line small molecule therapies in high-risk patients may help reduce colectomy rates.

How is severe UC defined?  

Severe ulcerative colitis was defined by Truelove and Witts in 19551 which reported on the use of cortisone in severe UC. Severe UC was defined as six or more bowel movements per day with visible blood in stools, and one or more of the following: fever > 100F/37.8C, tachycardia > 90 bpm, anemia (hemoglobin<= 10.5), or an ESR >= 30 mm per hour. Neither C-reactive protein (CRP) nor fecal calprotectin (FCP) were standard measurements in 1955. Kedia, et al.2 used the Truelove and Witts criteria to validate a laboratory definition of severe UC and found that an FCP > 782 mcg/g of stool could identify severe UC with a sensitivity of 84% and a specificity of 88%. CRP is often elevated in severe UC, and when positive, can be followed daily as a marker of response to therapy. FCP and ESR change more slowly than CRP and are less helpful as rapid dynamic markers of response to therapy. 

What is acute severe UC? 

In theory, acute severe UC indicates a flare of rapid onset, but the rapidity is not defined. As a practical definition, we generally define patients hospitalized for severe flares as having acute severe UC. In practice, this may include some patients with more chronic, ongoing flares, who have not responded to outpatient steroids or previous inpatient therapy with IV corticosteroids. These patients who have failed prior steroids (and/or prior biologics) are at particularly high risk for colectomy. 

Admission and initial assessment 

The initial assessment should include measurement of inflammation with CRP and FCP, testing for infection, usually including Clostroides difficile testing and a stool polymerase chain reaction (PCR) panel for enteric infection, and evaluating for toxic megacolon with abdominal x-ray, a complete blood count and differential, chemistries to detect baseline electrolyte and liver problems, and physical exam for toxic megacolon and dehydration. 

Infection with C. diff can be detected with PCR and antigen testing for toxin, though detected C. diff may be merely colonization, may activate a UC flare, or may be the primary driver of diarrhea. Decisions about when to treat C. diff and hold corticosteroid therapy can be difficult. In general, mild inflammation and a positive toxin antigen test should favor treatment with vancomycin for C. diff without starting steroids. A sigmoidoscopy more consistent with UC rather than C. diff, and a lack of substantial improvement on vancomycin after 48 hours should trigger initiation of corticosteroids. The absence of toxin antigen, more severe inflammation, and a scope consistent with active UC should favor early initiation of corticosteroids, even if this means co-treatment with vancomycin to cover Clostroides difficile

Stool PCR testing for other enteric infections and PCR for CMV are controversial, as many of the positive tests will be “red herrings” in the setting of a UC flare and may not be driving the clinical presentation. The presence of nausea or vomiting in the setting of a positive norovirus test suggests that this is a real infection, and occasional E. coli infections do occur in UC, particularly with recent steroid exposure. Very high CMV titers confirmed on biopsy can be primary CMV infections, especially after an extended course of corticosteroids. C. diff remains the most common colonic infection in UC and should be suspected as the primary driver when diffuse abdominal pain and fever are present and minimal or no blood in stool is seen. 

The initial abdominal film should be evaluated for colonic thumbprinting and the presence of free air under the diaphragm. Ideally these should be rare when patients present early in a flare, but the risk of perforation rises over time in patients who have failed outpatient or inpatient steroid therapy, and this is especially important in readmissions or hospital transfers. An abdominal exam suspicious for rebound, or a very high (or surprisingly low) white blood cell count with thumbprinting should precipitate an early call to your surgical colleagues to get them on board. 

Risk assessment 

Patients with ASUC are at increased risk of colectomy if they have failed prior steroids or biologics, are younger or former smokers, require early admission after diagnosis, have extensive colitis or deep ulcerations, have high CRP and ESR, or have low hemoglobin or albumin. The number of positive Truelove and Witts additional criteria (anemia, fever, tachycardia, ESR) have also been shown to be predictive of colectomy (Table 1).3 Early endoscopy (usually a flexible sigmoidoscopy with biopsies in the first 12 hours) can help prognosticate severity, and biopsies can help rule out CMV and HSV as infectious causes of colitis. 

Empiric therapy and prevention of complication 

All acute severe UC patients should receive empiric therapy to improve their symptoms and prevent complications. All patients should receive medical prophylaxis for venous thromboembolism, as both active severe UC and the use of corticosteroids increase the risk of venous thromboembolism (VTE). Patient mobility should not be a reason to avoid therapy with enoxaparin or unfractionated heparin, as these risk factors are unchanged by mobility. Confirm daily dosing with the patient, the responsible, nurse, and the medication administration record. 

Nearly all patients will be dehydrated upon admission, due to self-restriction of food and fluids to reduce bowel moments, in addition to many watery bowel movements. This should be ameliorated with infusion of IV fluids initially at 1 L per hour until thirst is no longer present, and urine output is frequent and clear. Patients with heart failure, renal failure, or other contraindications to volume infusion should be started at a lower rate and monitored closely. 

Most patients will have a limited appetite at the time of admission and should not force food intake. Many will be able to tolerate small amounts of high protein liquid nutrition, e.g., Boost or Ensure, until their appetite returns. When able to tolerate food, patients should start slowly with a high protein, low residue diet, often provided as a high protein breakfast at each meal and advance to full diet as tolerated. Many patients have severe urgency at theinitial presentation, and can benefit from a bedside commode, and twice daily 5-ASA suppositories to reduce this symptom. Patients in the hospital benefit from protected sleep time. Consider providing night quiet hours, limiting vitals and blood draws when possible, and dosing intravenous steroids early in the day (e.g., 6 AM and 2 PM for bid dosing) to reduce sleep disturbance. Discuss with each patient the common side effects of steroids and their effects on sleep, anxiety, depression, and PTSD. Each inpatient stay is also an opportunity for education, particularly on therapies for UC and surgical options for UC. Encourage patients to keep a pad and pen nearby to write down questions during the day. I often use the IBD School videos on YouTube to address particular education topics tailored to each patient. 

First line therapy 

When patients are first admitted to the hospital, and infection testing is pending, first line therapy with methylprednisolone, a corticosteroid, at a standard dose of 30 mg bid, is recommended. There is no evidence that doses higher than 1 mg per kilogram per day add any benefit. Alternative dosing schedules of once daily, three times daily, four times daily, or continuous dosing do not seem to have any additional benefit, though more frequent dosing may interfere with sleep. 

Over time, an increasing number of ASUC patients are presenting with prior biologic (usually anti-TNF) failure. Recent case-control data in high-risk patients with prior biologic failure treated with first line tofacitinib 10 mg three times daily in combination with intravenous solumedrol suggest initial presentation, and can benefit from a bedside commode, and twice daily 5-ASA suppositories to reduce this symptom. Patients in the hospital benefit from protected sleep time. Consider providing night quiet hours, limiting vitals and blood draws when possible, and dosing intravenous steroids early in the day (e.g., 6 AM and 2 PM for bid dosing) to reduce sleep disturbance. Discuss with each patient the common side effects of steroids and their effects on sleep, anxiety, depression, and PTSD. Each inpatient stay is also an opportunity for education, particularly on therapies for UC and surgical options for UC. Encourage patients to keep a pad and pen nearby to write down questions during the day. I often use the IBD School videos on YouTube to address particular education topics tailored to each patient. 

First line therapy 

When patients are first admitted to the hospital, and infection testing is pending, first line therapy with methylprednisolone, a corticosteroid, at a standard dose of 30 mg bid, is recommended. There is no evidence that doses higher than 1 mg per kilogram per day add any benefit. Alternative dosing schedules of once daily, three times daily, four times daily, or continuous dosing do not seem to have any additional benefit, though more frequent dosing may interfere with sleep. 

Over time, an increasing number of ASUC patients are presenting with prior biologic (usually anti-TNF) failure. Recent case-control data in high-risk patients with prior biologic failure treated with first line tofacitinib 10 mg three times daily in combination with intravenous solumedrol suggest a significant reduction of colectomy rates (Figure 1) with aggressive first line therapy.4 

All patients should be advised that colectomy is a reasonable option even at first line, as some patients will choose a one-time colectomy over lifelong maintenance medication. It is important for all patients to meet the local colorectal surgeons, usually on day two of admission, and to meet the wound care ostomy nurse, who will mark a site for optimal ostomy placement. A key part of patient education is to establish that colectomy is a reasonable therapeutic option, and to re-emphasize this regularly during the course of the hospital stay. 

Reassessment at 72 hours 

Patients should be monitored closely during their first 72 hours on steroids, including daily measurements of CRP, and tracking of bowel movements. The patient should be counseled on the options of colectomy and rescue therapy and should be prepared to make a decision on the next step if needed at 72 hours. There are three indices developed to estimate the likelihood of success of intravenous, steroids, and 72 hours. The CRP should be collected at 72h on steroids, and the most recent 24-hour bowel movement count used to calculate the Travis, Lindgren, and Ho prognostic indices, as described in the Michigan Severe UC Protocol.5 If these all indicate low risk of colectomy, you should plan a transition to oral corticosteroids, advance to full diet, and plan for a maintenance therapy. If any one of these indices indicates high risk, the patient should be prepared to choose between colectomy and rescue therapy, so that either option can be started in a timely fashion. 

Rescue therapy options 

The two best studied rescue therapies after corticosteroids have failed in ASUC are cyclosporine and infliximab, which had equivalent 98-day outcomes in the CYSIF trial. One of the challenges of starting any biologic medication in ASUC is the protein leak across the damaged colon. Infliximab has been shown to leak into stool effluent at a high rate, lowering drug levels in ASUC patients. Small molecules (methylprednisolone, cyclosporine, Jak inhibitors), in contrast, bind to receptors inside of cells. This lowers their serum level, and the amount of drug available to leak out of the colon. This makes the small molecules more attractive for induction of remission in ASUC. Limited data from a GETAID study suggest a high (79% at 3 months) success rate with tofacitinib after prior corticosteroid and biologic failure.6 

A second problem with using biologics for induction of remission in ASUC is the low trough levels that frequently result with a leaky colon. Particularly for older biologics prone to formation of anti-drug antibodies like infliximab, this increases the risk of forming blocking antibodies, making it more attractive to achieve induction with small molecules, and start biologics after the colon leak has been slowed. 

The third limitation of using a biologic for rescue therapy is that these drugs have a long half-life and tend to stay around for weeks at a time. If one is considering salvage therapy with a different medication, this compounds immunosuppression from steroids, the biologic rescue drug, and the addition of a 3rd salvage drug. It is usually wiser to use small molecules with more rapid washout for first and second line therapy if a 3rd line salvage therapy is being considered. 

Assessing rescue therapy 

The outcome from rescue therapy should be assessed between 72 and 108 hours after initiation. Daily CRP and a repeat FCP will be helpful, as these should continue to trend downward and enter the normal range. Bleeding in bowel movements should cease, and the number of bowel movements should be reduced. If bowel symptoms plateau, and CRP and/or FCP rise, these are bad prognostic signs, and generally mean colectomy in the very near future. In patients who have been on corticosteroids for some time and have a worsening of inflammation, it can be worth rechecking for CMV and/or rescoping with a flexible sigmoidoscopy to help inform the decision about colectomy. 

Should you salvage? 

Some patients, especially those new to ulcerative colitis, may resist the idea of colectomy, even after failure of corticosteroids and rescue therapy. The plan for next option should be an ongoing discussion during rescue therapy, with clear recommendation of colectomy as the standard of care. Salvage therapy entails significant risks, with multiple immunosuppressive medications that increase the risk of both infection and death. There are very limited data on salvage therapy with a 3rd immunosuppressive medication and some case series have documented high rates of infection, and occasional deaths. These risks may be decreased by the rapid washout of prior small molecules and may be increased by prior biologic therapies with long half-lives. 

Patients need to be aware of the risks of multiple immunosuppression, and there must be a clear plan for an exit to a long-term maintenance therapy that is acceptable to the patient before any salvage therapy is attempted. It must be clear to both the patient and the provider colectomy is the standard of care after failure of rescue therapy, as the data on salvage therapy is very limited, and includes significant negative outcomes. 

Preparing for colectomy 

Preparing a patient for a colectomy is an ongoing process during each admission for ASUC. Colostomy must be presented as a viable therapeutic option, and a good ostomy site should be marked early in the stay by a wound ostomy care nurse. If there has been no previous imaging of the small bowel, CT or MRI should be done to evaluate for Crohn’s disease rather than ulcerative colitis. An ongoing discussion with the surgeons should begin on day two of admission, and patient education about surgical options should be ongoing. When a decision is made to proceed to colectomy, immunosuppressive medications (including corticosteroids) should be stopped, and if possible, given time to wash out before surgery. When possible, nutritional status should be optimized, and an elective colectomy is always preferred over toxic megacolon, perforation, or an emergent colectomy. 

Preparing for discharge 

For the patient who achieves induction of remission during the hospitalization, planning for a successful discharge should begin as soon as the patient turns the corner. You should expect no blood in the stool and a CRP below 10 mg/L. Patient should be able to advance to a full diet without recurrence of symptoms. The patient should be able to stop all intravenous therapy and transition to oral therapy. Note that switching from 60 mg daily methylprednisolone to 60 mg prednisone is a drop of 20% in efficacy, while a transition to 40 mg prednisone is an 88% drop in efficacy. The patient should be able to walk around and maintain normal activity levels as if they were at home for 24 hours before discharge. After 24 hours on oral therapy, there should not be a sudden rise in CRP, and you should obtain a new FCP to establish a new baseline. Note that while CRP often rapidly normalizes, FCP (along with mucosal healing) may take months to normalize. Some practitioners will obtain a repeat flexible sigmoidoscopy, especially in high-risk patients, to establish a new baseline and to estimate the time to complete mucosal healing. It is important to obtain insurance approvals of all maintenance therapies, and schedule infusions if needed, before the patient leaves the hospital. 

After discharge 

After induction of remission and discharge, it is important to monitor patients closely, as there is a high rate of recurrence and readmission. We typically monitor CRP, FCP, and symptoms for any recurrence at 1, 3, and 6 weeks. We standardize our symptom collection with the UC-PRO instrument in Epic. The typical discharge plan will start the patient on prednisone at a dose of 40 or 60 mg (for more severe cases) daily, with tapering by 5 mg per week. There is sone data suggesting that effective induction of remission with cyclosporine may not need a prednisone taper,7 though this needs further study to determine if this is generalizable and whether this applies to other small molecules like JAK inhibitors. It is also important to check in on the patient after discharge to make sure that they have actually started their maintenance medication on schedule, without any insurance hiccups, and that they are tolerating this well. Readmissions and subsequent ASUC admissions increase the risk of colectomy, as documented by Dinesen.3

References 

1. Truelove & Witts. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ. 1955; 2(4947): 1041- 1048. 

2. Kedia, S, et al. Potential of Fecal Calprotectin as an Objective Marker to Discriminate Hospitalized Patients with Acute Severe Colitis from Outpatients with Less Severe Disease. Dig Dis Sci. 2018; 63(10): 2747-2753. 

3. Dinesen, L., et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010; 4(4): 431-437. 

4. Berinstein, J.A., et al. Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study. Clin Gast Hep. 2021; 19(10): 2112-2120. 

5. Higgins, P.D.R., et al. University of Michigan Severe Ulcerative Colitis Protocol, version 2.99. June 3, 2022, website updated annually. https://www.med.umich.edu/ ibd/docs/severeucprotocol.pdf 

6. Uzzan, M., et al. Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort. Aliment Pharmacol Ther. 2021; 54(3): 312-319. 

7. Tarabar, D., et al. A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. Inflamm Bowel Dis. 2022; 28(10): 1549-1554. 

Download Tables, Images & References

Cholangioscopy

Cholangioscopy

Read Article

Key Points

• Cholangioscopy has evolved substantively over the last few decades to enable a single operator to directly examine the biliary tree using digital platforms.

• Cholangioscopy-guided intraductal therapy with electrohydraulic or laser lithotripsy is a safe and effective treatment for difficult bile duct stones.

• Cholangioscopy with guided biopsies represents a powerful diagnostic tool for indeterminate biliary strictures and new diagnostic criteria and technology promises that its role will increase.

• The adverse event rates of cholangioscopy are acceptable when it is performed by trained endoscopists using appropriate precautions including judicious biliary stent use.

Technology to enable direct visualization of the bile duct has gone through several stages of revision.1 While widespread clinical use has emerged only over the past 5-10 years, the first percutaneous cholangioscopy was reported in 19512 and peroral exam in 1976.3 It was first utilized for laser and electrohydraulic lithotripsy in the late 1980’s.4,5 

The first commercially available cholangioscopes used a mother-baby system that  required a high degree of coordination between two endoscopists: one controlling the mother duodenoscope and the other controlling a slim through-the-channel baby scope. The major limitations of this system were the fragility of the cholangioscopes, suboptimal image quality and limited maneuverability related to the need for two operators.6 

Direct peroral cholangioscopy with ultraslim cholangioscopes, which did not pass through a “mother” scope, provided higher resolution images, and mitigated challenges associated with fragility. However, the technical success was low and inconsistent, due to the need to anchor a flexible scope through the mouth deeply into the biliary tree. Specific problems included unstable position, requirement for a large sphincterotomy, and the lack of the ability to examine the bile ducts beyond the bifurcation of the main hepatic duct given the scope size and need to inflate an anchoring balloon in the biliary tree itself.7,8 

These issues limited widespread use. In 2007, a cholangioscope which could be passed via the accessory channel and controlled by a single operator was introduced. These devices used a reusable fiberoptic cable in a disposable scope.9 A channel in the scope enables passage of a biopsy forceps and introduction of laser and electrohydraulic lithotripsy probes.10 The most recent major innovation in cholangioscopy has been the introduction of a single-use, digital imaging version of the single-operator cholangioscopes (DSOC) which provided a higher image quality, simplified assembly and a flexible introduction system (Figure 1).1,11 

Over the past decade, cholangioscopy has become a widely used tool in academic and community medical centers. In this article, we will address its role in biliary disease. It represents a primary tool for difficult choledocholithiasis, and the assessment of indeterminate biliary strictures. In addition to its major therapeutic and diagnostic roles, we will discuss technique, emerging applications, cost and safety of this technology. 

BASIC CHOLANGIOSCOPY TECHNIQUE 

Most contemporary cholangioscopic procedures are performed with a disposable DSOC via peroral approach during endoscopic retrograde cholangiopancreatography (ERCP). After testing the light and the dials of the cholangioscope, and flushing the channel with water for lubrication, the handle of the scope is strapped just below the duodenoscope working channel. An adequate sphincterotomy or balloon sphincteroplasty is indicated to allow passage of the cholangioscope. Then, the cholangioscope is advanced through the duodenoscope channel preferably over a previously inserted guidewire into the bile duct under fluoroscopic guidance. Once the cholangioscope is in a stable position in the distal or middle common bile duct, irrigation with sterile water allows visualization of the bile duct aided by four-way tip deflection. The cholangioscope is advanced over the guidewire to a targeted biliary site before the wire is removed to allow optimal visualization and to allow advancing any instruments through its channel if needed. It may be necessary to gently advance the duodenoscope forward to favor parallel alignment of the cholangioscope and the bile duct to allow deeper insertion. The locks on the duodenoscope and cholangioscope may need to be released to advance the cholangioscope.

These maneuvers may also be needed to advance instruments (i.e., electrohydraulic lithotripsy (EHL)/laser probe or biopsy forceps) through the cholangioscope channel. Another technique is to advance the cholangioscope gently forward at the same time as the instrument is passed through the working channel. Sometimes, it is necessary to advance the cholangioscope to the hilum to pass tools through its channel and then slowly back it distally toward the ampulla. Advancement of instruments (e.g., laser fiber and forceps) may be particularly difficult at the level of the cholangioscope traversing the duodenoscope elevator or deflected tip of cholangioscope. No force must be used to push instruments within the cholangioscope channel to avoid damage. Gentle advancement or withdrawal of the duodenoscope or cholangioscope and release of all locks is important to negotiate this challenge. Repetitive opening and closing of the forceps while advancing it through the cholangioscope channel may also facilitate successful advancement. 

Attention must be paid to the duodenoscope position throughout the procedure and fluoroscopy should be obtained intermittently to determine the location of the cholangioscope and avoid accidentally falling out of the bile duct. To optimize visibility, contrast use before cholangioscopy should be minimized. Additionally, irrigation with water or saline should be kept to a level necessary to facilitate evaluation to reduce the risk of bacterial translocation and the development of cholangitis, although it is not clear from available evidence whether irrigation is a definite risk factor for biliary infection.12 The four-way dials may need to be locked when a certain intervention is considered, such as sampling of a lesion or performing lithotripsy in an oblique position. However, the use of dial locking should be used with caution to avoid ductal injury and must not be used whenever the cholangioscope is advanced up within the bile duct. 

INDICATIONS FOR CHOLANGIOSCOPY 

Management of Choledocholithiasis 

ERCP is the primary treatment modality for bile ducts.13 A broad armamentarium of tools can be used through the duodenoscope channel to allow lithotripsy, stone removal and ductal clearance. These tools include extraction balloons, sweeping baskets, mechanical lithotripsy baskets, papillary dilation balloons, and biliary stents.14,15 Nevertheless, in approximately 10-15% of cases, fundamental techniques fail either due to very large stone size, extremely hard consistency, barrel or piston shape, faceted configuration or ductal features such as a diminutive orifice, distal narrowing or sigmoid shape.14, 16-19 

Cholangioscopy-guided lithotripsy represents a core therapeutic approach for the most difficult bile duct stones (Table 1). There are two commonly used modalities used to perform direct intraductal lithotripsy: electrohydraulic lithotripsy (EHL) and pulsed laser lithotripsy (LL). These modalities are most frequently guided by peroral cholangioscopes. While they may also be guided by fluoroscopy or percutaneously-introduced cholangioscopes, the former is limited by relatively blind targeting and the latter by hemobilia and bile leaks. 20,21 

EHL delivers high-energy shockwaves generated by high voltage electric sparks delivered via fiber advanced through the accessory channel of the cholangioscope. The bile ducts are irrigated with saline to allow transfer of energy to the stone and minimize buildup of thermal energy.22 The probe should be positioned about 2 mm from the stone and directed towards the center (Figure 2a) and typically application of energy will result in a shattering of the stone (Figure 2b). If a cavity forms in the center without fracture the EHL probe may be aimed at the resulting joints to disrupt the stone into small fragments (Figure 2c). In LL, the shockwave is generated by the creation of a plasma cloud by high energy pulsed light delivered through flexible fiber (via the cholangioscope) into an aqueous media (saline or water).23 An aiming light allows precise targeting and helps prevent bile duct injury (Figure 3a). Intermittent irrigation and suctioning of the bile duct to wash away the minute fragments allow optimal visibility during the lithotripsy and dissipate heat energy. When LL is performed, safety measures must be observed and the manufacturer’s instructions must be followed including proper eye protection.24 Several technical maneuvers to weaken stones are to drill centrally through its core (Figure 3b) versus cutting it horizontally by using a saw motion generated by rocking the laser probe back and forth using the cholangioscope controls (Figure 3c). 

A randomized trial demonstrated that peroral-cholangioscopy-guided lithotripsy reduced the need for surgical removal of difficult bile duct stones by four-fold.25 A meta-analysis of 2,204 patients with difficult bile duct stones revealed that the overall clearance was 92% (95% CI 90-94%).13 While overall adverse events for intraductal therapy was 8% (95% 6-11%), this was comparable to the rate for difficult stone treatment by conventional (non-intraductal) methods, 9% (95% 8-11%). The comparative safety and efficacy of cholangioscopy-guided EHL and LL has been investigated in a multicenter, international, observational study.26 Complete ductal clearance was high and comparable in both methods (97% and 99%, respectively). However, the mean procedure time was longer in the EHL group as compared to LL group (74 min and 50 min; P < 0.001). Adverse events were reported in 3.7% and they included cholangitis, bleeding and abdominal pain. Another prospective, multicenter study on peroral cholangioscopy-guided lithotripsy with EHL or LL in patients with difficult bile duct stones showed that ductal clearance was achieved within a single session in 80% (95% CI 73 – 86%) of patients.27 

Cholangioscopy may also enable stone removal without fluoroscopy and can be used to identify missed bile duct stones in the context of patients with marked ductal dilatation and other features which reduce sensitivity of cholangiography.28 Cholangioscopy guided intraductal therapy has also emerged as a safe and effective endoscopic approach for the dreaded scenario in which stones become impacted in lithotripsy baskets within the bile duct.29 While this problem used to frequently require surgery, in most cases effective intraductal lithotripsy of the impacted stone will result in a prompt release of the impacted apparatus (stone + basket) from the duct (Figure 4). Finally, baskets introduced directly through the cholangioscope may be used to target and remove stones, particularly if located in an obliquely oriented duct (Figure 5).30 

Therefore, cholangioscopy with intraductal therapy has a well-defined role in the management of difficult stones to obviate the need for surgery (Figure 6). Additionally, in cases in which there is suspicion of retained stones or other diagnostic uncertainty it has a burgeoning role. 

EVALUATION OF INDETERMINATE BILIARY STRICTURES 

Indeterminate biliary strictures represent a major and frequently encountered challenge for advanced endoscopists. While the ERCP brush cytology and trans-papillary intraductal forceps biopsy have high (95-99%) specificity for malignancy, the sensitivity is suboptimal (<50%) for both techniques (Figure 7a-b).33,34 

Fine needle aspiration of biliary strictures via endoscopic ultrasound (EUS-FNA) has a comparably high specificity, 97% (95% CI 94- 99%) and 80% (95% CI 74-86%), sensitivity.35 Furthermore, EUS-FNA specifically following negative ERCP-guided cytologic brushing and biopsy has a 77% sensitivity and 100% specificity (Figure 7c).36 Nevertheless, there is concern about malignant seeding for EUS-FNA of proximal or hilar biliary lesions, though trials suggest that this may be overstated.37 EUS-FNA is a contraindication for patients with cholangiocarcinoma who are potentially candidates for a liver transplant treatment protocol.38 

Given that cholangioscopes are introduced via the “natural” papillary orifice and do not cross a tissue plane there is less concern for seeding. It provides an opportunity both for visual assessment and diagnostic sampling. The identification of cholangioscopic visual features associated with benign, inflammatory and malignant diseases of the bile ducts has been the subject of multiple studies.39-44 Intraductal mass lesions and irregular nodules are strongly suggestive of malignancy (Figure 8).43 Dilated and tortuous vessels have also been proposed as concerning features.39,42 Papillary and villous projections are suggestive of neoplasia,44 while a smooth glandular surface is consistent with benign etiology (Figure 9). Diffuse but symmetric and homogenous narrowing may suggest a non-neoplastic inflammatory process such as primary sclerosing cholangitis (Figure 10) or IgG4 mediated cholangiopathy. Systematic review and meta-analysis of the visual features suggest a pooled diagnostic sensitivity of 60.1% (95% CI 54.9%-65.2%) and specificity of 98.0% (95% 96.0-99.0%).45 Nevertheless, studies of interobserver agreement suggest only slight to fair agreement for most individual visual features.46 

Several classification systems have been developed to better categorize the cholangioscopic impressions of the bile duct. The Monaco Classification was developed by a recent multicenter group of expert biliary endoscopists using direct peroral cholangioscopy and digital single-operator cholangioscopy.40 The interobserver agreement (IOA) was slight in scoring for ulceration, white linear bands, and pronounced pits. The IOA was fair in scoring for the presence of stricture, a lesion, mucosal changes, and abnormal vessels. The IOA was moderate in scoring for papillary projections. The presumptive diagnosis IOA was fair (κ = 0.31, SE = 0.02) (Table 2). The overall accuracy of Monaco Classification based on visual impression alone was 70%. An alternative classification system is the Carlos Robles Medrana (CRM) criteria.41 Recently, the authors of the Monaco and CRM criteria convened to develop the newest visual criteria for cholangioscopy, the Mendoza criteria.47 These include the presence of tortuous and dilated vessels, irregular nodularity, raised intra-ductal lesions, irregular or ulcerated surface, and friability. The authors report a diagnostic accuracy of 77% for the criteria, nevertheless these criteria require external validation. As the use of cholangioscopy expands and more studies on endoscopic features of bile duct diseases are performed, the accuracy of visual inspection will likely continue to improve over time. 

In addition to direct visualization of the bile duct lumen, cholangioscopy allows targeted biopsies using small diameter forceps which pass through the working channel of the cholangioscope (Figure 11). Systematic review and meta-analysis of observational studies indicated that the pooled sensitivity and specificity of cholangioscopy guided biopsies is 60.1% (95% CI 54.9%-65.2%) and 98.0% (95% CI 96.0%-99.0%), respectively.45 In a recent multicenter randomized trial, DSOC-guided biopsy sampling significantly improved the sensitivity of a tissue diagnosis, 68.2%, versus ERCP guided brushing, 21.4%. Specificity was 100% for both modalities.48 Given small size of biopsies specimen it is recommended to take multiple biopsies from each biliary lesion. While meta-analysis indicates reduced yield for 2 or fewer biopsies, the precise number is undefined.49 

Recently, a larger forceps passed via the cholangioscopes which obtains more tissue per pass has been introduced (Figure 11b). While the aim is to improve yield, improved performance has not yet been demonstrated in studies.50 

Given favorable performance characteristics and minimal risk of seeding it is frequently utilized in the central diagnostic algorithm of biliary strictures in patients who are potentially resectable, candidates for transplantation, and those who have failed other diagnostic maneuvers (Figure 12). 

FACILITATING THERAPY FOR CHALLENGING BILE DUCT STRICTURES 

Successful guidewire placement is essential to allow therapeutic interventions during ERCP such as dilation and decompression using stents. Using different kinds of guidewires with different characteristics (e.g., angled vs. straight tip, wire size, stiffness) along with trying different scope positions often allows successful guidewire placement. However, in some cases these conventional techniques and instruments fail to reach the duct of interest. By enabling direct visualization of bule ducts, cholangioscopy allows selective passage of wires and subsequent therapy into very specific biliary targets (Figure 13).51-55 In addition, selective bile duct cannulation by direct cholangioscopic visualization mitigates the likelihood of extensive fluoroscopy use and may reduce procedure time. 

OTHER INDICATIONS 

An important and specialized scenario where direct visualization by POC has been successfully used is the evaluation of biliary complications after liver transplantation. Post-transplant strictures may have extremely oblique angulation or high-grade nature, particularly following living donor procedures, which may benefit from cholangioscopy.56,57 In addition to facilitating guidewire placement across difficult angulation or strictures, cholangioscopy may have a diagnostic role in post-transplant patients to identify surreptitious mural ulceration retained sutures, and stones or casts which are not apparent on cholangiography.57,58 It is unclear whether the utilization of POC for evaluation of biliary complications during first ERCP is warranted. Nevertheless, it is worth considering in cases that are not responsive to initial ERCP with interventions and when there is diagnostic uncertainty. 

POC has been successfully used for a number of other indications. Prior to complex resection, it may be used to perform mapping which can guide surgery.59 It may also play an important diagnostic role to evaluate malignancy in choledochal cysts,60,61 guide tumor ablation with radiofrequency or photodynamic therapy62, and evaluate source of hemobilia.63-65 POC was also found beneficial in retrieval of migrated biliary stents.66 As technology, training and access to cholangioscopy grow, additional novel applications will emerge. 

COST AND ADVERSE EVENTS 

Cost and safety are additional vital considerations for the use of cholangioscopy in clinical practice. The cost of single operator cholangioscopes increased with conversion from fiberoptic to digital platforms. The cost of the latter many exceed $3000 per case which requires careful assessment of resource utilization. Definitive cost-effectiveness studies are needed. A model of the economic consequences of single-operator cholangioscopy in a Belgian hospital system found that early use of cholangioscopy-guided therapy for difficult stones could potentially result in cost savings by decreasing the overall number of procedures.67 

Prospective studies of cholangioscopy indicate that bacteremia and cholangitis occur in 8.8% and 6.6%, respectively.68 While meta-analysis does not suggest a higher rate of overall adverse events than conventional ERCP for indications such as difficult bile duct stones,13 likelihood of cholangitis is greater. This increases with hilar and multifocal strictures.69 In high-risk settings, i.e., primary sclerosing cholangitis, complex stones, and proximal strictures, administration of peri-procedural antibiotics such as fluoroquinolones and 3rd or 4th generation cephalosporins in addition to bile duct stent should be considered. Cholangioscopy should be avoided in cases of purulent. 

When laser lithotripsy is performed, sufficient irrigation and aspiration to optimize visibility along with strictly avoiding use of laser blindly are important precautions to avoid ductal injury. Other adverse events include post-ERCP pancreatitis, perforation, and bleeding, though the rates of these complications for cases with cholangioscopy do not appear to be significantly higher than adverse events from ERCP alone.9,12, 70-74 

Another important consideration is the use of general anesthesia to protect airways when irrigation may increase the fluid content of the upper GI tract. 

FUTURE DIRECTIONS 

Rapid advancements in medical technology have already expanded the use of and role of cholangioscopy. Deep learning algorithms promise to increase the diagnostic power of cholangioscopy as do integration of image enhancement techniques from other types of endoscopy including narrow band imaging.75 Technical advances will also make scopes easier to use and intensify their therapeutic potential. Direct POC using a novel multi-bending ultra-slim scope shortens procedure time and may improve success rates.76 Slimmer, more flexible scopes may facilitate cholangioscopy’s role in patients with primary sclerosing cholangitis and high-grade strictures where success is lower. Additionally, it will likely emerge as a high precision ablative therapy with radiofrequency and photodynamic therapy and future modalities.77-79 Simpler less expensive devices to exclude residual stones will likely emerge which will have a complementary role with cholangioscopes with broader therapeutic capability. 

CONCLUSION 

Cholangioscopy has emerged as a core tool in diagnosis and management of neoplastic and non-neoplastic biliary diseases. It is especially important in the treatment of complex bile duct stones and evaluation of indeterminate strictures. An expanding role in biliary practice including treatment of early neoplasia, pre-operative staging, and exclusion of residual stones is emerging. While cost might still be a limiting factor in some practices, the proper utilization of this tool in the appropriate clinical context is likely cost-effective as it improves non-operative management of biliary disease.

Wissam Kiwan, MD Assistant Professor of Medicine Advanced & Therapeutic Endoscopy Division of Gastroenterology and Hepatology Saint Louis University, St. Louis, MO James L. Buxbaum, MD, FASGE Associate Professor of Medicine, Keck Medicine of the University of Southern California, Los Angeles, CA

References 

1. Committee AT, Komanduri S, Thosani N, et al. Cholangiopancreatoscopy. Gastrointest Endosc 2016;84:209-21. 

2. Roca J, Flichtentrei R, Parodi M. [Progress in the radiologic study of the biliary tract in surgery; cholangioscopy and cholan­giography; utilization of apparatus; preliminary note]. Dia Med 1951;23:3420. 

3. Rösch W, Koch H, Demling L. Peroral Cholangioscopy. Endoscopy 1976;08:172-175. 

4. Ell C, Lux G, Hochberger J, et al. Laserlithotripsy of common bile duct stones. Gut 1988;29:746-51. 

5. Leung JW, Chung SS. Electrohydraulic lithotripsy with peroral choledochoscopy. BMJ 1989;299:595-8. 

6. Cotton PB, Kozarek RA, Schapiro RH, et al. Endoscopic laser lithotripsy of large bile duct stones. Gastroenterology 1990;99:1128-33. 

7. Larghi A, Waxman I. Endoscopic direct cholangioscopy by using an ultra-slim upper endoscope: a feasibility study. Gastrointest Endosc 2006;63:853-7. 

8. Moon JH, Choi HJ. The role of direct peroral cholangioscopy using an ultraslim endoscope for biliary lesions: indications, limi­tations, and complications. Clin Endosc 2013;46:537-9. 

9. Chen YK, Pleskow DK. SpyGlass single-operator peroral chol­angiopancreatoscopy system for the diagnosis and therapy of bile-duct disorders: a clinical feasibility study (with video). Gastrointest Endosc 2007;65:832-41. 

10. Chen YK, Parsi MA, Binmoeller KF, et al. Single-operator chol­angioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). Gastrointest Endosc 2011;74:805-14. 

11. Shah RJ, Raijman I, Brauer B, et al. Performance of a fully disposable, digital, single-operator cholangiopancreatoscope. Endoscopy 2017;49:651-658. 

12. Adler DG, Cox K, Milliken M, et al. A large multicenter study analysis of adverse events associated with single operator cholan­giopancreatoscopy. Minerva Gastroenterol Dietol 2015;61:179- 84. 

13. Committee ASoP, Buxbaum JL, Abbas Fehmi SM, et al. ASGE guideline on the role of endoscopy in the evaluation and manage­ment of choledocholithiasis. Gastrointest Endosc 2019;89:1075- 1105 e15. 

14. Thomas M, Howell DA, Carr-Locke D, et al. Mechanical lithotripsy of pancreatic and biliary stones: complications and available treatment options collected from expert centers. Am J Gastroenterol 2007;102:1896-902. 

15. Stefanidis G, Viazis N, Pleskow D, et al. Large balloon dilation vs. mechanical lithotripsy for the management of large bile duct stones: a prospective randomized study. Am J Gastroenterol 2011;106:278-85. 

16. Manes G, Paspatis G, Aabakken L, et al. Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy 2019;51:472-491. 

17. Kedia P, Tarnasky PR. Endoscopic Management of Complex Biliary Stone Disease. Gastrointest Endosc Clin N Am 2019;29:257-275. 

18. Trikudanathan G, Arain MA, Attam R, et al. Advances in the endoscopic management of common bile duct stones. Nat Rev Gastroenterol Hepatol 2014;11:535-44. 

19. Garg PK, Tandon RK, Ahuja V, et al. Predictors of unsuccessful mechanical lithotripsy and endoscopic clearance of large bile duct stones. Gastrointest Endosc 2004;59:601-5. 

20. Neuhaus H, Hoffmann W, Zillinger C, et al. Laser lithotripsy of difficult bile duct stones under direct visual control. Gut 1993;34:415-21. 

21. Ell C, Hochberger J, May A, et al. Laser lithotripsy of difficult bile duct stones by means of a rhodamine-6G laser and an integrated automatic stone-tissue detection system. Gastrointest Endosc 1993;39:755-62. 

22. Arya N, Nelles SE, Haber GB, et al. Electrohydraulic lithotripsy in 111 patients: a safe and effective therapy for difficult bile duct stones. Am J Gastroenterol 2004;99:2330-4. 

23. Patel KS, Calixte R, Modayil RJ, et al. The light at the end of the tunnel: a single-operator learning curve analysis for per oral endoscopic myotomy. Gastrointest Endosc 2015;81:1181-7. 

24. Villa L, Cloutier J, Comperat E, et al. Do We Really Need to Wear Proper Eye Protection When Using Holmium:YAG Laser During Endourologic Procedures? Results from an Ex Vivo Animal Model on Pig Eyes. J Endourol 2016;30:332-7. 

25. Buxbaum J, Sahakian A, Ko C, et al. Randomized trial of chol­angioscopy-guided laser lithotripsy versus conventional therapy for large bile duct stones (with videos). Gastrointest Endosc 2018;87:1050-1060. 

26. Brewer Gutierrez OI, Bekkali NLH, Raijman I, et al. Efficacy and Safety of Digital Single-Operator Cholangioscopy for Difficult Biliary Stones. Clin Gastroenterol Hepatol 2018;16:918-926 e1. 

27. Maydeo AP, Rerknimitr R, Lau JY, et al. Cholangioscopy-guided lithotripsy for difficult bile duct stone clearance in a single session of ERCP: results from a large multinational registry demonstrate high success rates. Endoscopy 2019;51:922-929. 

28. Ridtitid W, Luangsukrerk T, Angsuwatcharakon P, et al. Uncomplicated common bile duct stone removal guided by cholangioscopy versus conventional endoscopic retrograde chol­angiopancreatography. Surg Endosc 2018;32:2704-2712. 

29. Aloreidi K, Patel B, Atiq M. Intraductal cholangioscopy-guided electrohydraulic lithotripsy as a rescue therapy for impacted common bile duct stones within a Dormia basket. Endoscopy 2016;48:E357-E358. 

30. Fejleh MP, Thaker AM, Kim S, et al. Cholangioscopy-guided retrieval basket and snare for the removal of biliary stones and retained prostheses. VideoGIE 2019;4:232-234. 

31. Kim HJ, Choi HS, Park JH, et al. Factors influencing the technical difficulty of endoscopic clearance of bile duct stones. Gastrointest Endosc 2007;66:1154-60. 

32. Christoforidis E, Vasiliadis K, Tsalis K, et al. Factors significantly contributing to a failed conventional endoscopic stone clearance in patients with “difficult” choledecholithiasis: a single-center experience. Diagn Ther Endosc 2014;2014:861689. 

33. Navaneethan U, Njei B, Lourdusamy V, et al. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc 2015;81:168-76. 

34. Hu B, Sun B, Cai Q, et al. Asia-Pacific consensus guidelines for endoscopic management of benign biliary strictures. Gastrointest Endosc 2017;86:44-58. 

35. Sadeghi A, Mohamadnejad M, Islami F, et al. Diagnostic yield of EUS-guided FNA for malignant biliary stricture: a systematic review and meta-analysis. Gastrointest Endosc 2016;83:290-8 e1. 

36. DeWitt J, Misra VL, Leblanc JK, et al. EUS-guided FNA of proximal biliary strictures after negative ERCP brush cytology results. Gastrointest Endosc 2006;64:325-33. 

37. El Chafic AH, Dewitt J, Leblanc JK, et al. Impact of preoperative endoscopic ultrasound-guided fine needle aspiration on postop­erative recurrence and survival in cholangiocarcinoma patients. Endoscopy 2013;45:883-9. 

38. Heimbach JK, Sanchez W, Rosen CB, et al. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associ­ated with disease dissemination. HPB (Oxford) 2011;13:356-60. 

39. Seo DW, Lee SK, Yoo KS, et al. Cholangioscopic findings in bile duct tumors. Gastrointest Endosc 2000;52:630-4. 

40. Sethi A, Tyberg A, Slivka A, et al. Digital Single-operator Cholangioscopy (DSOC) Improves Interobserver Agreement (IOA) and Accuracy for Evaluation of Indeterminate Biliary Strictures: The Monaco Classification. J Clin Gastroenterol 2022;56:e94-e97.

Download Tables, Images & References

NUTRITION REVIEWS IN GASTROENTEROLOGY

The Importance of Assessing Muscle Health – Practical Tools for Clinicians

Read Article

Human body composition is an emerging field of science that looks beyond body mass index to explore the different distributions of muscle and adipose tissue on health outcomes. Declines in skeletal muscle mass and function (e.g., sarcopenia) independently contribute to adverse health outcomes and often reflect poor muscle health. Therefore, it is imperative for clinicians to better understand the different methodologies to measure muscle mass, as well as muscle function. Familiarity with the array of existing and emerging clinical tools and measures is a critical step to help clinicians identify and address poor muscle health. This article briefly reviews practical and emerging body composition methodologies (bioelectrical impedanceanalysis, dual energy x-ray absorptiometry, ultrasound, computed tomography) and offers clinicians tools to measure, quantify, and address muscle health concerns in their patients.

INTRODUCTION

Skeletal muscle (SM), the primary component of lean soft tissue or lean mass (LM), serves as the major protein reserve in the human body. Although decreases in SM mass and function are part of the natural aging process, an ever-increasing body of research supports that decreases in muscle health (e.g., sarcopenia) independently contribute to adverse clinical outcomes. Addressing the presence of sarcopenia in acute and chronically ill patient populations is crucial as this condition negatively impacts individual health (e.g., self-care, treatment response, quality of life) and increases the financial burden on healthcare systems.1 While excess adiposity is often a focal point of care for many clinicians, and body mass index (BMI) is the common clinical metric used to evaluate obesity, sarcopenia is highly prevalent across the BMI spectrum.2 Therefore, it is imperative for clinicians to better understand the different methodologies to measure muscle mass and muscle function (referred to as muscle health). Familiarity with the available tools and measures can help clinicians to identify this highly prevalent, clinically significant condition. 

Why Body Composition Matters 

Human body composition analysis is an emerging field of science that looks beyond BMI to explore the different distributions of SM and adipose tissue on health outcomes. Compromises in muscle health are the hallmark feature of sarcopenia; a clinical condition characterized by low muscle strength and low muscle mass.1 The more recent inclusion of muscle function into patient assessments is intended to facilitate better application and integration into clinical practice. Sarcopenia is occult, often difficult to detect on physical examination (PE) and may not automatically trigger nutritional interventions. Other physiological indications that coexist and may contribute to the onset of sarcopenia may include chronic illness, inflammation, poor oral intake, a sedentary lifestyle, and declining functional status. Weight loss is not considered a reliable indicator to identify or screen for sarcopenia3 and currently, there is no consensus on how best to measure muscle health. 

Clinicians are encouraged to use direct measures of muscle mass, as well as devices or tools to assess muscle function. It should be emphasized that further evaluation regarding the validity of assessment techniques for body composition applicable to a wide array of patient populations are recommended. This brief review intentionally focuses on the most common and emerging tools relevant to clinical practice. For a more in-depth appreciation on the development, use, strengths, and limitations of these and other body composition assessment tools, please refer to reference 4. Table 1 depicts several tools most applicable in the clinical setting. 

Measurement Techniques to Assess Body Composition 

Bioelectrical Impedance Analysis 

Bioelectrical Impedance Analysis (BIA) uses low-intensity, electric conduction with single, multiple, or a spectrum (BIS) of frequencies to determine estimates of total body water (TBW). By using predictive equations, TBW is used to calculate estimated fat free mass (FFM) and fat mass (FM).5 For clarity, FFM encompasses LM and bone, while FM refers to the actual lipid content in adipose tissue.6 To use BIA or BIS, electrodes are placed on the hand, wrist, foot, and/or ankle and a low intensity electric current(s) is applied creating measures of reactance and impedance (Figure 1). Body tissues such as FM with low amounts of water and electrolytes will produce a high impedance, compared to LM which will have low impedance reflecting the high water and electrolyte content.5 

Conventionally, BIA or BIS is a clinical favorite in multiple settings due to its low cost, portability, and noninvasive nature. However, BIA and BIS results are only considered valid and reliable when repeated measures are obtained over time and when steady state conditions have been met, especially those related to hydration and fluid status. For example, in patients with heart failure, a BIA measurement could produce falsely low estimates of body fat due to the increase in TBW. In contrast, an individual with decreased TBW such as dehydration, will produce falsely high measures of body fat as there is less conductivity measured. If clinicians or researchers decide to utilize BIA or BIS as a measurement tool, it is crucial to obtain baseline and follow up measures, and to consider the appropriate type of device, the intended target population for the device, and conditions of measurement (e.g., fasting requirements, fluid status, medications).5 Handheld and scale-type devices are readily available over the counter and easily incorporated into clinical practice. However, because manufacturers do not share their FFM and FM predictive equations, the same device must be used for follow-up measures to support valid comparisons. 

Dual Energy X-Ray Absorptiometry 

As the name implies, dual energy x-ray absorptiometry (DXA) relies on x-ray technology to procure information about bone density and body composition. It is conventionally used to diagnosis osteoporosis; however, since the 1980s DXA has gained popularity as a body composition assessment tool.7 DXA technology is based on two, low radiation photon energy x-rays measured with a detector after these two rays pass through the subject (Figure 1). The strength of photon x-ray beams is altered depending on the tissue they pass through, and thus this variation can be captured as body composition measurements. The ratio of the energy from the two beams can differentiate bone, FM, and LM. DXA is useful for measuring specific parts of the body and can provide insights on LM change, especially in appendicular regions.8 

Similar to BIA, DXA can be used on a wide range of body sizes and body types and is non-invasive, yet it remains a greatly underutilized tool in the outpatient setting due to issues surrounding access and availability.7 The practicality of using DXA for body composition assessment in the acute or inpatient setting greatly limits its use. Unlike BIA, DXA instrumentation is expensive, requires a dedicated room, and requires technician certification. Conventionally, DXA scanning captures images of the femoral or lumbar spine, as these are reference standards for determining osteoporosis risk. Obtaining body composition data requires whole-body imaging, which is only performed if requested and would likely pose additional labor and cost burden.6 Whole-body images relay information on regional and total adiposity, as well as appendicular LM (e.g., LM of the arms and legs combined) and total LM (e.g., trunk, head, appendages). Appendicular LM is adjusted for height and used to diagnose sarcopenia, which ignores muscle function. Like BIA, the reliability of DXA can be compromised in individuals with hydration issues, should be completed when individuals are fasted,9 and the output may not differentiate adipose tissue types (visceral vs. subcutaneous fat). Since 1999, DXA is used to characterize body composition in the on-going National Health and Nutrition Examination survey, providing population reference values for adults and children.10 However, DXA imaging for clinical assessment of body composition is still considered ‘investigational’ and therefore not routinely covered by insurers. 

Ultrasonography

There is growing interest in the utilization of ultrasound (US) as a body composition technique due to its portability, relative affordability, and ease in obtaining repeated measurements. Most work has focused on measuring visceral and subcutaneous adipose tissue (VAT and SAT, respectively), and more recently muscle.11 US uses high-frequency sound waves from tissues, where the amount of sound reflected depicts changes in acoustic impedance – the product of acoustic velocity and tissue density (Figure 1). As such, US can relay information about adipose tissue, muscle thickness and muscle cross-sectional area of measurement. Total body LM can be estimated via a regression equation using measures of muscle thickness from multiple sites. US can also be used to gauge “fatty infiltrated” muscle (also known as myosteatosis); a condition more common in persons with diabetes symbolizing metabolic and physiologic dysfunction.12 

The biggest limitation of US lies in the reliability of the operator. Even with the advent of standardized techniques, determining the minimal vs. maximal compression of the transducer onto the skin site by the operator can vary, and alter the thickness and quantifications of SM and SAT.12 Similar to BIA, BIS, or DXA, hydration, specifically edema, can present challenges to obtaining accurate body composition measures using US. However, with US technique training, edema is no longer an absolute contraindication for using this technique.13 Differences in US transducers allow for varying ranges of tissue penetration and window width (e.g., linear vs. curvilinear), which may be beneficial for patients with severe obesity or fluid overload.12 While US has the potential to be utilized within multiple patient populations, issues surrounding inter- and intra-individual measurement variation continue to pose barriers for making this technique more applicable in the clinical setting. 

Computed Tomography 

Due to software advances, computed tomography (CT) images conducted for clinical (diagnostic or surveillance) purposes can be utilized to obtain precise information related to adipose tissue and SM. Specifically, VAT, SAT and intramuscular adipose tissue (IMAT) can be individually quantified or comprised to create total adipose tissue (TAT). Additionally, SM mass and SM quality can be ascertained from CT images to diagnose sarcopenia and myosteatosis, respectively. Given the widespread use of CT imaging in patient care, these images serve as a rich archive of body composition data and are increasingly employed in prevalence and outcomes research.14 Conventionally, CT images inclusive of the third lumbar (L3) region (e.g., abdominal and/or pelvic) are used to examine body composition. 

While CTs are distinctly advantageous because of their superior precision relative to other body composition techniques, they remain largely a research tool. The barriers to utilizing CT images are immense, and include but are not limited to extensive training, access to the picture archiving and communications system to retrieve specific CT studies, expertise utilizing the body composition software, and/or personnel time for analyses. Due to concerns regarding radiation and expense, rarely are CTs advocated as prospective body composition technique.15 There are additional concerns related to the translation of these data to patient care (e.g., what are the implications of myosteatosis?) and a lack of clinically meaningful cut-points (e.g., high vs. low VAT). As such, advances are required to increase the immediate clinical applicability of body composition measures ascertained from CT imaging. 

Physical Examination, Anthropometric Measurements, and Muscle Function 

In instances where BIA, BIS, DXA, or US are not available, the use of anthropometric measurements and comprehensive PE are recommended to assess muscle health.11 Mid-upper arm and/or calf circumferences are easily obtained in the clinical setting and correlate with compromised muscle health. In addition, clinicians can be trained to evaluate qualitative signs of reduced muscle mass during their PE, taking a ‘head to toe’ approach focusing on the temples, neck, clavicle, shoulder, scapula, thigh, and calf areas (see Table 2). Nutrition focused PEs are a component of validated nutrition assessment tools, including the Subjective Global Assessment (SGA), and recommended by professional bodies such as the Academy of Nutrition and Dietetics (AND) and the American Society for Parenteral and Enteral Nutrition (ASPEN) to depict muscle wasting. However, PE and anthropometric measurements are more challenging in individuals with obesity and severe fluid abnormalities, as SM may be poorly differentiated. 

To complement the anthropometric and PE information gathered, it is imperative to measure muscle function for a comprehensive picture of muscle health. Endorsed by the European Working Group on Sarcopenia in Older People, several tests can be conducted at the bedside or in clinic to assess muscle function (See Table 2).1 Because of the undue influence of non-nutritive factors (e.g., neurologic impairment), it is not advised to uniformly prioritize muscle function tests over muscle mass assessment.11 For example, some patients may be too impaired to hold the hand dynamometer or too unbalanced to perform a sit-to-stand test. Muscle function testing can substantiate or support PE, or other clinical findings, regarding muscle health and put into proper context of patient care. 

Practical Applications for Clinicians 

Preserving or improving LM and/or muscle function is the overarching goal for any patient, especially the aging. Simply recognizing compromises in LM occur across all BMI strata is vital for clinicians to appreciate. Clinicians are encouraged to look beyond BMI and focus their treatments on simple messaging and early intervention referrals. 

Clinicians should take advantage of opportunities to assess eating patterns, honing in on nutrition-impact symptoms (e.g., taste change, gastrointestinal symptoms) or behaviors (e.g., skipping meals, eliminating of food groups) that preclude optimal oral intake. Additionally, incorporating methods to identify patients who report unstable socioeconomic status and/or food insecurity, as these factors increase the likelihood of inadequate dietary intake. Simple interventions, including calorically dense oral supplements or protein supplements (e.g., beverages, bars, powders) may be indicated at or between meals. Animal sources of protein have been shown to upregulate anabolic stimulation compared to plant-based proteins (apart from soy-based isolates) and possess higher levels of digestibility. Expert opinion recommends older adults with comorbid conditions aim to consume at least 65% of daily protein needs from animal sources, such as red meat, eggs, fish, poultry, and dairy. Patients following an exclusively plant-based diet (veganism or vegetarianism) should regularly incorporate soy or pea protein isolates as these plant proteins offer higher amino acid digestibility.16 Table 3 offers dietary intake probes and potential responses to support improved nutrition messaging. 

In patient populations with sarcopenia or at high risk of sarcopenia, dietary protein intake and physical activity are typically low which negatively affect rates of muscle protein synthesis.13 Increasing physical activity, specifically progressive resistance exercise training, can preserve or build LM. A 3-month pilot study demonstrates the value of a supervised resistance exercise program significantly and positively impacting quality of life, pain, LM and physical functioning in older patients with advanced cancer.17 Referrals to physical therapy and/or exercise physiologists to assess and individualize functional interventions, as well as engagement with registered dietitians and social workers to reduce nutrition, psychological, and socioeconomic barriers to oral intake are recommended. 

CONCLUSIONS 

The landscape of clinical practice is shifting to recognize the importance of muscle health and its impact on outcomes. Clinicians should arm themselves with the knowledge and tools to assess muscle mass and muscle function, utilizing readily available quantitative measures (BIA or DXA), anthropometrics (mid-upper arm or calf circumference), and/or enhanced PE methods. Recommendations regarding consistent, adequate oral intake with high quality protein sources are advocated for any patient with documented or suspected compromises in muscle health. Interdisciplinary collaborations are key to optimizing care and combating the untoward effects of compromised muscle health.

References 

1. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagno­sis. Age Ageing. 2019;48(1):16-31. 

2. Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutri­tional impact. Proc Nutr Soc. 2016;75(2):188-98.

3. Prado CM, Lieffers JR, Bowthorpe L, Baracos VE, Mourtzakis M, McCargar LJ. Sarcopenia and physical function in overweight patients with advanced cancer. Can J Diet Pract Res. 2013;74(2):69-74. 

4. Heymsfield S. Human body composition. 2nd ed. Champaign, IL: Human Kinetics; 2005. xii, 523 p. p. 

5. Vineis MA PS. A review of biolectiral impedance analysis. Support Line: Dietitians in Nutrition Support. 2015;37(3):18-23. 

6. Sheean P, Gonzalez MC, Prado CM, McKeever L, Hall AM, Braunschweig CA. American Society for Parenteral and Enteral Nutrition Clinical Guidelines: The Validity of Body Composition Assessment in Clinical Populations. JPEN J Parenter Enteral Nutr. 2020;44(1):12-43. 

7. Shepherd JA, Ng BK, Sommer MJ, Heymsfield SB. Body composition by DXA. Bone. 2017;104:101-5. 

8. Coltman A. Dual energy x-ray absorptiometry (DXA). Support Line: Dietitians in Nutrition Support. 2015;37(3):15-8. 

9. Hangartner TN, Warner S, Braillon P, Jankowski L, Shepherd J. The Official Positions of the International Society for Clinical Densitometry: acquisition of dual-energy X-ray absorptiometry body composition and considerations regarding analysis and repeatability of measures. J Clin Densitom. 2013;16(4):520-36. 

10. Kelly TL, Wilson KE, Heymsfield SB. Dual energy X-Ray absorptiometry body composition reference values from NHANES. PLoS One. 2009;4(9):e7038. 

11. Barazzoni R, Jensen GL, Correia M, Gonzalez MC, Higashiguchi T, Shi HP, et al. Guidance for assessment of the muscle mass phenotypic criterion for the Global Leadership Initiative on Malnutrition (GLIM) diagno­sis of malnutrition. Clin Nutr. 2022;41(6):1425-33. 

12. McGhee B RH. Application of ultrasonography for measuring change in lean body mass in acute care. Support Line: Dietitians in Nutrition Support. 2015;37(3):3-5. 

13. Sabatino A, Regolisti G, Bozzoli L, et al. Reliability of bedside ultrasound for measurement of quadriceps muscle thickness in critically ill patients with acute kidney injury. Clin Nutr. 2017;36(6):1710-5. 

14. Amini B, Boyle SP, Boutin RD, Lenchik L. Approaches to Assessment of Muscle Mass and Myosteatosis on Computed Tomography: A Systematic Review. J Gerontol A Biol Sci Med Sci. 2019;74(10):1671-8. 

15. Tolonen A, Pakarinen T, Sassi A, et al. Methodology, clinical applications, and future directions of body composition analysis using computed tomography (CT) images: A review. Eur J Radiol. 2021;145:109943. 

16. Ford KL, Arends J, Atherton PJ, et al. The impor­tance of protein sources to support muscle anabo­lism in cancer: An expert group opinion. Clin Nutr. 2022;41(1):192-201. 

17. Cormie P, Newton RU, Spry N, Joseph D, Taaffe DR, Galvão DA. Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases. Prostate Cancer and Prostatic Diseases. 2013;16(4):328-35. 

18. National Institute of Health Motor Measures: NIH; 2019 [Available from: https://www.healthmeasures. net/explore-measurement-systems/nih-toolbox/obtain-and-administer-measures/demonstration-videos.]

Download Tables, Images & References

Jojobet GirişmatbetcasibommeritkingcasibomcasibomgrandpashabetGrandpashabetgrandpashabetcasibomGrandpashabetzirvebetjojobetgrandpashabetGrandpashabetGrandpashabetGrandpashabetgrandpashabetcasibomjojobetjojobet girişjojobet güncel girişUltrabetjojobetmatbetdeneme bonusu veren sitelersezarcasinomadridbetmadridbetMadridbetMadridbetgrandpashabetHoliganbet girişcasibomgrandpashabet girişJojobetcasibomcasibomcasibomultrabetgrandpashabetultrabetgrandpashabet girişcasibombetciograndpashabet girişcasibom girişgrandpashabet girişgrandpashabetgrandpashabetholiganbetBetpas